


Rec'd PCT/PTO
PCT/IB 63/0 16 MAY 2005 #2
0 3 04



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



IB03/06281

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Stephen Hordley

Dated

20 November 2003



28MAR03 E795841/9 D00019
P01/7700 0.00-0307131.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference P033662GB

2. Patent application number
(The Patent Office will fill in this part)

27 MAR 2003

0307131.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CHIRON SRL
VIA FIORENTINA 1
53100 SIENA
ITALY

08555898001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

MENINGOCOCCUS SURFACE PROTEINS

5. Name of your agent (if you have one)

CARPMAELS & RANSFORD

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

43 BLOOMSBURY SQUARE
LONDON
WC1A 2RA

Patents ADP number (if you know it)

83001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 51

Claim(s) -

Abstract

Drawing(s) 3 x 3

8 Sequence listing: 21

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

A

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

Carpmaels & Ransford

27/03/2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Cameron Marshall

020 7242 8692

Carpmaels & Ransford

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

MENINGOCOCCUS SURFACE PROTEINS

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention is in the field of meningococcal biochemistry, in particular the trafficking and
5 localisation of meningococcal proteins.

BACKGROUND ART

The complete genome sequence of serogroup B *N.meningitidis* has been published [1] and has been subjected to analysis in order to identify candidate vaccine antigens [2]. The complete genome sequence of serogroup A *N.meningitidis* is also known [3].

10 Footnote 12 of reference 2 describes the authors' approach to antigen selection. Briefly, a first screening for coding capacity of the genome sequence was performed using computer programs included in the Wisconsin package version 10.0, Genetics Computer Group (GCG). BLASTX was used to classify ORFs as coding either for known cytoplasmic functions or for other functions. The cytoplasmic ORFs were "not further investigated" as candidate antigens.

15 A second screening step aimed at identifying putative proteins with a cellular localization spanning from the inner membrane to outside the bacterium was also used. This screening involved F-BLAST, FASTA, MOTIFS, FINDPATTERNS, and PSORT, as well as the ProDom, Pfam, and Blocks databases. ORFs were thus selected on the basis of features typical of surface-associated proteins such as transmembrane domains, leader peptides, homologies to known surface proteins, lipoprotein
20 signature, outer membrane anchoring motifs, and host cell binding domains such as RGD.

In total, reference 2 identified 570 ORFs within the genome as candidate vaccine antigens. 98.8% of these selected serogroup B ORFs were also found and conserved in serogroup A, and 95.3% were found and conserved in *N. gonorrhoeae*.

This "reverse genomics" approach to vaccine candidate selection is undoubtedly powerful, and has
25 been copied for other organisms [e.g. refs. 4 to 10], but it does not identify all surface-exposed proteins and vaccine candidates [11]. It is therefore an object of the invention to identify surface-exposed meningococcal proteins which are not identified by computer prediction methods.

DISCLOSURE OF THE INVENTION

The invention is based on the discovery of 217 proteins which, contrary to expectations, are found in
30 the membrane of *Neisseria meningitidis*. Of these 217, 76 in particular evade all algorithmic methods for predicting membrane localisation. Existing knowledge of protein trafficking pathways in meningococcus does not explain how or why these proteins are located in the bacterial membrane e.g. there is no apparent biochemical reason for a DNA helicase or a chromosomal replication initiator protein to be found in the membrane.

The 217 proteins are listed in Table I according to their 'NMB' numbering, which corresponds to the standardised nomenclature from reference 1. The NMB numbering can be used directly to query online databases *e.g.* a protein query of the NCBI Entrez system [12] using the term 'NMB1506' unequivocally identifies the Arginyl-tRNA synthetase of *N.meningitidis* (see Figure 5), leading to a single amino acid sequence. Details of the DNA sequences which encode these proteins are similarly accessible from the online databases.

Although the online databases are the most convenient source of information concerning the 217 proteins of the invention, and the most likely to be consulted by the skilled person, for formal reasons the amino acid sequences are also provided in a sequence listing (SEQ ID NO^s: 1 to 217).

Proteins of the invention

The invention provides a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 217.

It also provides a protein comprising an amino acid sequence which shares at least $x\%$ sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 217.

Depending on the particular sequence, x is preferably 50% or more (*e.g.* 60%, 70%, 80%, 90%, 95%, 99% or more). These proteins include allelic variants, homologs, orthologs, paralogs, mutants *etc.* of SEQ ID NO^s: 1 to 217. Typically, 50% identity or more between two proteins is considered to be an indication of functional equivalence. Identity between proteins is preferably determined by the Smith-Waterman homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters *gap open penalty=12* and *gap extension penalty=1*.

It is preferred that one or more of the differences these proteins compared to SEQ ID NO^s: 1 to 217 involves a conservative amino acid replacement *i.e.* replacement of one amino acid with another which has a related side chain. Genetically-encoded amino acids are generally divided into four families: (1) acidic *i.e.* aspartate, glutamate; (2) basic *i.e.* lysine, arginine, histidine; (3) non-polar *i.e.* alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar *i.e.* glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In general, substitution of single amino acids within these families does not have a major effect on the biological activity. Proteins of the invention may contain 1 or more (*e.g.* 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) conservative mutations.

The invention further provides a protein comprising a fragment of an amino acid sequence selected from the group consisting of SEQ ID NO^s: 1 to 217. The fragment should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n is 7 or more (*e.g.* 8, 10, 12, 14, 16, 18, 20, 30, 40, 50, 75, 100, 150, 200 or more). Preferred fragments include: (a) fragments which comprise an epitope; (b) fragments common to two or more of SEQ IDs 1 to

217; (c) SEQ IDs 1 to 217 with 1 or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, *etc.*) N-terminal residues deleted; (d) SEQ IDs 1 to 217 with 1 or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, *etc.*) C-terminal residues deleted; (e) SEQ IDs 1 to 217 without their signal peptides; and (f) SEQ IDs 1 to 217 with the N-terminal deleted up to and including a poly-glycine sequence (*i.e.* Gly_g, where $g \geq 3$ e.g. 4, 5, 6, 7, 8, 9 or more), referred to as 'ΔG' proteins. These preferred fragments are not mutually exclusive e.g. a fragment could fall into category (a) and (b), or category (c) and (d), *etc.*

Proteins can be prepared by various means e.g. by chemical synthesis (at least in part), by digesting longer polypeptides using proteases, by translation from RNA, by purification from cell culture (e.g. from recombinant expression or from *N.meningitidis* culture). *etc.* Heterologous expression in *E.coli* is a preferred preparative route.

Proteins can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, disulfide bridges, *etc.*).


Proteins are preferably prepared in substantially pure form (*i.e.* substantially free from other Neisserial or host cell proteins) or substantially isolated form.

Proteins are preferably meningococcal proteins.

Proteins of the invention may be attached to a solid support. They may comprise a detectable label (e.g. a radioactive or fluorescent label, or a biotin label).

Proteins of the invention may be located within a lipid bilayer. The invention thus provides a lipid bilayer (e.g. a cell membrane, a liposome, a bacterial ghost, an OMV, a bleb, *etc.*) including a protein of the invention. The bilayer preferably does not include native membrane components such as porins (PorA in particular, class I outer membrane proteins (OMPs), class III OMPs, *etc.*), LOS, LPS, PilC, Omp85, opacity proteins (e.g. Opa & Opc), pilins (e.g. PilC, PilT, *etc.*), P64k, *etc.*

Preferred fusion proteins follow the approach set out in references 13 to 15 in which two or more (e.g. 3, 4, 5, 6 or more) Neisserial proteins are joined such that they are translated as a single polypeptide chain. In general, such hybrid proteins can be represented by the formula:



wherein X is an amino acid sequence as defined above, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. The value of n is between 2 and x , and the value of x is typically 3, 4, 5, 6, 7, 8, 9 or 10. Preferably n is 2, 3 or 4; it is more preferably 2 or 3; most preferably, $n = 2$.

In some hybrid proteins, referred to as 'tandem' proteins, a -X- moiety has sequence identity to at least one of the other X moieties, as defined above e.g. X₁ is SEQ ID 1 and X₂ is a variant of X₁.

For X moieties other than X_1 , it is preferred that the native leader peptide should be omitted. In one embodiment, the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein *i.e.* the leader peptide of X_1 will be retained, but the leader peptides of $X_2 \dots X_n$ will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X_1 as moiety -A-.

For each n instances of [-X-L-], linker amino acid sequence -L- may be present or absent. For instance, when $n=2$ the hybrid may be $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-L}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-L}_2\text{-COOH}$, *etc.* Linker amino acid sequence(s) -L- will typically be short (*e.g.* 20 or fewer amino acids *i.e.* 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include short peptide sequences which facilitate cloning, poly-glycine linkers (*i.e.* Gly_n where $n = 2, 3, 4, 5, 6, 7, 8, 9, 10$ or more), and histidine tags (*i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG, with the Gly-Ser dipeptide being formed from a *Bam*HI restriction site, thus aiding cloning and manipulation, and the Gly_4 tetrapeptide being a typical poly-glycine linker.

-A- is an optional N-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (*e.g.* histidine tags *i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more). Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art. If X_1 lacks its own N-terminus methionine, -A- may be a methionine residue.

-B- is an optional C-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein trafficking, short peptide sequences which facilitate cloning or purification (*e.g.* comprising histidine tags *i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

Within SEQ ID NO^s 1 to 217, those marked with a '*' in Table 1 are preferred, as are SEQ IDs 206 to 217. In Table 1, the 76 sequences marked '**' are particularly preferred.

Nucleic acids of the invention

The invention provides nucleic acid encoding the proteins of the invention.

The invention also provides nucleic acid comprising sequences which share at least $x\%$ sequence identity with nucleic acid encoding a protein of the invention. Depending on the particular sequence, x is preferably 50% or more (*e.g.* 60%, 70%, 80%, 90%, 95%, 99% or more).

Furthermore, the invention provides nucleic acid which can hybridise to nucleic acid encoding a protein of the invention. Hybridisation reactions can be performed under conditions of different "stringency". Conditions that increase stringency of a hybridisation reaction of widely known and published in the art. Examples of relevant conditions include (in order of increasing stringency):

5 incubation temperatures of 25°C, 37°C, 50°C, 55°C and 68°C; buffer concentrations of 10 X SSC, 6 X SSC, 1 X SSC, 0.1 X SSC and their equivalents using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or de-ionized water. In some embodiments, the isolated nucleic acid of the

10 invention selectively hybridises under low stringency conditions; in other embodiments it selectively hybridises under intermediate stringency conditions; in other embodiments, it selectively hybridises under high stringency conditions. An exemplary set of low stringency hybridisation conditions is 50°C and 10xSSC. An exemplary set of intermediate stringency hybridisation conditions is 55°C and 1xSSC. An exemplary set of high stringent hybridisation conditions is 68°C and 0.1 x SSC.

15 Nucleic acid comprising fragments of nucleic acid encoding a protein of the invention are also provided. These should comprise at least n consecutive nucleotides from the coding sequences and, depending on the particular sequence, n is 10 or more (*e.g.* 12, 14, 15, 18, 20, 25, 30, 35, 40, 50, 75, 100, 200, 300 or more).

The invention provides nucleic acid comprising sequences complementary to those described above

20 (*e.g.* for antisense or probing purposes).

Nucleic acid of the invention can, of course, be prepared in many ways *e.g.* by chemical synthesis (at least in part), by digesting longer polynucleotides using restriction enzymes, from genomic or cDNA libraries, from the organism itself *etc.*

Nucleic acid of the invention can take various forms (*e.g.* single-stranded, double-stranded, linear,

25 circular, vectors, primers, probes *etc.*).

Nucleic acids of the invention may be attached to a solid support (*e.g.* a bead, plate, filter, film, slide, resin, *etc.*). Nucleic acids of the invention may include a detectable label (*e.g.* a radioactive or fluorescent label, or a biotin label). This is particularly useful where the polynucleotide is to be used in nucleic acid detection techniques *e.g.* where the nucleic acid is a primer or as a probe for use in

30 techniques such as PCR, LCR, TMA, NASBA, bDNA, *etc.*

Nucleic acids of the invention are preferably meningococcal nucleic acids.

The term "nucleic acid" includes DNA, RNA, DNA/RNA hybrids, and DNA or RNA analogs, such as those containing modified backbones or bases, and also peptide nucleic acids (PNA) *etc.*

Nucleic acids of the invention may be isolated and obtained in substantial purity, generally as other

35 than an intact chromosome. Usually, the polynucleotides will be obtained substantially free of other

naturally-occurring nucleic acid sequences, generally being at least about 50% (by weight) pure, usually at least about 90% pure.

5 Nucleic acids can be used, for example: to produce polypeptides; as probes for the detection of nucleic acid in biological samples; to generate additional copies of the polynucleotides; to generate ribozymes or antisense oligonucleotides; and as single-stranded DNA probes or as triple-strand forming oligonucleotides *etc.*

The invention provides vectors comprising nucleotide sequences of the invention (*e.g.* cloning or expression vectors) and host cells transformed therewith.

Outer membrane vesicles (OMVs)

10 One of the various approaches to immunising against *N.meningitidis* infection is to use outer membrane vesicles (OMVs). An efficacious OMV vaccine against serogroup B has been produced by the Norwegian National Institute of Public Health [*e.g.* ref. 16] but, although this vaccine is safe and prevents meningococcal disease, its efficacy is limited to the strain used to make the vaccine.

15 To increase the efficacy of OMV vaccines, it has been proposed to supplement them with additional immunogens. Reference 17 discloses compositions comprising OMVs supplemented with transferrin binding proteins (*e.g.* TbpA and TbpB) and/or Cu,Zn-superoxide dismutase. Reference 18 discloses compositions comprising OMVs supplemented by various proteins.

20 The inventors have found that the portion of the proteome present in OMVs prepared from one strain of *N.meningitidis* can be very different from that of another strain. However, the proteins present in OMVs from any given strain must be compatible with the OMV environment, and so such proteins can be used to supplement OMVs from other strains without needing to be concerned that the proteins might lose immunogenicity, or that they might destabilise the OMVs, *etc.*

25 In general, therefore, the invention provides a composition comprising: (a) OMVs prepared from a first strain of *N.meningitidis*; and (b) one or more proteins which are present in OMVs prepared from a second strain of *N.meningitidis*, but which are not present in OMVs prepared from said first strain. Thus the invention allows the inter-strain reactivity of OMVs to be improved, without requiring the mixing of OMVs from different strains.

30 The protein(s) of component (b) can be included in the composition in various ways. For example: (i) they can be purified from the second strain and added to component (a); (ii) they can be expressed recombinantly, purified, and added to component (a); or (iii) the first strain can be engineered such that it expresses said protein(s), either from its chromosomal DNA or from extrachromosomal DNA (*e.g.* a plasmid), or such that existing expression of said protein(s) is up-regulated, or such that trafficking of said protein(s) already expressed by the first strain is altered to direct it/them to a different cellular location, thereby causing it/them to be present in OMVs. In situation (iii), the
35 OMVs of component (a), prepared from the manipulated first strain, will already include the proteins

of component (b), but these proteins are not present in OMVs prepared from the un-manipulated or wild-type first strain. Thus the invention provides a composition comprising OMVs prepared from a genetically modified first strain of *N.meningitidis*, wherein said OMVs include one or more proteins which are (a) not present in OMVs prepared from said first strain prior to its being genetically modified, but which are (b) present in OMVs prepared from a second strain of *N.meningitidis*.

The *N.meningitidis* strains are preferably from serogroup B of *N.meningitidis*.

Methods for preparing OMVs are well known [e.g. refs. 16 to 26]. also describe OMV preparations from meningococcus. A preferred method involves deoxycholate extraction.

The proteins present in component (b) will depend on the meningococcal strain used to prepare the OMVs of component (a). However, preferred proteins for inclusion in component (b) are: NMB0007, NMB0018, NMB0031, NMB0035, NMB0051, NMB0052, NMB0088, NMB0089, NMB0109, NMB0110, NMB0124, NMB0126, NMB0130, NMB0132, NMB0138, NMB0139, NMB0143, NMB0154, NMB0157, NMB0168, NMB0171, NMB0182, NMB0204, NMB0214, NMB0219, NMB0280, NMB0313, NMB0336, NMB0359, NMB0375, NMB0382, NMB0387, NMB0410, NMB0423, NMB0426, NMB0427, NMB0461, NMB0462, NMB0477, NMB0546, NMB0554, NMB0586, NMB0595, NMB0604, NMB0610, NMB0617, NMB0618, NMB0623, NMB0626, NMB0631, NMB0634, NMB0638, NMB0652, NMB0663, NMB0703, NMB0757, NMB0758, NMB0763, NMB0787, NMB0854, NMB0875, NMB0876, NMB0889, NMB0920, NMB0943, NMB0944, NMB0946, NMB0954, NMB0955, NMB0957, NMB0959, NMB0983, NMB1011, NMB1046, NMB1053, NMB1055, NMB1124, NMB1126, NMB1127, NMB1131, NMB1153, NMB1162, NMB1164, NMB1165, NMB1191, NMB1199, NMB1201, NMB1228, NMB1240, NMB1252, NMB1285, NMB1301, NMB1313, NMB1323, NMB1332, NMB1339, NMB1341, NMB1342, NMB1358, NMB1392, NMB1429, NMB1437, NMB1445, NMB1457, NMB1460, NMB1497, NMB1506, NMB1518, NMB1533, NMB1540, NMB1554, NMB1567, NMB1572, NMB1574, NMB1576, NMB1577, NMB1594, NMB1612, NMB1642, NMB1668, NMB1684, NMB1710, NMB1714, NMB1762, NMB1796, NMB1799, NMB1808, NMB1812, NMB1849, NMB1854, NMB1855, NMB1861, NMB1869, NMB1874, NMB1903, NMB1921, NMB1934, NMB1936, NMB1946, NMB1949, NMB1953, NMB1969, NMB1972, NMB1988, NMB1998, NMB2039, NMB2069, NMB2086, NMB2096, NMB2101, NMB2102, NMB2103, NMB2129, NMB2134, NMB2138, NMB2154 and NMB2159. Particularly preferred are NMB0182, NMB0382, NMB0634, NMB0763, NMB1126, NMB1342, NMB1429, NMB1799 and NMB2039.

It will be appreciated that these references to NMB proteins are based on the genomic sequence of serogroup B strain MC58 [1], and that the corresponding proteins in any particular strain, and the genes encoding them, can readily be determined.

Compositions

According to a further aspect, the invention provides compositions comprising protein and/or nucleic acid and/or OMVs according to the invention. These compositions are preferably immunogenic compositions, such as vaccines, and are suitable for immunisation and vaccination purposes. Vaccines of the invention may be prophylactic or therapeutic, and will typically comprise an antigen

which can induce antibodies which are (a) capable of binding to a meningococcal membrane component and/or (b) bactericidal against meningococcus.

5 Compositions of the invention will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intranasal, ocular, aural, or pulmonary or other mucosal administration. Electrical methods may be used to for delivery e.g. delivery via electroporation.

The invention may be used to elicit systemic and/or mucosal immunity.

Dosage treatment can be a single dose schedule or a multiple dose schedule.

10 The immunogenic composition of the invention will generally include a pharmaceutically acceptable carrier, which can be any substance that does not itself induce the production of antibodies harmful to the patient receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly-metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive
15 virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Liposomes are suitable carriers. A thorough discussion of pharmaceutical carriers is available in ref. 27.

20 Neisserial infections affect various areas of the body and so the compositions of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The composition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition be prepared for oral administration e.g. as a
25 tablet or capsule, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration e.g. as drops.

30 The composition is preferably sterile. It is preferably pyrogen-free. It is preferably buffered e.g. at between pH 6 and pH 8, generally around pH 7.

Further components of compositions

Immunogenic compositions comprise an immunologically effective amount of immunogen, as well as any other of other specified components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a
35 series, is effective for treatment or prevention. This amount varies depending upon the health and

physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Dosage treatment may be a single dose schedule or a multiple dose schedule (e.g. including booster doses). The composition may be administered in conjunction with other immunoregulatory agents.

The composition will generally comprise an adjuvant. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (A) MF59 (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer) [see Chapter 10 of ref. 28; see also ref. 29]; (B) microparticles (*i.e.* a particle of ~100nm to ~150µm in diameter, more preferably ~200nm to ~30µm in diameter, and most preferably ~500nm to ~10µm in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(α-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone *etc.*), with poly(lactide-co-glycolide) being preferred ('PLG'), optionally being charged surface (e.g. by adding a cationic, anionic, or nonionic detergent such as SDS (negative) or CTAB (positive) [e.g. refs. 30 & 31]); (C) liposomes [see Chapters 13 and 14 of ref. 28]; (D) ISCOMs [see Chapter 23 of ref. 28], which may be devoid of additional detergent [32]; (E) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion [see Chapter 12 of ref. 28]; (F) Ribi™ adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (G) saponin adjuvants, such as QuilA or QS21 [see Chapter 22 of ref. 28], also known as Stimulon™; (H) chitosan [e.g. 33]; (I) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (J) cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, *etc.*), interferons (e.g. interferon-γ), macrophage colony stimulating factor, tumor necrosis factor, *etc.* [see Chapters 27 & 28 of ref. 28], RC529; (K) a saponin (e.g. QS21) + 3dMPL + IL-12 (optionally + a sterol) [34]; (L) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) [e.g. chapter 21 of ref. 28]; (M) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions [35]; (N) oligonucleotides comprising CpG motifs [36] *i.e.* containing at least one CG dinucleotide, with 5-methylcytosine optionally being used in place of cytosine; (O) a polyoxyethylene ether or a polyoxyethylene ester [37]; (P) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol [38] or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol [39]; (Q) an immunostimulatory oligonucleotide (e.g. a CpG oligonucleotide) and a saponin [40]; (R) an immunostimulant and a particle of metal salt [41]; (S) a saponin and an oil-in-water emulsion [42]; (T) *E.coli* heat-labile enterotoxin ("LT"), or

detoxified mutants thereof, such as the K63 or R72 mutants [e.g. Chapter 5 of ref. 43]; (U) cholera toxin ("CT"), or detoxified mutants thereof [e.g. Chapter 5 of ref. 43]; (V) double-stranded RNA; (W) aluminium salts, such as aluminium hydroxides (including oxyhydroxides), aluminium phosphates (including hydroxyphosphates), aluminium sulfate, *etc* [Chapters 8 & 9 in ref. 44]; (X) monophosphoryl lipid A mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g. RC-529 [45]; and (Y) other substances that act as immunostimulating agents to enhance the effectiveness of the composition [e.g. see Chapter 7 of ref. 28]. Aluminium salts (aluminium phosphates and particularly hydroxyphosphates, and/or hydroxides and particularly oxyhydroxide) are preferred adjuvants for parenteral immunisation. Toxin mutants are preferred mucosal adjuvants.

10 Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), *etc*.

15 Compositions of the invention may comprise antigens (e.g. protective antigens against *N.meningitidis* or against other organisms) in addition to the proteins mentioned above e.g. DTP antigens, Hib antigen *etc*. The composition may comprise one or more of the following further antigens:

- antigens from *Helicobacter pylori* such as CagA [46 to 49], VacA [50, 51], NAP [52, 53, 54], HopX [e.g. 55], HopY [e.g. 55] and/or urease.
- a saccharide antigen from *N.meningitidis* serogroup A, C, W135 and/or Y, such as the oligosaccharide disclosed in ref. 56 from serogroup C [see also ref. 57] or the oligosaccharides of ref. 58.
- 20 – a saccharide antigen from *Streptococcus pneumoniae* [e.g. 59, 60, 61].
- an antigen from hepatitis A virus, such as inactivated virus [e.g. 62, 63].
- an antigen from hepatitis B virus, such as the surface and/or core antigens [e.g. 63, 64].
- an antigen from *Bordetella pertussis*, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B.pertussis*, optionally also in combination with pertactin and/or agglutinogens 2 and 3 [e.g. refs. 65 & 66].
- 25 – a diphtheria antigen, such as a diphtheria toxoid [e.g. chapter 3 of ref. 67] e.g. the CRM₁₉₇ mutant [e.g. 68].
- a tetanus antigen, such as a tetanus toxoid [e.g. chapter 4 of ref. 87].
- 30 – a saccharide antigen from *Haemophilus influenzae* B [e.g. 57].
- an antigen from hepatitis C virus [e.g. 69].
- an antigen from *N.gonorrhoeae* [e.g. 70, 71, 72, 73].
- an antigen from *Chlamydia pneumoniae* [e.g. refs. 74 to 80].
- an antigen from *Chlamydia trachomatis* [e.g. 81].
- 35 – an antigen from *Porphyromonas gingivalis* [e.g. 82].

- polio antigen(s) [e.g. 83, 84] such as IPV.
- rabies antigen(s) [e.g. 85] such as lyophilised inactivated virus [e.g. 86, RabAvert™].
- measles, mumps and/or rubella antigens [e.g. chapters 9, 10 & 11 of ref. 87].
- influenza antigen(s) [e.g. chapter 19 of ref. 87], such as the haemagglutinin and/or neuraminidase surface proteins.
- an antigen from *Moraxella catarrhalis* [e.g. 88].
- an protein antigen from *Streptococcus agalactiae* (group B streptococcus) [e.g. 89, 90].
- a saccharide antigen from *Streptococcus agalactiae* (group B streptococcus).
- an antigen from *Streptococcus pyogenes* (group A streptococcus) [e.g. 90, 91, 92].
- an antigen from *Staphylococcus aureus* [e.g. 93].
- an antigen from *Bacillus anthracis* [e.g. 94, 95, 96].
- an antigen from a virus in the flaviviridae family (genus flavivirus), such as from yellow fever virus, Japanese encephalitis virus, four serotypes of Dengue viruses, tick-borne encephalitis virus, West Nile virus.
- a pestivirus antigen, such as from classical porcine fever virus, bovine viral diarrhoea virus, and/or border disease virus.
- a parvovirus antigen e.g. from parvovirus B19.
- a prion protein (e.g. the CJD prion protein)
- an amyloid protein, such as a beta peptide [97]
- a cancer antigen, such as those listed in Table 1 of ref. 98 or in tables 3 & 4 of ref. 99.

The composition may comprise one or more of these further antigens.

Toxic protein antigens may be detoxified where necessary (e.g. detoxification of pertussis toxin by chemical and/or genetic means [66]).

Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. DTP combinations are thus preferred.

Saccharide antigens are preferably in the form of conjugates. Carrier proteins for the conjugates include the *N.meningitidis* outer membrane protein [100], synthetic peptides [101,102], heat shock proteins [103,104], pertussis proteins [105,106], protein D from *H.influenzae* [107], cytokines [108], lymphokines [108], streptococcal proteins, hormones [108], growth factors [108], toxin A or B from *C.difficile* [109], iron-uptake proteins [110], etc. A preferred carrier protein is the CRM197 diphtheria toxoid [111].

Antigens in the composition will typically be present at a concentration of at least 1 µg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

5 Immunogenic compositions of the invention may be used therapeutically (*i.e.* to treat an existing infection) or prophylactically (*i.e.* to prevent future infection).

As an alternative to using proteins antigens in the immunogenic compositions of the invention, nucleic acid (preferably DNA *e.g.* in the form of a plasmid) encoding the antigen may be used.

Medical methods etc.

10 The invention also provides nucleic acids or proteins or OMVs of the invention, or antibodies which bind to proteins of the invention, for use as medicaments (*e.g.* as vaccines). It also provides the use of nucleic acid or protein or OMVs according to the invention in the manufacture of a medicament (*e.g.* a vaccine or an immunogenic composition) for treating or preventing infection due to a *Neisseria*. This will generally be *N.meningitidis* but, due to inter-species cross-reactivity, it may also be *N.gonorrhoeae*.

15 The invention also provides a method of treating (*e.g.* immunising) a patient (*e.g.* a human), comprising administering to the patient a therapeutically effective amount of nucleic acid and/or protein and/or OMVs according to the invention.

20 The invention also provides a method of raising antibodies in an animal, comprising administering to the patient an immunologically effective amount of nucleic acid and/or protein and/or OMVs according to the invention.

25 The invention also provides a method of detecting *N.meningitidis* bacteria in a sample, comprising the steps of: (a) contacting an antibody (*e.g.* monoclonal or polyclonal) which binds to a protein of the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes. The method is particularly suitable for detecting intact bacteria because the proteins of the invention are present in the membrane. If the correct protein is used, it is also useful for distinguishing between *N.meningitidis* strains.

30 The invention also provides nucleic acids or proteins or OMVs of the invention, or antibodies which bind to proteins of the invention, for use as diagnostic reagents. It also provides the use of nucleic acid or protein or OMVs according to the invention, or antibodies which bind to proteins of the invention, in the manufacture of a reagent for diagnosing infection due to a *Neisseria*.

The invention also provides a method for investigating *N.meningitidis*, wherein the method includes a step of performing 2D electrophoresis on a membrane fraction from the bacterium.

Techniques

A summary of standard techniques and procedures which may be employed in order to perform the invention (e.g. to utilise the disclosed sequences for immunisation or diagnosis) follows. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.

General

- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature e.g. Sambrook *Molecular Cloning; A Laboratory Manual, Second Edition* (1989) and *Third Edition* (2001); *DNA Cloning, Volumes I and ii* (D.N Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed, 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Transcription and Translation* (B.D. Hames & S.J. Higgins eds. 1984); *Animal Cell Culture* (R.I. Freshney ed. 1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide to Molecular Cloning* (1984); the *Methods in Enzymology* series (Academic Press, Inc.), especially volumes 154 & 155; *Gene Transfer Vectors for Mammalian Cells* (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), *Immunochemical Methods in Cell and Molecular Biology* (Academic Press, London); Scopes, (1987) *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.), and *Handbook of Experimental Immunology, Volumes I-IV* (D.M. Weir and C. C. Blackwell eds 1986).
- Standard abbreviations for nucleotides and amino acids are used in this specification.

Definitions

- A composition containing X is "substantially free of" Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.
- The term "comprising" means "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional to X, such as X+Y.
- The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell. A further examples would be two epitopes from the same or different proteins which have been assembled in a single protein in an arrangement not found in nature.
- An "origin of replication" is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.

A "mutant" sequence is defined as DNA, RNA or amino acid sequence differing from but having sequence identity with the native or disclosed sequence. Depending on the particular sequence, the degree of sequence identity between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (e.g. 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the Smith-Waterman algorithm as described above).

5 As used herein, an "allelic variant" of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs essentially at the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic
10 variant can also comprise an alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions (e.g. see US patent 5,753,235).

Expression systems

The Neisserial nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, plants, bacteria, and yeast.

15 i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream
20 of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In *Molecular Cloning: A Laboratory Manual*, 2nd ed.].

25 Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or
30 regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal
35 RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) *Science* 236:1237; Alberts et al. (1989) *Molecular Biology of the Cell*, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) *EMBO J.* 4:761] and the
40 enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al.

(1982) *PNAS USA* 79:6777] and from human cytomegalovirus [Boshart et al. (1985) *Cell* 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) *Trends Genet.* 2:215; Maniatis et al. (1987) *Science* 236:1237].

5 A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

10 Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

15 Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) *Cell* 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) *Trends Biochem. Sci.* 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*].

25 Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) *Cell* 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) *Mol. Cell. Biol.* 9:946] and pHEBO [Shimizu et al. (1986) *Mol. Cell. Biol.* 6:1074].

40 The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of polynucleotide(s) in liposomes, direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g. Hep G2), and a number of other cell lines.

5 ii. Baculovirus Systems

10 The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site
15 for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

15 After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987)
20 (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its
25 owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

30 Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, *Virology* (1989) 17:31.

35 The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, 42:177) and a prokaryotic ampicillin-resistance (*amp*) gene and origin of replication for selection and propagation in *E. coli*.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region

which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

- 5 Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), *J. Gen. Virol.* 69:765.
- 10 DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) *Gene*, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-
- 15 insect origin, such as those derived from genes encoding human α -interferon, Maeda et al., (1985), *Nature* 315:592; human gastrin-releasing peptide, Lebacqz-Verheyden et al., (1988), *Molec. Cell. Biol.* 8:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA*, 82:8404; mouse IL-3, (Miyajima et al., (1987) *Gene* 58:273; and human glucocerebrosidase, Martin et al. (1988) *DNA*, 7:99, can also be used to provide for secretion in insects.
- 20 A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.
- 25 Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.
- 30 After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith
- 35 *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.* (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays* 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of
- 40 the polyhedrin promoter.

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between ~1% and ~5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15µm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers & Smith, *supra*; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and *Trichoplusia ni* (WO 89/046699; Carbonell et al., (1985) *J. Virol.* 56:153; Wright (1986) *Nature* 321:718; Smith et al., (1983) *Mol. Cell. Biol.* 3:2156; and see generally, Fraser, et al. (1989) *In Vitro Cell. Dev. Biol.* 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, e.g. Summers and Smith *supra*.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g. HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g. proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

iii. Plant Systems

There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to

the references described above in Vaulcombe et al., *Mol. Gen. Genet.* 209:33-40 (1987); Chandler et al., *Plant Molecular Biology* 3:407-418 (1984); Rogers, *J. Biol. Chem.* 260:3731-3738 (1985); Rothstein et al., *Gene* 55:353-356 (1987); Whittier et al., *Nucleic Acids Research* 15:2515-2535 (1987); Wirsal et al., *Molecular Microbiology* 3:3-14 (1989); Yu et al., *Gene* 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R.L. Jones and J. MacMillin, *Gibberellins*: in: *Advanced Plant Physiology*, Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, *Plant Cell*, 2:1027-1038(1990); Maas et al., *EMBO J.* 9:3447-3452 (1990); Benkel and Hickey, *Proc. Natl. Acad. Sci.* 84:1337-1339 (1987)

Typically, using techniques known in the art, a desired polynucleotide sequence is inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker; and, for *Agrobacterium* transformations, T DNA sequences for *Agrobacterium*-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable marker gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, *Plant Mol. Biol. Reprtr*, 11(2):165-185.

Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.

The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only one expression cassette, although two or more are feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region, plant 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5' and 3' ends of the cassette allow for easy insertion into a pre-existing vector.

A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed.

While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.

Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the "intron" region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, *Cell* 41:95-105, 1985.

The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, *Mol. Gen. Genet.*, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., *Nature*, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., *Nature*, 327, 70-73, 1987 and Knudsen and Muller, 1991, *Planta*, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley. Yet another method of introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79, 1859-1863, 1982.

The vector may also be introduced into the plant cells by electroporation. (Fromm et al., *Proc. Natl. Acad. Sci. USA* 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersion*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Hererocallis*, *Nemesia*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Lolium*, *Zea*, *Triticum*, *Sorghum*, and *Datura*.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected. Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.

iv. Bacterial Systems

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) [Raibaud *et al.* (1984) *Annu. Rev. Genet.* 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) [Chang *et al.* (1977) *Nature* 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) [Goeddel *et al.* (1980) *Nuc. Acids Res.* 8:4057; Yelverton *et al.* (1981) *Nucl. Acids Res.* 9:731; US patent 4,738,921; EP-A-0036776 and EP-A-0121775]. The *g*-laotamase (*bla*) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I. Gresser)], bacteriophage lambda PL [Shimatake *et al.* (1981) *Nature* 292:128] and T5 [US patent 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [US patent 4,551,433]. For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and *lac* operon sequences that is regulated by the *lac* repressor [Amann *et al.* (1983) *Gene* 25:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci.* 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier *et al.* (1986) *J. Mol. Biol.*

189:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci.* 82:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO-A-0 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine *et al.* (1975) *Nature* 254:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of *E. coli* 16S rRNA [Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook *et al.* (1989) "Expression of cloned genes in *Escherichia coli*." In *Molecular Cloning: A Laboratory Manual*].

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* or *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO-A-0 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai *et al.* (1984) *Nature* 309:810]. Fusion proteins can also be made with sequences from the *lacZ* [Jia *et al.* (1987) *Gene* 60:197], *trpE* [Allen *et al.* (1987) *J. Biotechnol.* 5:93; Makoff *et al.* (1989) *J. Gen. Microbiol.* 135:11], and *Chey* [EP-A-0 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated [Miller *et al.* (1989) *Bio/Technology* 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [US patent 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) [Masui *et al.* (1983), in: *Experimental Manipulation of Gene Expression*; Ghrayeb *et al.* (1984) *EMBO J.* 3:2437] and the *E. coli* alkaline phosphatase signal sequence (*phoA*) [Oka *et al.* (1985) *Proc. Natl. Acad. Sci.* 82:7212]. As an additional example, the signal sequence of the alpha-

amylase gene from various *Bacillus* strains can be used to secrete heterologous proteins from *B. subtilis* [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EP-A-0 244 042].

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EP-A- 0 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies *et al.* (1978) *Annu. Rev. Microbiol.* 32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: *Bacillus subtilis* [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541], *Escherichia coli* [Shimatake *et al.* (1981) *Nature* 292:128; Amann *et al.* (1985) *Gene* 40:183; Studier *et al.* (1986) *J. Mol. Biol.* 189:113; EP-A-0 036 776, EP-A-0 136 829 and EP-A-0 136 907], *Streptococcus cremoris* [Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655]; *Streptococcus lividans* [Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655], *Streptomyces lividans* [US patent 4,745,056].

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl_2 or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See e.g. [Masson *et al.* (1989) *FEMS Microbiol. Lett.* 60:273; Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541, *Bacillus*], [Miller *et al.* (1988) *Proc. Natl. Acad. Sci.* 85:856; Wang *et al.* (1990) *J. Bacteriol.* 172:949, *Campylobacter*], [Cohen *et al.* (1973) *Proc. Natl. Acad. Sci.* 69:2110; Dower *et al.* (1988) *Nucleic Acids Res.* 16:6127; Kushner (1978) "An improved method for transformation of *Escherichia coli* with ColE1-derived plasmids. In *Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering* (eds. H.W. Boyer and S. Nicosia); Mandel *et al.* (1970) *J. Mol. Biol.* 53:159; Taketo (1988) *Biochim. Biophys. Acta* 949:318; *Escherichia*], [Chassy *et al.* (1987) *FEMS Microbiol. Lett.* 44:173 *Lactobacillus*]; [Fiedler *et al.* (1988) *Anal. Biochem* 170:38, *Pseudomonas*]; [Augustin *et al.* (1990) *FEMS Microbiol. Lett.* 66:203, *Staphylococcus*], [Barany *et al.* (1980) *J. Bacteriol.* 144:698; Harlander (1987) "Transformation of *Streptococcus lactis* by electroporation, in: *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss III); Perry *et al.* (1981) *Infect. Immun.* 32:1295; Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655; Somkuti *et al.* (1987) *Proc. 4th Evr. Cong. Biotechnology* 1:412, *Streptococcus*].

v. Yeast Expression

Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EP-A-0 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO-A-0 329 203). The yeast *PHO5* gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (US Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the *ADH2*, *GAL4*, *GAL10*, OR *PHO5* genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EP-A-0 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, *inter alia*, [Cohen *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:1078;

Henikoff *et al.* (1981) *Nature* 283:835; Hollenberg *et al.* (1981) *Curr. Topics Microbiol. Immunol.* 96:119; Hollenberg *et al.* (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast *Saccharomyces cerevisiae*," in: *Plasmids of Medical, Environmental and Commercial Importance* (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon *et al.* (1980) *Gene* 11:163; Panthier *et al.* (1980) *Curr. Genet.* 2:109;].

5 A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

10 Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA
15 sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See *e.g.* EP-A-0 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (*e.g.* ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (*e.g.* WO88/024066).

20 Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

25 DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the genes for invertase (EP-A-0012873; JPO 62,096,086) and A-factor (US patent 4,588,684). Alternatively, leaders of non-yeast origin exist, such as an interferon leader, that also provide for secretion in yeast (EP-A-0060057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated
30 alpha-factor leaders (usually about 25 to about 50 amino acid residues) (US Patents 4,546,083 and 4,870,008; EP-A-0 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (*e.g.* see WO 89/02463.)

35 Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

40 Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression

constructs are often maintained in a replicon, such as an extrachromosomal element (e.g. plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein *et al.* (1979) *Gene* 8:17-24], pCI/1 [Brake *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:4642-4646], and YRp17 [Stinchcomb *et al.* (1982) *J. Mol. Biol.* 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See *e.g.* Brake *et al.*, *supra*.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver *et al.* (1983) *Methods in Enzymol.* 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as *ADE2*, *HIS4*, *LEU2*, *TRP1*, and *ALG7*, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of *CUP1* allows yeast to grow in the presence of copper ions [Butt *et al.* (1987) *Microbiol. Rev.* 51:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, *inter alia*, the following yeasts: *Candida albicans* [Kurtz, *et al.* (1986) *Mol. Cell. Biol.* 6:142], *Candida maltosa* [Kunze, *et al.* (1985) *J. Basic Microbiol.* 25:141], *Hansenula polymorpha* [Gleeson, *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302], *Kluyveromyces fragilis* [Das, *et al.* (1984) *J. Bacteriol.* 158:1165], *Kluyveromyces lactis* [De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:737; Van den Berg *et al.* (1990) *Bio/Technology* 8:135], *Pichia guilliermondii* [Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141], *Pichia pastoris* [Cregg, *et al.* (1985) *Mol. Cell. Biol.* 5:3376; US Patent Nos. 4,837,148 and 4,929,555], *Saccharomyces cerevisiae* [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J.*

Bacteriol. 153:163], *Schizosaccharomyces pombe* [Beach and Nurse (1981) *Nature* 300:706], and *Yarrowia lipolytica* [Davidow, *et al.* (1985) *Curr. Genet.* 10:380471 Gaillardin, *et al.* (1985) *Curr. Genet.* 10:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See *e.g.* [Kurtz *et al.* (1986) *Mol. Cell. Biol.* 6:142; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; *Candida*]; [Gleeson *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302; *Hansenula*]; [Das *et al.* (1984) *J. Bacteriol.* 158:1165; De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:1165; Van den Berg *et al.* (1990) *Bio/Technology* 8:135; *Kluyveromyces*]; [Cregg *et al.* (1985) *Mol. Cell. Biol.* 5:3376; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; US Patents 4,837,148 & 4,929,555; *Pichia*]; [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163 *Saccharomyces*]; [Beach & Nurse (1981) *Nature* 300:706; *Schizosaccharomyces*]; [Davidow *et al.* (1985) *Curr. Genet.* 10:39; Gaillardin *et al.* (1985) *Curr. Genet.* 10:49; *Yarrowia*].

Pharmaceutical Compositions

Pharmaceutical compositions can comprise polypeptides and/or nucleic acid of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of the clinician.

For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (*e.g.* see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Vaccines

Vaccines according to the invention may either be prophylactic (*ie.* to prevent infection) or therapeutic (*ie.* to treat disease after infection).

Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with "pharmaceutically acceptable carriers," which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, *etc.* pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, *etc.*; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO 90/14837; Chapter 10 in *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating

complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (*e.g.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, *etc.*), interferons (*e.g.* gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), *etc.*; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), *etc.*

The immunogenic compositions (*e.g.* the immunising antigen/immunogen/polypeptide/protein/ nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (*e.g.* nonhuman primate, primate, *etc.*), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

The immunogenic compositions are conventionally administered parenterally, *e.g.* by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (*e.g.* WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination may be employed [*e.g.* Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648; see later herein].

Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence *in vivo* can be either constitutive or regulated.

The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) *Cancer Gene Therapy* 1:51-64; Kimura (1994) *Human Gene Therapy* 5:845-852; Connelly (1995) *Human Gene Therapy* 6:185-193; and Kaplitt (1994) *Nature Genetics* 6:148-153.

These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US patent 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.

Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (e.g. HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) *J Virol* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC No. VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

The gene therapy vectors of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a sequence encoding a thymidine kinase polypeptide such as those disclosed in US 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar), pHSVlac described in Geller (1988) *Science* 241:1667-1669 and in WO90/09441 & WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) *Human Gene Therapy* 3:11-19 and HSV 7134, 2 RH 105 and GAL4 described in EP 0453242 (Breakefield), and those deposited with ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in US patents 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in US Serial No. 08/405,627, filed March 15, 1995, WO94/21792, WO92/10578, WO95/07994, US 5,091,309 and US 5,217,879 are employable. Such alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques.

Preferably, alphavirus vectors with reduced cytotoxicity are used (see USSN 08/679640).

DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.

5 Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, *Nature* 339 (1989) 385 and Sabin (1973) *J. Biol. Standardization* 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) *J Cell Biochem* L401; pox viruses such as canary pox virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) *Proc Natl Acad Sci* 86:317; Flexner (1989) *Ann NY Acad Sci* 569:86, Flexner
10 (1990) *Vaccine* 8:17; in US 4,603,112 and US 4,769,330 and WO89/01973; SV40 virus, for example ATCC VR-305 and those described in Mulligan (1979) *Nature* 277:108 and Madzak (1992) *J Gen Virol* 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in US 5,166,057 and in Enami (1990) *Proc Natl Acad Sci* 87:3802-3805; Enami & Palese (1991) *J Virol* 65:2711-2713 and Luytjes (1989) *Cell* 59:110, (see also McMichael (1983) *NEJ Med*
15 309:13, and Yap (1978) *Nature* 273:238 and *Nature* (1979) 277:108); human immunodeficiency virus as described in EP-0386882 and in Buchschacher (1992) *J. Virol.* 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah
20 virus, for example ATCC VR-369 and ATCC VR-1243; Kyuzlagach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Trinita virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) *Proc Soc Exp Biol Med* 121:190.

Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see US Serial No. 08/366,787, filed December 30, 1994 and Curiel (1992) *Hum Gene Ther* 3:147-154 ligand linked DNA, for example see Wu (1989) *J Biol Chem* 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see US Serial No.08/240,030, filed May 9, 1994, and US Serial No. 08/404,796, deposition of photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in US Patent 5,149,655, ionizing radiation
35 as described in US5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) *Mol Cell Biol* 14:2411-2418 and in Woffendin (1994) *Proc Natl Acad Sci* 91:1581-1585.

Particle mediated gene transfer may be employed, for example see US Serial No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level
40 expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described

in Wu & Wu (1987) *J. Biol. Chem.* 262:4429-4432, insulin as described in Hucked (1990) *Biochem Pharmacol* 40:253-263, galactose as described in Plank (1992) *Bioconjugate Chem* 3:533-539, lactose or transferrin.

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO90/11092 and US 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in US 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in USSN. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in US 5,149,655; use of ionizing radiation for activating transferred gene, as described in US 5,206,152 and WO92/11033

Exemplary liposome and polycationic gene delivery vehicles are those described in US 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697; and WO91/14445; in EP-0524968; and in Stryer, *Biochemistry*, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) *Biochem Biophys Acta* 600:1; Bayer (1979) *Biochem Biophys Acta* 550:464; Rivnay (1987) *Meth Enzymol* 149:119; Wang (1987) *Proc Natl Acad Sci* 84:7851; Plant (1989) *Anal Biochem* 176:420.

A polynucleotide composition can comprises therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

Delivery Methods

Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered *ex vivo*, to cells derived from the subject; or (3) *in vitro* for recombinant protein expression. The subjects to be treated can be mammals or birds. Also, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (e.g. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g. WO93/14778. Examples of cells useful in *ex vivo* applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells.

5 Generally, delivery of nucleic acids for both *ex vivo* and *in vitro* applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

Polynucleotide and polypeptide pharmaceutical compositions

10 In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide compositions.

A. Polypeptides

15 One example are polypeptides which include, without limitation: asioloorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin; interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.

B. Hormones, Vitamins, etc.

20 Other groups that can be included are, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.

C. Polyalkylenes, Polysaccharides, etc.

25 Also, polyalkylene glycol can be included with the desired polynucleotides/polypeptides. In a preferred embodiment, the polyalkylene glycol is polyethylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also, chitosan and poly(lactide-co-glycolide)

D. Lipids, and Liposomes

The desired polynucleotide/polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.

30 Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) *Biochim. Biophys. Acta.* 1097:1-17; Straubinger (1983) *Meth. Enzymol.* 101:512-527.

35 Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7416); mRNA (Malone (1989) *Proc. Natl.*

Acad. Sci. USA 86:6077-6081); and purified transcription factors (Debs (1990) *J. Biol. Chem.* 265:10189-10192), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY. (See, also, Felgner *supra*). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, *e.g.* Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See *e.g.* Straubinger (1983) *Meth. Immunol.* 101:512-527; Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198; Papahadjopoulos (1975) *Biochim. Biophys. Acta* 394:483; Wilson (1979) *Cell* 17:77; Deamer & Bangham (1976) *Biochim. Biophys. Acta* 443:629; Ostro (1977) *Biochem. Biophys. Res. Commun.* 76:836; Fraley (1979) *Proc. Natl. Acad. Sci. USA* 76:3348; Enoch & Strittmatter (1979) *Proc. Natl. Acad. Sci. USA* 76:145; Fraley (1980) *J. Biol. Chem.* (1980) 255:10431; Szoka & Papahadjopoulos (1978) *Proc. Natl. Acad. Sci. USA* 75:145; and Schaefer-Ridder (1982) *Science* 215:166.

E.Lipoproteins

In addition, lipoproteins can be included with the polynucleotide/polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, IDL, LDL, and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.

Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.

A lipoprotein can comprise more than one apoprotein. For example, naturally occurring chylomicrons comprises of A, B, C, & E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, & E apoproteins, LDL comprises apoprotein B; HDL comprises apoproteins A, C, & E.

The amino acid of these apoproteins are known and are described in, for example, Breslow (1985) *Annu Rev. Biochem* 54:699; Law (1986) *Adv. Exp Med. Biol.* 151:162; Chen (1986) *J Biol Chem* 261:12918; Kane (1980) *Proc Natl Acad Sci USA* 77:2465; and Utermann (1984) *Hum Genet* 65:232.

Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in *Meth. Enzymol.* 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.

Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in *Meth. Enzymol.* (*supra*); Pitas (1980) *J. Biochem.* 255:5454-5460 and Mahey (1979) *J Clin. Invest* 64:743-750. Lipoproteins can also be produced by *in vitro* or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) *Annu Rev Biophys Chem* 15:403 and Radding (1958) *Biochim Biophys Acta* 30: 443. Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Technologies, Inc., Stoughton, Massachusetts, USA. Further description of lipoproteins can be found in Zuckermann *et al.* WO98/06437.

F.Polycationic Agents

Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide/polypeptide to be delivered.

Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both *in vitro*, *ex vivo*, and *in vivo* applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.

The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as (X174, transcriptional factors also contain domains that bind DNA and therefore may be useful as nucleic acid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.

Organic polycationic agents include: spermine, spermidine, and putrescine.

The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.

Synthetic polycationic agents which are useful include, for example, DEAE-dextran, polybrene. Lipofectin™, and lipofectAMINE™ are monomers that form polycationic complexes when combined with polynucleotides/polypeptides.

Nucleic Acid Hybridisation

"Hybridization" refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support

(Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook *et al.* [*supra*] vol.2, chapt.9, pp.9.47 to 9.57.

“Stringency” refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200°C below the calculated T_m of the hybrid under study. The temperature and salt conditions can often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook *et al.* at page 9.50.

Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1 µg for a plasmid or phage digest to 10^{-9} to 10^{-8} g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides, substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 µg of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 10^8 cpm/µg. For a single-copy mammalian gene a conservative approach would start with 10 µg of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than 10^8 cpm/µg, resulting in an exposure time of ~24 hours.

Several factors can affect the melting temperature (T_m) of a DNA-DNA hybrid between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the hybridization buffer. The effects of all of these factors can be approximated by a single equation:

$$T_m = 81 + 16.6(\log_{10} C_i) + 0.4[\%(G + C)] - 0.6(\%\text{formamide}) - 600/n - 1.5(\%\text{mismatch}).$$

where C_i is the salt concentration (monovalent ions) and n is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) *Anal. Biochem.* 138: 267-284).

In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (*ie.* stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabelled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.

In general, convenient hybridization temperatures in the presence of 50% formamide are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly,

using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

Nucleic Acid Probe Assays

Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA. A probe is said to "hybridize" with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.

The nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells. mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding sequence.

The probe sequence need not be identical to the Neisserial sequence (or its complement) — some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected. Also, the nucleic acid probe can include additional nucleotides to stabilize the formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex. For example, a non-complementary nucleotide sequence may be attached to the 5' end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.

The exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like. For example, for diagnostic applications, depending on the complexity of the analyte sequence, the nucleic acid probe typically contains at least 10-20 nucleotides, preferably 15-25, and more preferably ≥ 30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.

Probes may be produced by synthetic procedures, such as the triester method of Matteucci *et al.* [*J. Am. Chem. Soc.* (1981) 103:3185], or according to Urdea *et al.* [*Proc. Natl. Acad. Sci. USA* (1983) 80: 7461], or using commercially available automated oligonucleotide synthesizers.

The chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated *e.g.* backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase *in vivo* half-life, alter RNA affinity, increase nuclease resistance *etc.* [*e.g.* see Agrawal & Iyer (1995) *Curr Opin Biotechnol* 6:12-19; Agrawal (1996) *TIBTECH* 14:376-387]; analogues such as peptide nucleic acids may also be used [*e.g.* see Corey (1997) *TIBTECH* 15:224-229; Buchardt *et al.* (1993) *TIBTECH* 11:384-386].

Alternatively, the polymerase chain reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in: Mullis *et al.* [*Meth. Enzymol.* (1987) 155: 335-350]; US patents 4,683,195 & 4,683,202. Two 'primers' hybridize with the target nucleic acids and are used to prime the reaction. The primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.

A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase, they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labelled probe will hybridize to the Neisserial sequence (or its complement).

Also, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook *et al* [*supra*]. mRNA, or cDNA generated from mRNA using a polymerase enzyme, can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labelled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labelled probe are detected. Typically, the probe is labelled with a radioactive moiety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the overall strategy for 2D-PAGE. The individual gels are shown as Figures 2 to 4. Figure 5 shows the results of a protein query of the NCBI Entrez system using the term 'NMB1506'.

MODES FOR CARRYING OUT THE INVENTION

The overall strategy for identifying membrane proteins was to use two dimensional electrophoresis to separate the proteins in a *N.meningitidis* membrane preparation, followed by identification of proteins found in the electrophoretic gel. This experiment was not straightforward because, as is well known, preparing a membrane fraction which is not contaminated with cytoplasmic proteins is extremely difficult.

Some of the proteins identified by electrophoresis were expected to be there, but many were not. Furthermore, several proteins which were annotated as "hypothetical" have now been shown to exist *in vivo* — they are not artefacts. A further point to note is that proteins visible on a 2D gel must be expressed at least at a moderate level, thus making them useful targets for binding.

Preparation of membrane fraction

To prepare the membrane fraction, *N.meningitidis* strain MC58 was growth in liquid "base for the isolation of pathogenic Neisseria" (GC, Difco), supplemented with 4g/l glucose, 0.1 g/l glutamine, and 2.2 mg/l cocarboxylase, at 37°C in a humidified atmosphere containing 5% CO₂. Bacteria were harvested at OD_{600nm}=0.5 by centrifugation at 10,000 g for 20 minutes. The pellet was resuspended with 10 ml Tris-base containing the EDTA-free protease inhibitor cocktail used according to the manufacturer (Roche Diagnostic Mannheim, Germany). The bacteria were inactivated 45 minutes at 56°C, cooled in ice in presence of 1,000 U benzonase, and were disrupted with a French Press at

18000 psi (4 passages). The lysate was centrifuged at 70,000 g overnight at 5°C. The pellet was washed twice with 40mM Tris-base and resuspended in 10 ml of 5M urea, 2M thiourea, 2% (w/v) CHAPS, 2% (w/v) ASB 14, 0.5% (v/v) C.A., 2mM TBP and centrifuged at 100,000 g at 10°C for 3 hours. Supernatant containing solubilised membrane proteins was aliquoted and stored at -80°C.

- 5 This process is quick, easy to use, and results in a membrane preparation with little or no contamination from cytosolic proteins [e.g. refs. 112 to 115]. It was improved by using new techniques for the solubilisation of bacterial membrane proteins prior and during to isoelectric focusing, in order to optimise the separation of outer membrane proteins by two-dimensional electrophoresis (2DE). Thiourea was thus used with the urea as chaotropic agents [112], the
10 zwitterionic detergent ASB-14 was used in association with CHAPS [116], and tributyl phosphine was added prior to 2DE [117].

2D electrophoresis

- 200µg of the membrane proteins were brought to a final volume of 125 µl with reswelling solution (7M urea, 2M thiourea, 2% (w/v) CHAPS, 2% (w/v) ASB 14, 2% (v/v) adequate ampholine
15 (Amersham Pharmacia Biotech (Piscataway, NJ), 2 mM thiobutyl phosphine). The proteins were absorbed overnight onto an Immobiline DryStrip (7 cm; pH-gradient 3-10 non linear, pH-gradient, 4-7 or 6-11 linear) using the Immobiline Dry-Strip Reswelling Tray (Amersham Pharmacia Biotech (Piscataway, NJ). Proteins were then separated by 2D electrophoresis. The first dimension was run on an IPGphor Isoelectric Focusing Unit (Amersham Pharmacia Biotech, Piscataway, NJ), The
20 proteins were separated applying sequentially 150 V for 35 min., 500 V for 35 min., 1000 V for 30 min, 2600 V for 10 min., 3500 V for 15 min., 4200 V for 15 min., and then 5000 V to reach 10kVh. For the second dimension, the strips were equilibrated as described in ref. 117 and the proteins were separated on a linear 9-16% acrylamide SDS-PAGE (1.5 mm thick, 6 cm high) using the Mini Proten II Cell from BioRad. The 2D gel was stained with colloidal Coomassie [118]. Gels were scanned
25 with a Personal densitometer SI (Molecular Dynamics) at 12 bits and 50 µm per pixel.

- The initial 2D IPG gradient gel is shown in Figure 2. 325 protein spots were visualised by colloidal Coomassie blue. In order to increase the spot number, 200µg of the same protein fraction was separated on 2D gels with a pH gradients of 4-7 (Figure 3) and 6-11 (Figure 4). 498 and 187 spots were visualised by colloidal Coomassie blue in these gels, respectively. Each gel was performed and
30 analysed in duplicate, with no major differences observed between duplicates.

Spot excision

A total of 1,867 protein spots were excised from the three gels, plus the duplicated gels, in-gel digested with trypsin, and the generated peptides were analysed by MALDI-TOF mass spectrometry. Proteins were identified by interpreting their peptide mass fingerprint using the software Mascot.

The protocol used for in-gel digestion was a modification of reference 119. Protein spots were excised from the gel, washed sequentially with Milli-Q water and acetonitrile (1/1, v/v), and dried by a Speed Vac vacuum centrifuge apparatus (Savant, Holbrook, NY). The pieces of gel were re-hydrated by adding 7-10 μ l of a solution of 50 mM ammonium bicarbonate, 5 mM CaCl_2 containing 12 mg/l trypsin sequencing grade (Roche Diagnostic Corporation, Indianapolis, IN). The tryptic digestion was allowed to run for 18 hours at 37°C. Following digestion, the peptides were extracted by sonication in a sonicator bath with 50 μ l 50% acetonitrile, 5% TFA for 30 min. The extraction was repeated, extract solutions were pooled together and the volume was reduced to 10 μ l in a Speed Vac vacuum centrifuge apparatus. The samples were automatically prepared for mass spectrometry using the MAP II (Bruker, Bremen, Germany). The instrument was programmed to perform a desalting of the sample with ZIP-TIP (C18, Millipore). The peptides were eluted from the ZIP TIP with a solution of 5 g/l of 2,5-dihydroxybenzoic acid in 50% acetonitrile/0,1% TFA and directly loaded onto the Anchorchip (400 μ m, Bruker, Bremen, Germany). The samples were allowed to air dry at room temperature.

15 *Excised spot analysis*

MALDI-TOF spectra were acquired on a Bruker Biflex II MALDI-TOF (Bremen, Germany) equipped with the SCOUT 381 multiprobe ion source in a positive-ion reflector mode. The acceleration voltage was set to 19 kV and the reflector voltage was set to 20 kV. Typically about 100 laser shots were average per spectrum from a 337 nm N₂ laser. Spectra were externally calibrated using a combination of angiotensin II (1,046.54 Da), substance P (1,347.74 Da), Bombensin (1,619.82 Da) and ACTH18-39 (Clip human, 2,465.20 Da). Peptides were selected in the mass range of 700-3000 Da. Resulting values for monoisotopic peaks were used for search using the software Mascot run on a database containing the genome information of *N.meningitidis* and *C.pneumoniae*. All the searches were performed using a window of 500 ppm as constraint, allowing one missed cleavage, and considering propionamide cysteines as fixed modification, and oxidized methionine as variable modification. Signals generated from keratin digestion or trypsin autolysis were not considered for the search in the database. Proteins were successfully identified when the MOWSE score was superior to 47. When proteins were identified with an inferior Mowse score, Post Source Decay (PSD) experiments were performed to confirm the identification. PSD spectra of the parent ions were built by pasting the spectra obtain with successive reflector voltage from 20 to 0.59 V.

Within the Figure 2 gel, 261/325 spots were identified by peptide mass fingerprint. When the same protein was identified in two or more samples from a train of spots clearly arising from isoforms of the same protein, the identification was extended to cover all spots in this row. When needed, the identification of the proteins were confirmed by PSD experiments, mainly for protein with a Mr inferior to 15 kDa. The remaining 64/325 spots contained too little protein material to give an unambiguous identification. The identified 261 spots were encoded by 138 separate genes, of which

11 were confirmed by PSD experiments. An additional 18 proteins were identified from the duplicated gel.

The Figure 3 gel allowed the identification of 194 unique proteins, of which 72 were not identified from the Figure 2 gel. Similarly, the Figure 4 gel allowed the identification of 87 unique proteins of which 26 were not identified from the Figure 2 gel.

The identified proteins are listed in Table 1, with columns indicating which gel they were found in. In summary, among the 1,867 proteins spots processed, 1,433 proteins were identified. The identified spots represent 250 unique proteins. Only 8.8% of the proteins were identified from the pH 6–11 gels which confirms the difficulty of separating very basic proteins by 2DE. The identified proteins cover 11.58% of the predicted ORFs encoded by the genome [1].

Within the 250 proteins, 45 acted as positive controls, as they had previously been identified as useful vaccine/diagnostic antigens in references 120 to 122. These 45 proteins are indicated with a '+' in Table 1. The remaining 205 proteins are listed as SEQ ID NO^s 1 to 205.

Within the remaining 205 proteins, 138 completely elude the PSORT subcellular localisation algorithm [123, 124]. These 138 are marked with a '**' in Table 1, and it is particularly surprising to find these proteins in the membrane. Of these 138, 76 elude various algorithmic predictions, and this subset is marked '**'.

OMV analysis

In a separate series of experiments, outer membrane vesicles from serogroup B strains 394/98 (New Zealand) and H44/76 (Norway) were proteomically analysed. Sera from humans immunised with one of the two OMV preparations were analysed, and nine specific immunogenic proteins were identified: NMB 0182, 0382, 0634, 0763, 1126, 1342, 1429, 1799 & 2039. Of these 9 proteins: NMB 0382, 0634, 0763, 1342, 1429 & 2039 are in common with SEQ IDs 1 to 205; NMB0182 is a known immunogen [125]; NMB1126 (gi:7226362; SEQ ID 206) is annotated as 'hypothetical protein', having been identified only through GLIMMER2 prediction, and was not previously recognised as an immunogen; NMB1799 (gi:7227052; SEQ ID 207) is annotated as 'S-adenosylmethionine synthetase', which is a metabolic enzyme which would not normally be expected to be immunoaccessible. SEQ IDs 208-217 were not previously recognised as immunogens.

Proteins which were present in the 394/98 OMVs, but not in the H44/76 OMVs, were: 0007, 0018, 0031, 0051, 0052, 0089, 0110, 0130, 0132, 0168, 0214, 0336, 0375, 0423, 0427, 0462, 0554, 0586, 0604, 0610, 0623, 0626, 0634, 0652, 0758, 0854, 0920, 0944, 0954, 0955, 0959, 0983, 1046, 1055, 1127, 1153, 1191, 1199, 1201, 1228, 1240, 1285, 1313, 1332, 1339, 1358, 1392, 1437, 1457, 1460, 1506, 1518, 1533, 1554, 1572, 1577, 1594, 1612, 1642, 1668, 1684, 1710, 1762, 1796, 1812, 1849, 1854, 1855, 1861, 1874, 1903, 1921, 1949, 1953, 2086, 2102, 2129, 2134, 2138, 2159.

Proteins which were present in the H44/76 OMVs, but not in the 394/98 OMVs, were: 0143, 0204, 0280, 0313, 0410, 0477, 0546, 0638, 0889, 1011, 1124, 1162, 1342, 1540, 1714, 1799, 1808, 1969, 1998, 2069, 2103, 2154.

Proteins which were present in both OMV preparations were: 0035, 0088, 0109, 0124, 0126, 0138, 0139, 0154, 0157, 0171, 0182, 0219, 0359, 0382, 0387, 0426, 0461, 0595, 0617, 0618, 0631, 0663, 0703, 0757, 0763, 0787, 0875, 0876, 0943, 0946, 0957, 1053, 1126, 1131, 1252, 1301, 1323, 1341, 1429, 1445, 1497, 1567, 1574, 1576, 1869, 1934, 1936, 1946, 1972, 1988, 2039, 2096, 2101.

- 5 It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

TABLE 1

	NMB	ID (gi:722xxxx): name / MW / pI	Gel (Fig.)			Note
			2	3	4	
1	0010	5235: phosphoglycerate kinase / 41902 / 5.12		X		
2	0018	5244: pilin PilE / 15 246 / 9.21	X		X	
3	0030	5249: methionyl-tRNA synthetase / 76 853 / 5.44		X		
4	0035	5255: conserved hypothetical protein / 40 218 / 4.74	X	X		+
5	0038	5258: UDP-N-acetylglucosamine pyrophosphorylase / 49 013 / 6.48	X		X	
6	0045	5266: signal recognition particle protein / 45 142 / 4.85		X		*
7	0051	5271: twitching motility protein / 45 675 / 6.51	X		X	*
8	0052	5272: twitching motility protein PilT / 38 050 / 6.61	X		X	**
9	0068	5288: polysialic acid capsule biosynthesis protein SiaC / 38821 / 5.35		X		*
10	0088	5306: outer membrane protein P1, putative / 45 902 / 9.35	X		X	+
11	0089	5307: pyruvate kinase II / 52 435 / 5.27	X	X		*
12	0109	5324: conserved hypothetical protein / 43 188 / 6.77	X		X	*
13	0115	5331: nitrogen assimilation regulatory protein NtrX / 46373 / 4.98	X			**
14	0124/0139	5341-5357: translation elongation factor TU / 42 909 – 42 925 / 5.07	X	X	X	**
15	0126	5343: transcription antitermination protein NusG / 20 550 / 6.03	X	X		**
16	0128	5345: 50S ribosomal protein L1 / 24 102 / 9.59	X	X	X	*
17	0130	5347: 50S ribosomal protein L10 / 17 594 / 7.91	X	X	X	**
18	0131	5348 : 50S ribosomal protein L7/L12 / 12623 / 4.60		X		
19	0132	5349: DNA-directed RNA polymerase, beta subunit / 155 945 / 5.34	X	X	X	
20	0133	5351: DNA-directed RNA polymerase, beta' subunit / 154660 / 6.86			X	*
21	0137	5355: 30S ribosomal protein S7 / 10646 / 10.33			X	*
22	0138	5356: elongation factor G (EF-G) / 77 244 / 5.08	X	X	X	**
23	0140	5358: 30S ribosomal protein S10 / 11799 / 7.57			X	**
24	0142	5360: 50S ribosomal protein L3 / 22664 / 10.03			X	**
25	0143	5361: 50S ribosomal protein L4 / 23248 / 9.92			X	**
26	0144	5362: 50S ribosomal protein L23 / 11268 / 9.85			X	
27	0154	5372: 50S ribosomal protein L5 / 20 323 / 9.49	X	X	X	**
28	0156	5374: 30S ribosomal protein S8 / 14257 / 9.73			X	*
29	0157	5375: 50S ribosomal protein L6 / 18 892 / 9.63		X	X	*
30	0159	5377: 30s ribosomal protein S5 / 18235 / 10.04			X	*
31	0168	5386: DNA-directed RNA polymerase, alpha subunit / 36 076 / 4.94	X	X	X	**
32	0171	5389: septum site-determining protein MinD / 29 559 / 5.70	X	X		**
33	0173	5391: transcriptional regulator, LysR family / 34 071 / 5.74	X	X		
34	0181	5400: outer membrane protein OmpH, putative / 19261 / 9.23		X		+
35	0182	5401: outer membrane protein Omp85 / 86 254 / 8.37	X		X	+
36	0191	5411. ParA family protein / 27 150 / 5.53	X			+
37	0193	5413: glucose inhibited division protein A / 69 808 / 6.57	X		X	*
38	0196	5417: ribonuclease E / 102087 / 5.97		X	X	*
39	0212	5433: DNA gyrase subunit B / 88 188 / 5.46	X	X		*

40	0214	5436: oligopeptidase A / 76 054 / 5.16	X	X		+
41	0219	5441: 3-oxoacyl-(acyl-carrier-protein) synthase II / 43 221 / 5.36		X		
42	0246	5468: NADH dehydrogenase I, F subunit / 48007 / 5.66		X		*
43	0278	5503: thiol:disulfide interchange protein DsbA / 23 228 / 5.16 / 18	X	X	X	+
44	0286	5510: conserved hypothetical protein / 22120 / 5.04		X		*
45	0292	5516: conserved hypothetical protein / 22080 / 5.37		X		+
46	0294	5518: thiol:disulfide interchange protein DsbA / 23 566 / 5.09 lipo	X	X	X	
47	0329	5549: type IV pilus assembly protein / 61 965 / 5.42	X	X		*
48	0335	5555: 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase / 29 410 / 5.42	X	X		**
49	0336	5556: enoyl-(acyl-carrier-protein) reductase / 25 252 / 5.45 / 22		X		
50	0337	5557: branched-chain amino acid aminotransferase, putative / 36421 / 5.80		X		
51	0345	5566: cell-binding factor, putative / 31507 / 9.23			X	+
52	0351	5572: transaldolase / 37 578 / 5.09		X		**
53	0359	5581: glutamate--ammonia ligase / 52137 / 5.20	X	X	X	*
54	0382	5603: outer membrane protein class 4 / 23 969 / 6.26	X	X	X	
55	0387	5608:ABC transporter, ATP-binding protein / 62 073 / 5.23		X	X	+
56	0390	5612: maltose phosphorylase / 85 490 / 5.36	X	X		*
57	0391	5613: beta-phosphoglucomutase / 23728 / 5.08		X		
58	0426	5649: cell division protein FtsA / 44 061 / 5.33	X	X		
59	0427	5651: cell division protein FtsZ / 41 487 / 4.94	X			
60	0446	5671: chorismate mutase/prephenate dehydratase / 39778 / 5.65		X		
61	0462	5689: spermidine/putrescine ABC transporter, periplasmic ... / 50 556 / 6.92	X	X		
62	0466	5693: aspartyl-tRNA synthetase / 68 125 / 5.28	X	X	X	**
63	0477	5705: conserved hypothetical protein / 19758 / 5.19		X		**
64	0530	5755: glycosyl hydrolase, family 3 / 39554 / 5.39		X		**
65	0537	5762: conserved hypothetical protein / 31 150 / 4.77		X		+
66	0540	5765: aspartate aminotransferase / 43 929 / 6.52	X	X	X	**
67	0546	5772: alcohol dehydrogenase, propanol-preferring / 36 548 / 5.65	X	X		*
68	0550	5777: thiol:disulfide interchange protein DsbC / 26 451 / 6.93	X			+
69	0554	5780: dnaK protein / 68 792 / 4.85	X	X	X	+
70	0564	5791: Na(+)-translocating NADH-quinone reductase, subunit F / 42 303 / 4.95	X	X		
71	0569	5796: Na(+)-translocating NADH-quinone reductase, subunit A / 48 636 / 6.20	X	X	X	+
72	0589	5819: 50s ribosomal protein L19 / 13760 / 10.45			X	**
73	0595	5825: DNA-binding response regulator / 24 780 / 5.44	X	X		**
74	0604	5834: alcohol dehydrogenase, zinc-containing / 38394 / 5.47		X		
75	0610	5840: spermidine/putrescine ABC transporter, ATP-binding protein / 47 425 / 6.03	X	X		*
76	0617	5847: transcription termination factor Rho / 47 306 / 6.23	X		X	**
77	0618	5848:phosphoenolpyruvate synthase / 87 170 / 5.01	X	X	X	**
78	0623	5854: spermidine/putrescine ABC transporter, periplasmic ... / 39 511 / 5.38	X	X		
79	0626	5856: peptide chain release factor 3 / 59 589 / 5.43		X		+
80	0631	5861: phosphate acetyltransferase Pta, putative / 50306 / 4.83	X	X		
81	0634	5862: iron(III) ABC transporter, periplasmic binding protein / 35806 / 9.60			X	
82	0637	5866: argininosuccinate lyase / 51 245 / 5.22	X	X		**

83	0641	5870: inorganic pyrophosphatase / 19 812 / 4.71		X		**
84	0663	5888: outer membrane protein NsgA / 18386 / 9.64			X	
85	0667	5893: hypothetical protein / 45 292 / 5.97 / 16	X	X		+
86	0697	5925: dimethyladenosine transferase / 29269 / 7.11			X	**
87	0703	5932 : competence lipoprotein ComL / 29 273 / 8.72	X		X	
88	0711	5938: conserved hypothetical protein / 33516 / 6.11		X		**
89	0720	5946: threonyl-tRNA synthetase / 72 692 / 5.86	X	X		*
90	0724	5951: phenylalanyl-tRNA synthetase, alpha chain / 37 334 / 5.46	X	X	X	**
91	0728	5955: phenylalanyl-tRNA synthetase, beta chain / 86 050 / 5.19	X	X		*
92	0743	5972: ubiquinone/menaquinone biosynthesis methyltransferase UbiE / 27 366 / 7.14	X		X	**
93	0757	5987: phosphoribosylaminoimidazole-succinocarboxamide synthase / 32476 / 5.26		X		**
94	0758	5988: polyribonucleotide nucleotidyltransferase / 76 422 / 5.35	X	X	X	
95	0763	5993: cysteine synthase / 32 821 / 6.06	X	X		*
96	0768	5999: twitching motility protein PilT / 41 508 / 7.64	X	X	X	+
97	0778	6009: uroporphyrin-III C-methyltransferase HemX, putative / 46 320 / 5.33	X	X		
98	0787	6019: amino acid ABC transporter, periplasmic amino acid-binding protein / 26 995 / 5.42	X	X		+
99	0791	6024 : peptidyl-prolyl cis-trans isomerase / 181853 / 5.05		X		**
100	0798	6031: cell division protein FtsH / 70 058 / 5.07 / 20	X			+
101	0801	6034: delta-aminolevulinic acid dehydratase / 36878 / 5.23		X		+
102	0804	6038: NAD(P)H nitroreductase, putative / 24687 / 6.17		X		*
103	0814	6048: histidyl-tRNA synthetase / 41 746 / 5.45	X	X		**
104	0815	6050: adenylosuccinate synthetase / 46 250 / 5.77	X	X	X	*
105	0828	6063: ADP-L-glycero-D-mannoheptose-6-epimerase / 38 437 / 5.68	X	X		
106	0853	6089: conserved hypothetical protein / 23 136 / 5.67		X		+
107	0854	6090: histidyl-tRNA synthetase / 48 465 / 5.57	X	X		**
108	0875	6113: ribose-phosphate pyrophosphokinase / 35 598 / 5.41	X	X		**
109	0876	6114: 50S ribosomal protein L25 / 20 956 / 6.60	X	X	X	*
110	0878	6116: threonine dehydratase / 55585 / 5.41		X		
111	0884	6122: superoxide dismutase / 21 893 / 5.78	X	X		*
112	0885	6124: replicative DNA helicase / 52 089 / 5.04	X	X		**
113	0889	6127: hypothetical protein / 21970 / 6.40		X		+
114	0894	6131: aminotransferase, class I / 44 013 / 5.79		X		**
115	0920	6158 : isocitrate dehydrogenase / 80163 / 5.57	X	X	X	*
116	0928	6166: hypothetical protein / 43 815 / 9.01	X			+
117	0944	6182 : 5-methyltetrahydropteroyltriglutamate-homocysteine methyltransferase / 85 078 / 5.27	X	X		
118	0946	6184: peroxiredoxin 2 family protein/glutaredoxin / 26 912 / 4.80	X	X		*
119	0947	6186 : lipoamide dehydrogenase, putative / 44527 / 5.66	X	X		
120	0950	6189: succinate dehydrogenase, flavoprotein subunit / 66 787 / 5.84	X	X		+
121	0955	6194: 2-oxoglutarate dehydrogenase, E1 component / 105 082 / 6.24	X	X	X	
122	0956	6195: 2-oxoglutarate dehydrogenase, E2, dihydrolipoamide succinyltransferase / 41491 / 5.14		X		
123	0959	6199: succinyl-CoA synthetase, beta subunit / 41666 / 5.06		X		
124	0960	6200: succinyl-CoA synthetase, alpha subunit / 30 548 / 6.00	X	X		
125	0983	6223 : phosphoribosylaminoimidazolecarboxamide formyltransferase ... / 56 803 / 5.90		X		

126	0997	6237: D-lactate dehydrogenase / 64001 / 6.32			X	
127	1031	6270 : 3-isopropylmalate dehydrogenase / 39172 / 4.91		X		**
128	1044	6284: ferredoxin--NADP reductase / 29 314 / 5.72	X	X		*
129	1046	6286: threonine synthase / 51870 / 5.31		X		*
130	1053	6294: class 5 outer membrane protein / 28 009 / 9.68 / 20	X	X	X	
131	1057	6297: gamma-glutamyltranspeptidase / 65 071 / 5.99	X	X		+
132	1070	6309: 2-isopropylmalate synthase / 55 397 / 5.68		X		**
133	1073	6313: conserved hypothetical protein / 42 032 / 4.60		X		**
134	1127	6364: oxidoreductase, short chain dehydrogenase/reductase family / 25 917 / 5.99	X	X		**
135	1131	6368: chaperone protein HscA / 66166 / 5.18		X		**
136	1150	6387: dihydroxy-acid dehydratase / 64 503 / 5.89	X	X		*
137	1164/1126	6400-6362: hypothetical protein / 22 025 / 8.03 (duplicated gene)	X		X	+
138	1199	6435: GTP binding protein / 67 260 / 5.04	X	X		+
139	1201	6438: IMP dehydrogenase / 53 383 / 6.72	X			*
140	1206	6443: bacterioferritin B / 18075 / 4.60		X		**
141	1228	6467: homoserine dehydrogenase / 44 737 / 5.254 / 20	X	X		
142	1231	6470: ATP-dependent protease La / 90590 / 6.18		X	X	*
143	1238	6478: peptidyl-prolyl cis-trans isomerase-related protein / 53213 / 5.68	X	X		+
144	1240	6480: ABC transporter, ATP-binding protein / 60 779 / 5.09	X	X		**
145	1252	6492: phosphoribosylformylglycinamide cyclo-ligase / 36 974 / 4.71	X			**
146	1285	6525: enolase / 46 134 / 4.78	X	X		+
147	1301	6541: 30S ribosomal protein / 61 177 / 4.9	X	X	X	*
148	1302	6542: integration host factor, beta subunit / 11796 / 9.98			X	**
149	1313	6554: trigger factor / 48 325 / 4.72	X	X		**
150	1320	6562: 50S ribosomal protein L9 / 15 747 / 6.62	X	X	X	
151	1323	6565: 30S ribosomal protein S6 / 13 949 / 6.37	X	X	X	**
152	1324	6566: thioredoxin reductase / 33961 / 5.16		X		
153	1328	6571: conserved hypothetical protein / 27021 / 6.41			X	*
154	1339	6583:prolyl-tRNA synthetase / 62 992 / 5.09	X	X	X	**
155	1341	6585:pyruvate dehydrogenase, E1 component / 99 562 / 5.5	X	X	X	**
156	1342	6586 : pyruvate dehydrogenase, E2, dihydrolipoamide acetyltransferase / 55 223 / 5.29	X	X		*
157	1343	6587: hypothetical protein / 16 339 / 4.99	X			**
158	1344	6588: pyruvate dehydrogenase, E3 component, lipoamide dehydrogenase / 62358 / 5.07		X		
159	1345	6590: hypothetical protein / 57 143 / 5.13		X		+
160	1347	6591: extragenic suppressor protein SuhB / 28 469 / 5.82	X	X		*
161	1356	6601: Glu-tRNA(Gln)amidotransferase, subunit A / 51 280 / 5.44	X			*
162	1358	6603: Glu-tRNA(Gln) amidotransferase, subunit B / 51 912 / 5.05	X	X		**
163	1372	6618:ATP-dependent Clp protease, ATP-binding subunit ClpX / 45 100 / 5.18		X		*
164	1379	7413462: nifS protein / 44832 / 5.62		X		**
165	1390	6628: glucokinase / 34 951 / 8.59	X		X	
166	1392	6630: glucose-6-phosphate 1-dehydrogenase / 54124 / 5.30	X	X	X	**
167	1425	6664: lysyl-tRNA synthetase, heat inducible / 57312 / 5.34	X	X		**
168	1429	6669: outer membrane protein PorA / 40 129 / 8.73	X	X	X	

169	1445	6686: recA protein / 37 612 / 5.18		X		*
170	1452	6693: conserved hypothetical protein / 40 598 / 8.33	X			*
171	1457	6698: transketolase / 71 659 / 5.45	X	X	X	*
172	1471	6711: tryptophanyl-tRNA synthetase / 37 616 / 5.65	X	X		*
173	1472	6713: clpB protein / 95 195 / 5.41		X		**
174	1483	6723: lipoprotein NlpD, putative / 42991 / 9.55			X	+
175	1506	6749: arginyl-tRNA synthetase / 62 803 / 5.24		X		
176	1518	6762: acetate kinase / 42 410 / 5.76	X	X		
177	1533	6778: H.8 outer membrane protein / 16 886 / 4.61 / 17	X	X		
178	1536	6781: preprotein translocase SecA subunit / 103 295 / 5.05	X	X		*
179	1560	6807: glutamyl-tRNA synthetase / 64 650 / 57.74	X	X		**
180	1567	6815: macrophage infectivity potentiator / 26 875 / 5.50	X	X		+
181	1572	6819: aconitate hydratase 2 / 92 716 7 5.42	X	X		
182	1574	6822: ketol-acid reductoisomerase / 36 439 / 5.65	X	X		**
183	1577	6825: acetolactate synthase III, large subunit / 62 813 / 5.88	X	X		
184	1581	6829: histidinol dehydrogenase / 46324 / 5.07	X	X		
185	1583	6831: imidazoleglycerol-phosphate dehydratase / 34002 / 8.61			X	**
186	1584	6833: 3-hydroxyacid dehydrogenase / 30 378 / 5.33		X		+
187	1594	6843: spermidine/putrescine ABC transporter, periplasmic ... / 40 234 / 5.52	X	X		+
188	1595	6845: alanyl-tRNA synthetase / 96 038 / 5.54	X		X	**
189	1604	6853: phosphoglycerate mutase / 25 959 / 5.59	X	X		**
190	1612	6862 : amino acid ABC transporter, periplasmic amino acid-binding protein / 27 68 / 4.87	X	X		+
191	1613	6863: fumarate hydratase, class I / 54 951 / 5.12	X	X		+
192	1621	6872: glutathione peroxidase / 20129 / 5.18		X		**
193	1636	gi 7443356 opacity protein, authentic frameshift / 27180 / 9.52			X	
194	1640	6890: phosphoserine aminotransferase / 41651 / 5.20		X		*
195	1642	6892: N utilization substance protein A / 55 752 / 4.54	X	X		**
196	1655	6907: adenine specific methylase, putative / 33 956 / 4.36	X			*
197	1684	6938: seryl-tRNA synthetase / 47 883 / 5.60	X			**
198	1691	6945: dihydropteroate synthase / 30 313 / 5.30		X		
199	1710	6965: glutamate dehydrogenase, NADP-specific / 48 490 / 5.98	X	X		**
200	1714	6969. multidrug efflux pump channel protein / 48 482 / 8.38 / lipo	X		X	+
201	1716	6971: membrane fusion protein / 40 209 / 8.60	X		X	
202	1796	7050: conserved hypothetical protein/ 20 931 / 5.73	X	X		
203	1809	----: putative; pilN protein, authentic frameshift / 22 258 / 9.00	X			
204	1810	7063: pilO protein / 19 870 / 4.74		X		
205	1811	7064: pilP protein / 20126 / 4.94		X		
206	1812	----.putative, pilQ protein, authentic frameshift / 83 151 / 10.75 / 25	X	X	X	
207	1835	7090: tyrosyl-tRNA synthetase / 47437 / 5.76		X		*
208	1838	7093: GTP-binding protein, putative / 39 376 / 4.80	X	X		**
209	1839	7094: formate-tetrahydrofolate ligase / 59063 / 5.85	X	X		+
210	1843	7099: transcriptional regulator, MarR family / 16 583 / 5.15		X		**
211	1849	7105: carbamoyl-phosphate synthase, small subunit / 40 587 / 5.54	X	X		

212	1854	7110: hypothetical protein / 25 131 / 8.95	X		X	**
213	1855	7111: carbamoyl-phosphate synthase, large subunit / 117 377 / 5.10	X	X		
214	1856	7112: transcriptional regulator, LysR family / 33367 / 5.55		X		+
215	1859	7116: S-adenosylmethionine:tRNA ribosyltransferase-isomerase / 38216 / 6.20		X		*
216	1861	7118: acetyl-CoA carboxylase, biotin carboxylase / 49 599 / 5.88	X	X	X	**
217	1862	7119: ribosomal protein L11 methyltransferase / 32144 / 4.36		X		
218	1864	7121: glutamate-1-semialdehyde 2,1-aminomutase / 45 315 / 5.33		X		*
219	1869	7127: fructose-bisphosphate aldolase / 38 337 / 5.48	X	X	X	+
220	1870	7128: hypothetical protein / 26 964 / 7.23	X		X	+
221	1903	7160: chromosomal replication initiator protein DnaA / 58 029 / 5.93		X		**
222	1920	7178: GMP synthase / 57686 / 5.53	X	X		
223	1921	7179: 3-oxoacyl-(acyl-carrier-protein) reductase / 26 068 / 5.95	X	X	X	*
224	1930	7187: glycyl-tRNA synthetase, beta chain / 74 574 / 5.86	X	X		
225	1934	7192: ATP synthase F1, beta subunit / 50 391 / 5.01	X	X	X	
226	1936	7194: ATP synthase F1, alpha subunit / 55 291 / 5.43	X	X	X	*
227	1937	7195: ATP synthase F1, delta subunit / 19 526 / 5.02		X		**
228	1938	7196: ATP synthase F0, B subunit / 17128 / 5.64		X		
229	1946	7205: outer membrane lipoprotein / 29 258 / 5.01	X	X	X	+
230	1953	7212: stringent starvation protein A / 23 165 / 6.23	X	X	X	**
231	1966	7226 :ABC transporter, ATP-binding protein / 29 286 / 5.58		X		*
232	1968	7228: aldehyde dehydrogenase A / 52257 / 5.20	X	X		
233	1972	7233: chaperonin, 60 kDa / 57 423 / 4.9	X	X	X	+
234	1982	7243: DNA polymerase I / 103 184 / 5.21		X		*
235	1996	7259: phosphoribosylformylglycinamide synthase / 143 854 / 5.31	X	X		*
236	2000	7264: conserved hypothetical protein / 33468 / 4.77		X		**
237	2039	7300 : major outer membrane protein PIB / 33 786 / 6.54	X	X	X	
238	2057	7319: 50S ribosomal protein L13 / 16212 / 9.72			X	**
239	2079	7341: aspartate-semialdehyde dehydrogenase / 39 858 / 5.40		X		*
240	2086	7348: GTP-binding protein / 41 930 / 5.52		X		*
241	2091	7353: hemolysin, putative / 21804 / 9.81			X	+
242	2096	7359: malate:quinone oxidoreductase / 53 9687 / 5.51	X	X		+
243	2101	7364: 30S ribosomal protein S2 / 26 899 / 9.04	X			**
244	2102	7365: elongation factor TS (EF-TS) / 30 330 / 5.30	X	X		**
245	2103	7366: uridylate kinase / 25896 / 6.17			X	*
246	2129	7385: argininosuccinate synthase / 49 664 / 5.18	X	X		*
247	2138	7395: peptide chain release factor 2 / 41 487 / 5.18	X			**
248	2154	7412: electron transfer flavoprotein, alpha subunit / 32 579 / 4.99		X		*
249	2155	7413: electron transfer flavoprotein, beta subunit / 26 948 / 6.08	X	X	X	**
250	2159	7417: glyceraldehyde 3-phosphate dehydrogenase / 35 845 / 5.40	X	X		*
TOTALS 7			156	194	87	

REFERENCES (the contents of which are hereby incorporated in full)

- [1] Tettelin *et al.* (2000) *Science* 287:1809-1815.
- [2] Pizza *et al.* (2000) *Science* 287:1816-1820.
- [3] Parkhill *et al.* (2000) *Nature* 404:502-506.
- [4] Cole (2002) *Eur Respir J Suppl.* 36:78s-86s.
- [5] McClelland *et al.* (2001) *Nature* 413:852-856.
- [6] De Groot *et al.* (2000) *Vaccine* 19:4385-4395.
- [7] Stephens (2000) *J Infect Dis* 181 Suppl 3:S521-523.
- [8] Tettelin *et al.* (2001) *Science* 293:498-506.
- [9] Weinstock *et al.* (2000) *Res Microbiol* 151:151-158.
- [10] Wizemann *et al.* (2001) *Infect Immun* 69:1593-1598.
- [11] Grifantini *et al.* (2002) *Nat Biotechnol.* 20:914-921.
- [12] <http://www.ncbi.nlm.nih.gov/entrez>
- [13] WO01/64922.
- [14] WO01/64920.
- [15] WO03/020756.
- [16] Bjune *et al.* (1991) *Lancet* 338(8775):1093-1096.
- [17] International patent application WO00/25811.
- [18] International patent application WO01/52885.
- [19] de Kleijn *et al.* (2001) *Vaccine* 20:352-358.
- [20] US patent 5597572.
- [21] US patent 5747653.
- [22] European patent application 0680512.
- [23] International patent application WO01/09350.
- [24] International patent application WO02/09746.
- [25] European patent 0449958
- [26] International patent application WO01/91788.
- [27] Gennaro (2000) *Remington: The Science and Practice of Pharmacy*. 20th edition, ISBN: 0683306472.
- [28] *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995 (ISBN 0-306-44867-X).
- [29] WO90/14837.
- [30] WO02/26212.
- [31] WO98/33487.
- [32] WO00/07621.
- [33] WO99/27960.
- [34] WO98/57659.
- [35] European patent applications 0835318, 0735898 and 0761231.
- [36] Krieg (2000) *Vaccine* 19:618-622; Krieg (2001) *Curr opin Mol Ther* 2001 3:15-24; WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581 *etc.*
- [37] WO99/52549.
- [38] WO01/21207.
- [39] WO01/21152.
- [40] WO00/62800.
- [41] WO00/23105.

-
- [42] WO99/11241.
 - [43] Del Giudice *et al.* (1998) *Molecular Aspects of Medicine*, vol. 19, number 1.
 - [44] *Vaccine Design...* (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
 - [45] Johnson *et al.* (1999) *Bioorg Med Chem Lett* 9:2273-2278.
 - [46] Covacci & Rappuoli (2000) *J. Exp. Med.* 19:587-592.
 - [47] WO93/18150.
 - [48] Covacci *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 5791-5795.
 - [49] Tummuru *et al.* (1994) *Infect. Immun.* 61:1799-1809.
 - [50] Marchetti *et al.* (1998) *Vaccine* 16:33-37.
 - [51] Telford *et al.* (1994) *J. Exp. Med.* 179:1653-1658.
 - [52] Evans *et al.* (1995) *Gene* 153:123-127.
 - [53] WO96/01272 & WO96/01273, especially SEQ ID NO:6.
 - [54] WO97/25429.
 - [55] WO98/04702.
 - [56] Costantino *et al.* (1992) *Vaccine* 10:691-698.
 - [57] Costantino *et al.* (1999) *Vaccine* 17:1251-1263.
 - [58] International patent application WO03/007985.
 - [59] Watson (2000) *Pediatr Infect Dis J* 19:331-332.
 - [60] Rubin (2000) *Pediatr Clin North Am* 47:269-285, v.
 - [61] Jedrzejewski (2001) *Microbiol Mol Biol Rev* 65:187-207.
 - [62] Bell (2000) *Pediatr Infect Dis J* 19:1187-1188.
 - [63] Iwarson (1995) *APMIS* 103:321-326.
 - [64] Gerlich *et al.* (1990) *Vaccine* 8 Suppl:S63-68 & 79-80.
 - [65] Gustafsson *et al.* (1996) *N. Engl. J. Med.* 334:349-355.
 - [66] Rappuoli *et al.* (1991) *TIBTECH* 9:232-238.
 - [67] *Vaccines* (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.
 - [68] Del Giudice *et al.* (1998) *Molecular Aspects of Medicine* 19:1-70.
 - [69] Hsu *et al.* (1999) *Clin Liver Dis* 3:901-915.
 - [70] International patent application WO99/24578.
 - [71] International patent application WO99/36544.
 - [72] International patent application WO99/57280.
 - [73] International patent application WO02/079243.
 - [74] International patent application WO02/02606.
 - [75] Kalman *et al.* (1999) *Nature Genetics* 21:385-389.
 - [76] Read *et al.* (2000) *Nucleic Acids Res* 28:1397-406.
 - [77] Shirai *et al.* (2000) *J. Infect. Dis.* 181(Suppl 3):S524-S527.
 - [78] International patent application WO99/27105.
 - [79] International patent application WO00/27994.
 - [80] International patent application WO00/37494.
 - [81] International patent application WO99/28475.
 - [82] Ross *et al.* (2001) *Vaccine* 19:4135-4142.
 - [83] Sutter *et al.* (2000) *Pediatr Clin North Am* 47:287-308.
 - [84] Zimmerman & Spann (1999) *Am Fam Physician* 59:113-118, 125-126.
 - [85] Dreesen (1997) *Vaccine* 15 Suppl:S2-6.

-
- [86] *MMWR Morb Mortal Wkly Rep* 1998 Jan 16;47(1):12, 19.
 - [87] *Vaccines* (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.
 - [88] McMichael (2000) *Vaccine* 19 Suppl 1:S101-107.
 - [89] Schuchat (1999) *Lancet* 353(9146):51-6.
 - [90] International patent application WO02/34771.
 - [91] Dale (1999) *Infect Dis Clin North Am* 13:227-43, viii.
 - [92] Ferretti *et al.* (2001) *PNAS USA* 98: 4658-4663.
 - [93] Kuroda *et al.* (2001) *Lancet* 357(9264):1225-1240; see also pages 1218-1219.
 - [94] *J Toxicol Clin Toxicol* (2001) 39:85-100.
 - [95] Demicheli *et al.* (1998) *Vaccine* 16:880-884.
 - [96] Stepanov *et al.* (1996) *J Biotechnol* 44:155-160.
 - [97] Ingram (2001) *Trends Neurosci* 24:305-307.
 - [98] Rosenberg (2001) *Nature* 411:380-384.
 - [99] Moingeon (2001) *Vaccine* 19:1305-1326.
 - [100] EP-A-0372501
 - [101] EP-A-0378881
 - [102] EP-A-0427347
 - [103] WO93/17712
 - [104] WO94/03208
 - [105] WO98/58668
 - [106] EP-A-0471177
 - [107] WO00/56360
 - [108] WO91/01146
 - [109] WO00/61761
 - [110] WO01/72337
 - [111] *Research Disclosure*, 453077 (Jan 2002)
 - [112] Molloy *et al.* (2000) *Eur J Biochem* 267(10):2871-81
 - [113] Molloy *et al.* (2001) *Electrophoresis* 22(9):1686-96
 - [114] Phadke *et al.* (2001) *Proteomics* 1(5):705-20.
 - [115] Nouwens *et al.* (2000) *Electrophoresis* 21(17):3797-809.
 - [116] Chevallet *et al.* (1998) *Electrophoresis* 19(11):1901-9.
 - [117] Herbert *et al.* (1998) *Electrophoresis* 19(5):845-51.
 - [118] Doherty *et al.* (1998) *Electrophoresis* 19(2):355-63.
 - [119] Wilm *et al.* (1996) *Nature* 379(6564):466-9.
 - [120] WO99/24578.
 - [121] WO99/36544.
 - [122] WO99/57280.
 - [123] Nakai & Kanehisa *Proteins* 11(2):95-110
 - [124] Nakai (2000) *Adv Protein Chem* 54:277-344.
 - [125] WO01/38350

SEQUENCE LISTING

SEQ ID	NMB	Sequence
1	0010	MAFLKLTQENVQGKTVLIRADMNVPFKDGKISDDTRIRASLASIKYCVDN GASVIVMTHLGRPTEGEFHPEDDVAP VAHLGSLGKDVKVLNDWRENKPALNAGDVMVLQNVIRINKGEKKNDLELGKAYASLCDVFVNDAFGTAHRAQAST EAVAQAAPVACAGVLMAGELDALGKALKQPARPMVAIVAGSKVSTKLTILESLADKVDQLIVGGGIANTFLLAEGK AIGKSLAEDHDLVEESKKIMAKMAAGGSVPLPTD VVVAKAFAADAEAVVKDIAADAEAVVKDIADVAEDEMI LDIG PKSAAALADLLKAAGTVVWNGPVGVFEFDQFAGGTKALAEAI AQSKAFSIAGGGDTLAAIAKFGVTEQIGYISTGG GAFLEFLEGKELPAVAALEKRG
2	0018	MNTLQKGFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQKS AVTEYYLNHGEWPGNNTSAGVATS SEIKGKYVKSVEVKNVTAQMASSNVNNEIKGKLSLWAKRQNGSVKWF CGQPVT RD KAKAANDDV TAAAAANGK KIDTKHLPSTCRDASDAS
3	0030	MTRKILVTSALPYANGSIHLGHMVEHIQTDVWVRFQKLRGHACHYCCADDTHTGTPVMLAAQKQGIAPEDIKAVRE EHLADFTGFFIGYDNYSTHSPENKQFSQDIYRALKANGKIESRVIEQLFDPEKQMF L PDRFVKGECPKCHAQDQY GDNCEVCCTTYSPTELINPYSAVSGTKPELRESEHFFFKLGE CADFLKAWTSGNNPHDGKPHLQAEALNKMKEWL EGEETLSWDWISRDAPYFGFEIPDAPGKYFYVWLDA PVGMYASFKNLCDRIGVDFDEYFKADSQTEMYHF I GKDI LYFHALFWPAMLHFSGHRAPTGVYAHGFLTVDGQKMSKSRGTITAKSYLEQGLNPEWMRYIIAAKLSKIEDIDL NLQDFISRVNSDLVGKYVNIAARASGFI AKRFEGRLKDVADSELLAKLTAQSEIAECYESREYAKALRDIMALAD IVNEYVDANKPWELAKQEGQDERLHEVCSELINAFMTLAYLAPVLPQTAANA AKFLNLEAITWANTRDTLGKHAI NKYEHLMQRVEQKQVDDLEANKQSIAAAAA PAAEEGKYEKVAEQASFDDFMKIDMRVAKVLNCEAVEGSTKLLKF LLDFGFEKRIIFSGIAASYPNPAELNGRMVIAVANFAPRKMAGVSGMILSAATADGKLLD VDTGAQPGDKV G
4	0038	MPQNTLNI VILAAGKGTMYSKMPKVLHRI GGPVGRVIDTAAALNPQNICVVI GHGKEQVLDTVKR DVVWEQT EQLGTGHAVKTALPHLSAEGRTLVLVYGDVPLIDVETLETLEAAGNEVG L L TDVPNDPTGLGRIIRDSNGSVTAIV EEKDADAVQKAVKEINTGILVLPNAKLENWLNLS SNNAQGEYYLTDLIAKAVADGKIVHPVQVRASHLAAGVNNK LQLTELERIFQTEQAQELLKAGVTLRDPARFDLRGLKHGQDVVIDVNCIFEGDIELGDNVEIGANCVIKNAKIGA NSKIAPFSHLESCVGENNRIGPYARLRPQARLADDDHVGNFVEIKNAAI GKGTKANHLTYIGDAEVGCKTNFGAG TIIANYDGVHKKTVIGDEVRI GSNVCVLVAPVTLGNKVTGAGSTITRNVEDNKLALARARQTVIEGWVRPEKDKQ
5	0045	MFSFFRRKKKQETPALEEAQIQETA AKAESLAQIVENIKEDAESLAESVKGQVESAVETVSGAVEQVKETVAEML SEAEAAEKAQVEAAKEAVAETVGEAVGQVQEA VATT EHKLGWAARLKQGLTKSRDKMAKSLAGVFGGQIDE DLYEELTVLITSDMGMEATEYLMKDVRDRVSLKGLKDGNE LRALKEALYDLI KPLEKPLVLPETKEPFVIMLAG INGAGKTTSIGKLAKYFQAQGSVLLAAGDTFRAAAREQLQAWGERNNVTVISQTTGDSAAVCFDAVQA AKARGID IVLADTAGRLPTQLHLMEEIKKVKRVLQAMPDAPHEIIVVLDANIGQNAVNVKAFDDALGLTGLIVTKLDGTAK GGILAALASDRPVPVRYIGVGEIGIDLRPFDAFV DALLD
6	0051	MNTDNLHDILDEM VQVYSQKKQSRSETPAEIGAHFHLDRLCETAE AQNASDILISKGFPPSLKINSALT PQPQK ALTGEETAIAAASTMNAEQSEIFRRDGEINYSVQSRSGTRYRANAYHSQGSAGLVLRINHVI PQMQLGLPEK LK DLAVAPRGLLIIVGPTSGSKSTTMATMLEHRNKTLP SHIVTIEDPIEFYKPRRCITQREIGVDTINWQTAVQNA MRQSPDVVICIGEVRSRESMEYAMQLAQTHLCIFTLHANTAPQSLERILNFYPKEQHNQILIDIALNLGTGIIICQRL ALKQDKTGR TAVVDLLINTPAIQDFILKGLMNI SKIMETAKTDMQTMQNL FELYRHGIISYEEALRQSVSANN LRLHIQLHKEGKTP ELLYDRVNGNLIS
7	0052	MQITDLLAFGAKNKASDLHLSSGISPMIRVHGDMRRINLP EMSAEVGNMVT SVMNDHQRKIYQONLEVDFS FELP NVARFRVNAFNIGRPAAVFTIPSTVLSLEELKAPSTFQKIAESPRGMVLVTGPTSGSKSTT LAAMINYINETQP AHILTIEDPIEFVHQSKSLINQRELHQHTLSFANALRSALREDPDVILV GEMRDPETIGLALTAETGHLVFGTIL HTTGAAKTVDRIVDVFPAGEKEMVRSMLES L TAVISQNLKTHDGNRVASHEILIANPAVRNLIRENKITQINS VLQTGQASGMQTMQSLQSLVRQGLIAP EVARRAQNSESMSF
8	0068	MQNNNEFKIGNRSVGYNHEPLICEIGINHEGSLKTA FEMVDAAYNAGAEVVKHQTHIVEDEMSDEAKQVIPGNAD VSIYEIMERCALNEEDEIKLKEYVESKGMIFISTPFSRAAALRLQRM DI PAYKIGSGECNNYPLIKLVASF GKPII LSTGMNSIESIKKSVEIIREAGVPYALLHCTNIYPTPYEDVRLGGMNDLSEAFPDAIIGLSDHDTLDNYACLGAVAL GGSILERHFTDRMDRPGPDIVCSMNPDTFKELKQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADKDIKKGEL LSGDNLWVKRPGNGDFSVNEYETLFGKVAACNIRKGAQIKKTDIE
9	0089	MNQTSRDLTRISHNTKIVATLPGSNNVELLEDMIRVGGNLNVVRNFN SHGTPEFHQENALIVREAAKRAGQEIAII ADLQGPKIRVVGKIAGGGIELNKGETVLDAALEGEGTREAVGLDYRDL PDDVAAGDVLWLDG L LTLTVESVEGSR IITRVENSHVLKSNKGINKRGGLSAGALTEKDFRDLKTAIAIGCDYLAISFVKSAEDLHIAKAVEEEMKGSTAV RPGLVSKIERVEAIENLDEIILAGDGIMVARGDLAVEGVHAAPALQKRMIRRARELRRFSITATQMMESMITNPV PTRAEVSDVANAVLDGTDVAMCSAETA V GAYPFETVSQMAIICAAAEKEQDSLNGVAEQVEYPEAVSTNLAVAGGA VSVARAVHAKAIVALTESGSTAFEISRHNITLPIFALTPSVSAQRMMAMYRGVRPLILATSTDHDTALNEVETMLV EHNILHSGDQYIITSGSQMRESGSTNTLEVLVRK
10	0109	MLKCGTFFITRHI PRGCRRFFQPNQARQTEIYQIRGTVMQRIITLLCAAGMAFSTQT LAANLEVRPNAPERYTVK QGDTLWGISGKYLSPWQWGR LWDANRDQIHNPDLIYPDQVLVLRHVDGEPRLGLEQTDGIPVVKMSPDKEVSGYG IPAI DVNFYRIFMRHPQIVSRKETAAPRLLSGPEGRLLYTKGTRVYTKGLKEPGRYLYTRINKNITDPDTGKFLG QEVA FSGIVRSLDYTDSVLEQRSKQAGERPKDNEYHTRTHPLITPLRTPSIQPLVVETAISEIQGDYLMKMPEDT

		DRFNMMHPESRPVQAKIVSVFEGTRIAGQFQTITIDKGEADGLDKGTVLSLYKRKKTMOVDLNNFKSRDTVELI STPAEEVGLAMVYRTSEHLSSAIILENISDISVGDTAANPRDLNIPDQGRSRVKFGFNRSE
11	0115	MRSSDILIVDDEIGIRDLLEILQDEGYSVALAENAEARKLRHQARPAMVLLDIWMPDCDGITLLKEWAKNGQLN MPVVMMSGHASIDTAVEATKIGAI DFLEKPI SLQKLLSAVENALKYGAQTETGPVFDKLGNSAAIQEMNREVGA VKCASPVL LTGEAGSPFETVARYFHKNGTWPVSPARVEYLIDMPMELLQKAEGGVLYVGDIAQYSRNIQAGIAFIV GKAHRRVRVVASGSRAAGSDGIACEEKLAE LLESVVRIPPLRMQHEDI PFLIQGIACNVAESQKIAPASFSEEA LAALTRYDWPGNFDQLQSVVATLLLEADGQEI GAGAVSSLLGQNVPAEGAEDMVGGFNFNLPLRELREEVERRYFE YHIAQEGQNSQVAQKVG LERTHL YRKLKQLGIGVSRRAGEKTEE
12	0124	MAKEKFERSKPHVNVGTIGHVDHGKTTTLTAALTTILAKKFGGAAKAYDQIDNAPEEKARGITINTSHVEYETETRH YAHVDCPGHADYVKNMITGAAQMDGAILVCSAADGPMPTREHILLARQVGVPYIIVFMNKCDDVDAELLELVEM EIRDLLSSYDFPGDDCPIVQGSALKALEGDAAYEEKIFELAAALDSYIPTPERAVDKPFLLPIDVFSISGRGTVV TGRVERGIIHVGEIEIVGLKETQKTTCTGVEMFRKLLDEGQAGDNVGVLLRGTKREDVERGQVLAKPGTITPHTK FKAEVYVLSKEEGRHTPFFANYRPQFYFRTTDVTGAVTLEEGVEMVMPGENVTITVELIAPIAMEEGLRFAIREG GRTVGAGVSSVIA
13	0126	MSKKWYVVQAYSGFENQVRILEERIAREEMGDYFGQIILVPVEKVVDIRNGRKTISERKSYPGYVLVEMEMTDDSW HLVKSTPRVSGFIGGRANRPTPISQREAEIILQQVQTGIEKPKPKVEFEVGGQVRVNEGPFADFNQVVEEVNRYERN KLRVSVQIFGRETPVELEFSQVEKIN
14	0128	MAKVSRLKALRSSVEANKLYAIDEAIALVKAATAKFDESVDVSFNLGVDPRKSDQVIRGSVVLPGTGKITRVA VFTQGANAEAAKEAGADIVGFEDLAAEIKAGNLFDDVVIASPDAMRIVGQLGTILGPRGLMPNPKVGTVPNVAAEA VKNKAGQVQYRTDKAGIVHATIGRASFAEADLKENFDALLDAIVKAKPAAKGOYLKKA VAVSSTMGLGIRVDTSS VNN
15	0130	MSLNIETKKVAVEEISAAIANAQTLVVAEYRGISVSSMTELARANARKEGVYLRVLKNTLARRAVQGTSAFELADQM VGPLVYAASEDAVAAKVLHQFAKKDDKIVVKAGSYNGEVMNAAQVAELASIPSREELLSKLLFVMQAPVSGFARG LAALAEKKAGEEAA
16	0131	MAITKEDILEAVGSLTVMELNDLVKA FEEKFGVSAAAVAVAGPAGAGAADAEEKTEFDVVLASAGDQKVGVIKVV AITGLGLKEAKDIVDGAPKTIKEGVSKAEAEIQKQLEEGAKVEIK
17	0132	MCMNYSFTEKKRIRKSFAKRENVLEVPFLATQIDSYAKFLQLENAFDKRTDDGLQAAFNSIFPIVSHNGYARLEF VHYTLGEPLFDIPECQLRGITYAAPLRARIRLVILDKEASKPTVKEVRENEVYMGEIPLMTPSGSEFVINGTERVIV SQLHRS PGVFFEHDKGKTHSSGKLLFSARIIPYRGSWLD FEFDPKDLLYFRIDRRRKMPVTILLKALGYNNEQILD IFYDKETFYLSNGVQTDLVADRLKGETAKVDILDKEGNVLVAKGRITAKNIRDITNAGLTRLDVEPESLLGKAL AADLIDSETGEVLASANDEITEELLAKFDINGVKEITTYINELDQGAYISNTLRDTETAGRQAARVAIYRMMRPG EPTTEEAVEQLFNRLFSEDSYDL SRVGRMKFNTRTYEQKLSAQONS WYGRLLNETFAGADKGGYVLSVEDIVA SIATLVELRNHGEVDDIDHLGNRRVRVSGELTENQFRSGLARVERAVKERLNQA ESENLMPHDLINAKPVSAAIK EFFGSSQLSQFMDQTNPLSEVTHKRRVSALGPGGLTRERAGFEVRDVHPHYGRVCPIETPEGPNIGLINSLSVYA RTNDYGFLETYPYRRVIDGKVTEEIDYLSAIEEGRYVIAQANADLSDGNLIGDLVTCREKETIMATPDRVQYMDV ATGQVVSVAASLIPFLEHDDANRALMGANMQRQAVPCLRPEKPMVGTGIERSAVDSATAI VARRGGVVEYVDANR VVIRVHDDATAGEVGVDIYNLVKFTRSNQSTNINQRPVAKAGDVLQRGDLVADGASTDFGELALQONMTIAFMPW NGYNYEDSILISEKVAADDRYTSIHIEELNVVARDTKLGAEDITRDPNLSERMQNRLDESIGVYI GAEVEAGDVL VGKVT PKGETQLTPEEKLRAIFGEKASDVKDTSLRMPGTMSGTVIDVQVFTREGIQRDKRAQSIIDSELKRYRLD LNDQLRIFDNDADFRIERMIVGQKANGGPMKLAKGSEITTEYLAGLPSRHDWFDIRLTDEDLAKQLELIKVSLQKQ REEADELYEIKKKKL TQDELQPGVQKMKVVFIAIKRRLQAGDKMAGRHNKGVVSRILPVEDMPYMDGRFPVDIV LNPLGVPSRMNIGQILEVHLGWAAGKIGERIDRLKEQRKAGELREFLNRLYNGSGKKEDLDALTDEEIIELASNL RKGASFASPVFDGAKSEIREMLNLAYPSDDPEVEKLGFNDSKTQITLYDGRSGEAFDRKVTVMHYLKLHHLVD EKM HARSTGPYSLVTQOPLGGKAQFGGQRFGE MEVWALEAYGAAYTLQEMLT VKSDDVNGRTKMYENIVKGEHKID AGMPESFNVLVKEIRSLGLDIDLERY
18	0133	MNLLNLFNPLQTAGMEEFDAIKIGIASPETIRSWSYGEVKKPETINYRTFKPERDGLFCAKIFGPVKDYECCLCGK YKRLKFKGVTCEKCGVEVTL SKVRRERMGHIELAAPVAHIWFLKSLPSRLGMVLDMTLRDIERYLYFEAFVVTDPG MTPLORRQLLTEDDYYNKLDEYDGFDAKMGAGIRELLRLNVAGEIEILRQELESTGSDTKIKKIAKRLKVLEA FHRSGMKLEWMIMDVLPVLPDLRPLVPLDGGRFATSDLNDLYRRVINNRNRLKRLLELHAPDIIVRNEKRMLQEA VDSL LDNGRRGKAMTGANKRPLKSLADMIKKGGRFRQNLGKRVDYSGRSVITVGPYLRHLQCGLPKKMALELFK PFIHFKLEKQGLASTVKA AKLVEQEVPEVWDILEEVI REHPIMLN RAPTLHRLGIAQEFPILEGKAIQLHPLVC AAFNADFDGDMAVHVPLSLEAQMEARTLMLASNNVLS PANGEP IIVPSQDIVGLGYMTRDRINAKGEGSLFADV KEVHRAYHTKQVELGTKITVRLREWVKNEAGEFEPVNNRYETT VGRALLSEILPKGLPFEYVNKALKKKEISKLIN ASFRLCGLRDTVIFADHLMYTGFGFAAKGGISIAVDDMEIPKEKAALLAEANA EVKEIEDQYRQGLVTNGERYNKV VDIWRAGDKIAKAMMDNLSKQKVIDRAGNEVDQESFNSIYMMADSGARSAAQIKQLSGMRGLMAKPDGSI IETP ITSNFREGLTVLQYFIATHGARKGLADTALKTANSYGLTRRLVDVTQDLVVVEDDCGTSDFGVKMAVVQGGDVIEA LRDRLGRVTASDVDPSSGETLVEAGTLLTEKLVD MIDQSGVDEVKVRTPTCKTRHGLCAHCYGRDLARGKLVN AGEAVGVIAAQSIGEPGTQLTMRFTFHIGGAASRAAASQVEAKSNGTARFSSQMRYVANNKGELVVIGRSCVVIH DDIGRERERHKVPYGAILLVQDGM AIAKAGQTLATWDPHTRPMITEHAGMVKFENVEEGVTAKQTDVTLSTLV IDGKRSSSSASKLLRPVTKLLDENGVEICIPGTSTPVSMAFPVGAVITVREGQEI GKGDVLARIPQASSKTRDITG GLPRVAELFEARVPKDAGMLAEITGTVSFGKETGKQRLIVTDVDGVAYETLISKEQIILVHDGQVNNRGETIVDG AVDPHDILRLQGI EALARYIVQEVQEVYRLQGVKISDKHIEV IIRQLRRVNIADAGETG FITGEQVERGDVMAAN

		EKALEEGKEPARYENVLLGITKASLSTDSFISAASFQETTRVLTEAAIMGKQDELRLKENVIVGRLI PAGTGLTY HRSRHQQWQEVEQETAETQVTDE
19	0137	MPRRREVPKRDVLPDPKFGSVLTKFMNVLMDGKKSVAERIVYGALEQIEKKTGKVAIEVFNEAIANAKPIVEVK SRRVGGANYQVPVEVRPSRRLALAMRWVRDAARKRGEKSMDLRLAGELIDASEGRGGALKKREEVHRMAEANKAFS HFRF
20	0138	MARKTPISLYRNIGISAHIDAGKTTTTERILFYTGLTHKLGEVHDGAATTDYMEQEQRGITITSAAVTSYWSGMA KQFPEHRFNIIDTPGHVDFTFEVERSMRVLGDGAVMVYCAVGGVQPOSETVWRQANKYQVPRLAFVNKMDRQGANFF RVVEQMKTRLRANPVPIVIPVGAEDNFGSVVDLLKMKSIWNEVDKGTTFYTGDI PAELVETAEWRQNMIEAAAE ASEELMDKYLGGDELTEEEIVGALRQRTLAGEIQPMLCGSAFKNKGVRMLDAVVELLPAPTDIPPVQGVNPNTTE ADSRQASDEEKFSALAFKMLNDKYVGLTTFIRVYSGVVKSGDTVLNSVKGTRERIGRLVQMTAADRTEIEEVRAGD IAAAIGLKDVTGTGETLCAESAPIILERMEFPEPVIHIAVEPKTKADQEKMGIALNRLAKEDPSFRVRTDEESGQTI ISGMGELHLEIIVDRMKREFGVEANIGAPQVAYRETIRKAVKAEYKHAKQSGGKGQYGHVVIEMEPMEPGGEGYEF IDEIKGGVIPREFIPSVDKGIRDTLPNGIVAGYPVVDVIRLVLFGSYHDVDSQLAFELAASQAFKEGMRQASPAL LEPIMAVEVETPEEYMGDVMGDLNRRRGVVLGMDDDGIGGKKVRAEVPLAEMFGYSTDLRSATQGRATYSMEFKKY SEAPAHIAAAVTEARKG
21	0140	MANQKIRIRLKAYDYALIDRSAQEIVETAKRTGAVVKGPIPLPTKIERFNILRSPHVNKTSREQLEIRTHRLRMDI VDWTDKTTDALMKLDDLPAVDVDEIKVQ
22	0142	MTLGLVGRKVGMRVDFDEQGVSVPTVLDMSANRVTQVKS KDTDGYTAVQVTFGQKKANRVNKAEGHFAKAGVEA GRGLIEFALTEEKLAELKAGDEITVSMFEVQGLVDVTGTSKGKGFSGTIKRHNFGAQRSTSHGNSRSHRVPGSIGMA QDPGRVFPGRMAGQYGNKTATVQKLEVVVRDAERQLLVKGAVPGAVNSDVVVVRPSVKVGA
23	0143	MELKVIDAKGVSGSLSVSDALFAREYNEALVHQLVNAYLANARSGNRAQKTRADEVKHSTKKPWRQKGTGRARSGM TSSPLWRKGGRAFPNKPDENFTQKVNRMKMYRAGMATILSQLTRDERLFAIEALTAETPKTKVFAEQVKNLGLEQVL FVTQQLDENVYLASRNLPNVLVLEAQQVDPYSLRYKKVITTKDAVAQLEEQWV
24	0144	MNQQLRTQVILAPIVSEKSNVLAEKRNQMTFFKVLANATKPEIKA AVELLFGVQVADVTVTITKGKVKRFGRTLGRR SDVKKAYVSLAAGQELDLEAAAAADKE
25	0154	MARLREFYKETVVPPELVKQFGYKSVMEVPRIKITLNMVGVEAVADKKVMEHAVSDLEKIAGQKPVVTVARKSIAG FKIRDNPVPGCKVTLRRDQMFEFLDRLITIALPRVRDFRGVSGKSF DGRGNYNMGVREQIIFPEIEYDKIDALRGL NITITTTAKTDEEAKALLSLFKFFFKG
26	0156	MSMHDPISDMLTRI RNAQRANKAAVAMPSSKLKCAIAKVLKEEGYIEDFAVSSDVKSILEIQLKYYAGRPVIEQIK RVS RPGLRIYKASSEIPSVMNGLGIAIVSTSKGVMTRDKARSQGVG GELL CIVA
27	0157	MSRVAKNPVTV PAGVEVKFGAEALVIGKNGELSFPLHSDVAIEFNDGKLT FVANNSSKQANAMSGTARALVSNMV KGVSEGFQKRLQIGVGYRAQAQKILNLSLGFSHP IYVEMPEGVSVQTPSQTEIVLTGSDKQVVGQVAAEIRAFR APEPYKGGVRYVGEVVMKEAKKK
28	0159	MAKHEIEERGDGLIEKMAVNVRVTVKVKGGRIMAFSALT VVG DGDGRIGMGKGSKEVPVAVQKAMDQARRSMIKV PLKNGTIHHEVIGRHGATKVF MQPAKEGSGVKAGGPMRLVFDAMGIHNI SAKVHGSTNPNYIVRATLDGLSKLHTP ADIAAKRGLTVEDILGVNHG
29	0168	MQNSTTEFLKPRQIDVNTFSATRAKVS MPFERFGHTLGNALRRILSSMNGFAPTEVAIAGVLHEYSTVDGIQE DVVDILILNIKGIVFKLHGSRQVQLVLKKS GSGVVSAGDIELPHDVEILNPGHVI CHLADNGQIE MEIKVEQGRGYQ SVSGRQVVRDENRQIGAIQLDASFSPISRVSF EVEPARVEQRTDLDKLVLDIETDGSIDPEEAVRSAARILIDQMS IFADLQGT PVEEVEEKAPPIDPVLLRPVDDLELT VRSANCLKAEDIYYIGDLIQRTE TELKT PNLGRKSLNEIKE VLASKGLTLGSKLEAWPPVGLEKP
30	0171	MAKIIVVTSGKGVGKTTTSASIAITGLALRGYKTAVIDFDVGLRNLDLIMGCERRVVDLINVIOGEATLNQALIK DKNCENFILPASQTRDKDALTREGEKVMQELSGKMGFEYIICDSPAGIEQGALMALYFADEAIVTTNPEVSSV RDSDRILGILQSKSHKAEQGGSVKEHLITRYSPERVAKGEMLSVQDICDILHIPLLGVIPESQNVLQASNSGEPV IHQDSVAASEAYKDVIARLLGENREMRFLAEKKSFFKRLFGG
31	0173	MTLTELRIVAVAQERHFGRAARRCFVSQPTLSIAIKKLEELAVSLFDRSSNDIITTEAGERIVAQARKVLEAE LIRHLANEQNELEGAFKLGLIFTVAPYLLPKLIVSLRRAPKMLMLEENYHTLTESLKRGDVDAIIVAEPFQE PGIVTEPLYDEPFFVIVPKGHSFEELDAVSPRMLGEEQVLLLTGEGNMRDQVLS SCSSELA AKQRIQGLTNTLQSS INTIRHMVASGLAISVL PATALTENDHMLFSIIPFEGTPPSRRVVLAYRRNFVRPKALSAMKAAIMQSQLHGVSFI CD
32	0193	MTHMIYPKTYDVI VVG GGHAGTEAALAAARMGAQTLLLSHNIETLGQMSCNP SIGGIGKGLVRELDALGGAMALA TDKSGIQFRRLNASKGA AVRATRAQADRILYKAAIREMLENQENLDLFQQA VEDVTL DGERISGVITAMGVEFKAR AVVLTAGTFLSGKIHIGLENYEGGRAGDPAKSLGGRLELKL PQGRLTGTGTPRIDGRTIDFSQLTEQPGDTPVP VMSVRGNADMHPROQVSCWITHTNTQTHDIIRSGFDRSPMFTGKIEGVGPRYCP SIEDKINRFADKDSHQIFLEPEG LTHEYYPNGISTSLPFDI QIALVRSMKGLENALILRPGYAIEYDYFDPRLKASLETKTIAGLFFAGQINGTTGY EAAAAQGLLAGANAVQYVRGQDPLLRLREQAYLGVLDLITKGVNEPYRMFTSRAEYRLQLREDNADMRLTEDGY KIGLVSEAQWRMFNEKREAVEREIQLRKTWYTPQKLAEGEQIRVFGQKLSREANLHDLRLRPNLDYAALMTLEGA MPSENLSAEVIEQVEIQVKYQYIDRQNEEIDSRREDIETLKLPGIDYGVKGLSAEVQKQLNQHKPETVGQASRI SGVTPAAVALLMVHLKRGFKDAK
33	0196	MKRMLFNATQAEELRVAIVDQGNLLDLDIETLGKEQRKGNIIYKGIITRIEPSLEACFVDYGTDRHGFLPFKEVSRS YFQDYEGGRARIQDVLKEGMEVIVQVEKDERGNKGAAALTFISLAGRYLVLMNNPRGGVSRRIEGEERQELKAA

		MAELDIPNGMSIIARTAGIGRSAAEELEWDLNLYLKQLWQAIIEEAGKAHDPYLLFMESSLLIRAIRDYFRPDIGEIL VDNQEVYDQVAEFMSYVMPGNIGRLKLYEDHTPLFSRFQIEHQIESAFSRVSLPSGGAIVIDHTEALVSDVNSA RATRADIETDAFTKNMEAAEEVARQMLRLDLGGLVVIDFIDMENPKHQRDVENVLRDALKKDRARVQMGKLSRFG LLELSRQRLKPALGESSHVACPRCACTGVIRGIESTALHVLRI IQEAMKDNTGEVRAQVPVDVATFLLNEKRAEL FAMEERLDVNVVLI PNHLENPHYEINRIRTDDEVEDGEPYSYKRVAEPEEDESAPFGGEEKAKAARPEPAVKGVHR TSPAPTAPEKKTSWWDSEFKAWLKRIFGGSETQAAPAAETSEKRSTANRSGSRANRRQNPRRSKREGSKVEVREV AGKTAGEARADKAETRNNGNRRRNERGDRAAERANEAEIQSRNVQPAATVADAAAPSETEVQTGKRRRNGSRSERG QTAPETATVAETTQTAENTPSEPHTAEDKGSKPKSERNRERDSRDAKERRERNQDRRQNGKKRNPISAAKIE QYLNHDTADKVRSAAHVFGETDANAPITVSIADPVAERDLPTASPAVSNQDAPVYDAAEKIRRATAAILPEGAT PKAEAQEMPSETATFTAEEQARETAQTGGLVLIETDPAALKAWAAQPEVQAGRGLRSEQPKPSEVATVPAEEMI QVETROG
34	0212	MTEQKHEEYGADSIQVLEGLEAVRKRPGRMYIGTDQDGSGLHMHVFEVLDNAIDEALAGHCDKITVTIHDHSHSVSA DNGRGMPTGIHPKEGRSAAEVIMTVLHAGGKFDNNSYKISGGLHGVGVSVVNALSDWVTLTIYRDGKEHFVRVFRG ETEEPLKIVGSDKKGTTRVFLASTETFGNVEYSFDILAKRIELSFLNNGVDIELTDERDGKHESFALSGGVAGF VQYMRKKTPLHEKIFYAFGEKDGMSVECAMQWNSYQESVQCFTNNIPQRDGGTHLTALRQVMTRTINNYIEANE VAKKAKVETAGDDMREGLTCVLSVKLPDPKFFSSQTKDKLVSGEIGFVVNEVISQALTDLFLEENPNEAKIITGKIVD AARAREAARKAREITRRKGVMDGLGLPGKLADCOEKDPALSELVYVEGDSAGGSAMQGRDRKFQAILPLKGI LNV EKARFEKMLASQEVATLITALGAGIGKEEFNAEKLYRHRIIMTDADVDGAHIRTLLTFFYRQMPDELVERGYIYI AQPLYKAKYKQERYLKDELEKDQWLLGLALEKAKIISDGRTEGAELADTAKQFLLAKTVIEQESRFVDELVLRL AMHASPIDLTSSNADKAVAEISGLLDEKEVALERIEGHEGHRFIKITRKLHGNVMVSYIEPKFLNSKAYQTLTQ TAAALKGMVGEKALYKGENGYDADS FETALDILMSVAQKMSIQRYKGLGEMNPEQLWETTMDDPAVRLLKVRIE DAIAADEVFVTLMGDEVEPRRAFIENNALIAQNIDA
35	0219	MSQRRVITGLGQVSPVGNVVAEAWDTLLTGKSGIGAITRFDTSINSRVAGEVRGFDIGQYISAKEARRMDVFIH YGI AALQAIADSGLDDEVNLDKDRIGVNI GSGIGLPGIEVTGKAVIEGGARKINPFFIPGSLINLISGHVTILK GYRGPSYGMVSACTTGAHAIGDSLRIKYGADIMVAGGAEGAISTLGVGGAAMKALSTRNDPATASRPWDKGR DGFVIGEGAGILVLEELEHAKKRGAKIYAEIVGFGMSDAYHITAPNEEGPALAVTRALKDAGINPEDVDYVNAHG TSTPLGDANETKALKRAFGEHAYKTVVSSTKMTGHLLGAAGGVEAVYSILAIHDGKIPTTINI FEQDVEAGCDLD YCANEARDAEIDVAISNSFGFGGTNGTLVFKRFG
36	0246	MAIQSGVIFDQVDTANPCDWTLDEYVKRGYATLRKILSENISQTDVIDEVKTSGLRGRGGAGFPTGLKWSFMPR SFPGEKYVCNTDEGEPTFKDRDIIMFNPHALIEGMI IAGYAMGAKAGYNIHGEIFEGYQRFEEALEQARAAGF LGKNI LGSDFEFELFAHHGYGAYICGEETALLESLEGKKQPRFKPPFPASFGLYGKPTTINNTETFSVPFIIRD GGQAFADKGI PNAGGTKLFCISGHVERPGNYEVLGT PFAEVLK MAGGMRGKKL KAVIPGGSSAPVLPADIMMQT NMDYDSISKAGSMLGSGAII VMDEDVCMVKALERLSYFYDESCGQCTPCREGTGWLYRIVHRIVEGKGKMEDLDL LDSVGNQMAGRTICALADA AVFPVRSTKHFDEFVHYIEHGGPMKEHKWGGW
37	0286	MNFTRLNQVLSTVQKKGNTFSDSPLNSFGGALVAGVASMLLNGKNRKTITKIGSTAALGYLAYRGYQWQONKG RATVTSQDFQPAGEETEYTSRTVLRMTIAAASDGMIDEAERTTIEQESGTDPEAAWLAAYRLPASIEDIAAV GNDEALAAEAYLAARLVCA DLSRKETVFLARLSQALKLDDNLVESLERQLGF
38	0294	MKLKTLALTSLLTLLAALACSKQAETSVPADSAQSSSSAPAAPAE LNEG VNYTVLSTPI PQQAGKIEVLEFFGYFC PHCAHLEPVLSEHIKTFKDDTYMRREHVVGDEM KPLARLAAAVEMAGESDKANSIIFDAMVNQKINLADTDTLKK WLSEQTAFDGKKVLA AFEAPESQARAAQMEELTNKFQISGTPPTIVGGKYQVEFKDWQSGMTTIDQLVDKVRREEQK KPQ
39	0329	MSVGLLRILVQNQVVTVEQAEHYNESQAGKEVLPMLFSDGVISPKSLAALIARVFSYSILDLRHYPRHRVLMGV TEEQMVFEHCVFVFRGDKVFFAVSDPTQMPQIQKTVSAGIEVELVIVEDDQLAGLLDWGSRSTSLQELGEGQ EEEEHSTLYIDNEEAEDGPVPRFIHKTLS DALRSGASDIHFEFYEHNARIRFVDGQLREVQPPIAVRGQLASRI KVMRSLDISEKRI PQDGRMQLTFQKGKGPVDFRVSTLPTLFGEKVMMRILNSDAASLNIDQLGFEPFQKLLLEAI HRPYGMVLVTGPTGSGKTVSLYTCNLINTESVNIATAEDPAEINLPGINQVNVNDKQGLTFAAALKSFLRQDPDI IMVGEIRDLETADIAKAAQTGHMVSTLHTNNAPATLSRMLNMGVAPFNIASSVSLIMAQRLLRLRCSCKQVE RPSASALKEVGFTDEDLAKDWKLYRAVGCDRCRGQYKGRAGVYEVMPISEEMQVRVIMNNGTEVDILDVAYKEGMV DLRRAGILKVMQGITSL EEV TANTND
40	0335	MSLQNI IETAFENRADITPTTVTPEVKEAVLETIRQLDSGKLVAERLGVGEWKVNEWAKKAVLLSFRIQDNEVLN DGVNKYFDKVP TKFADWSEDEFKNAGFRAVPGAVARRGSFVAKNVVLMPSYVNI GAYVDEGAMVD TWATVGSQAQI GKNVHLSGGVGIGGLEPLQAAPTIIEDNCFI GARSEIVEGVIVEGSGVISMGVFIGQSTKIFDRTTGEIYQGRVP AGSVVVSGSMPSKDGSHSLYCAVIVKRVD AQTAKTSVNELLRGI
41	0336	MGFLQGGKILITGMI SERSIAYGIAKACREQGAELAFYVVDKLEERVVRKMAAELDSELVFRCDVASDDEINQVFA DLGKHWDGLDGLVHSGIFAPKEALSGDFLDSISREAFNTAHEISAYSLPALAKAARPMRGRNSAIVALS YLGAVR AIPNYNVMGMAKASLEAGIRFTAACLGKEGIRCNGISAGPIKTLAASGIADFGKLLGHVAHNPLRRNVTIEEVGN TAAFLSDDLSSGITGEITYVDGGYSINALSTEG
42	0337	MSRPVPAVFGSVFHSQMPVLAYREGKWQPTIEWQSSQDLSLAPGAHALHYGSECFEGLKAFRQADGKIVLFRPTANI ARMQASADILHLPRPETEAYLDALIKLVKRAAEIPDAPAALYLRPTLIGTDPVIGKAGSPSETALLYILASPVGD YFKVGSVPVKILVETEHIRCAPHMGRVKCGGNYASAMHVLKAKAEYGANQVLFPCPNGDVQETGASNFILINGDEI I TKPLTDEFLHGVTRDSVLTVAKDLGYTVSERNTVDELKAAVENGAEAILTGTAAVISPVTSFVIGGKEIEVKSQE RGYAIRKAITDIQYGLAEDKYGWLVEVC

43	0351	MTILSDVKALGQQIWLNDLSRSLVQSGELAQMLKQGVCSNPAIFQKAFAGDALYADEIAALKQONLSPKQRYE TMVADVRAACDVCLAEHESTGGKTFVSLVSELSKDAQGTVEEARRLYAAIGCKNAMIKVPATDAGIDALETL VSDGISVNLTLFSLRAQTLKAYAAARGIAKRLAAGQSVAHIQVVSFFISRVDGALDTPDLHLKGKIAIALAKA AYQDWAQYFGSPEFAALETGANRVQLLWASTGVKNPAYPDTLYVDSLIGAHVTNTVPDATLKAFLDHGTAKATLT EGVEEAQAQLAETAALGIDVETLATRLQEDGLKQFEEAFKLLAPLA
44	0359	MSIKNAVKLIEESEARFVDLRFTDTKGKQHFTVPAIVLEDPPEWFENGQAFDSSIGGWKGIQASDMQLRPDAS TAFVDPFYDDATVVLTCDDVIDPADGQGYDRDPRSIARRAEAYLKSSGIGETAYFGPEPEFFVFDGIEFETDMHKTR YEITSESGAWASGLHMDGQNTGHRPTVKGGYAPVAPIDCGQDLRSAMVNILEELGIEVEVHHSEVGTGSQMEIGTR FATLVKRADQTDQMKYVIQNVAHNFGKTATFMPKPIMGDNGSGMHVHQSIIWKDQONLFAQDGYAGLSDTALYYIGG IIKHAKALNAITNPSTNSYKRLVPHFEAPTCLAYSANKRSASIRIPSVNSSKARRIEARFPDPTANPYLAFALML AGLDGQNKIHPGDPADKNLYLDPPEEDALVPTVCASLEELAAALKADHEFLLRGGVFSKDWIDSYIAFKEEDVRR IRMAPHLEFEMYSL
45	0382	MTKQLKLSALFVALLASGTAVAGEASVQGYTVSGQSNEIVRNNGECWKNAYFDKASQGRVECGDAVAPEPEPEP EPAPAPVVVVEQAPQYVDETIISLAKTLFGFDKDSLRAEAQDNKVLQRLSRTNVQSVRVEGHTDFMGSDKYNQA LSERRAYVVANNLVSNGVPVSRISAVGLGESQAQMTQVCEAEVAKLGAKVSKAKKREALIACIEPDRRVVKIRSI VTRQVPAHNNHQH
46	0390	MYTRIMEISPWTLRSKLEKEHKRLQESLTSLNGYMGMRGSFEETYSADSHLGTYYIAGVWFPDKTRVGGWKNNGYP KYFGKAINAFNFSKVKIFVDGQEVLDLAKNDVAGFSVELDMQHGVLRSSFTVFGVRFNVCKELSVAKELAVIRWEA VSVDGKTHQVRIDSIIDADVKNEDSNYEKFQVLDKGVSDSL SYIAAQTVANPFGVEQFIVNAEQTFAGSFKALG GSQTDWQVSNSEFESEVGSTPETFEKRVIVTTSRDYQSLAEVKAAGRALSEKIAGVAFETLLDAHAKAGWLHRWEIAD VVIQSGDEAQGIRFNLFLQFSTYYGEDARLNI GPKGFTGEKYGGATYWDTEAYAVPLYLALAEPEVTRNLLQYR NQLPQAQHNAREQGLAGALYPMVFTFTGIECHNEWEITFEEIHRNGAIPIAYINYNTYTDEGYLAKEGLEVLVEVS RFWADRVHFSKRNKGYMIHGVTPNEYENNINNNWYNTLAAWVLDYTREALAKYPRPDLNVRADLEKWDISAN MYRPHDEELGVFVQHDGFLDKDIRPVSALESPDDLPLNQKWSWKILRSPFIKQADVLQGIYFFSDRFNIDEKRRNF DFYEPMTVHESSSPCIHSILAAELGKEEKAVEMYQRTARLDDNYNNDTEDGLHITSMTGSWLAIVQGFQAMKTW GGKLSFAPFLPSAWTGYAFHINYRGLIKVAVGKENVVFTLLKGESLDLQVYGKIDITLDGSHTVALEK
47	0391	MTFTAVLFDLDGVITDTAEYHYRAWKLAEEELGISIDRKFNELKGVSRDSDLKRIIAHGKKTVSEAEFAELTRRK NDNYVEMIQAVKPEDVYPGILPLLEALRANGKKIALASAKNGPFLRLERMGLTHFFDAIADPAVAHSPAPDIFL AAAEVGDADIRQCIGIEDAAAGVAAIKAAAGALPIGVGKAEDLGSIDIALVSGTAELTYAYLQSVWEQSGR
48	0426	MEQQQRYISVLDIGTSKVLALIGEVODDKINIVGLQAPSRLRAGMVTNIDATVQAIQAVNDAELMADTKITH VTTGIAGNHIRSLNSQGVVKIKDGEVTOADIDRAIETAKAINIPDQKILDAVVQDYIIDTQLGVREPIGMSGVRL DTRVHIITGASTAVQNVQKCIERCGLSKSDQIMLQPLASQAVLTEDEKDLGVCVIDIGGGTTDIAVYMNAGAIRHTS VIPAGGNLITKDLKSLRTPLDAAEYIKIHYGVASCDTEGLGEMIEVPGVGDRTSRQVSSKVLAAIISARIQEIFG VVLGELQKSGFPKEVLNAGIVLTGGVSMMTGIVEFAEKIFDLPVRTGAPQEMGGLSDRVTRPRFSTAIGLLHAACK LEGNLPQEPENGAVQEREGGGGLLARLKRWIENSF
49	0427	MEFYVDVAESAVSPAVIKVILGGGGGCNAINNMVANNVRGVEFISANTDAQSLAKNHAAKRIQLGTNLTRGLGAGA NPDIGRAAAQEDREAEIEAIRGANMLFITTMGGGTGTGSAPVVAEIAKSLGILTVAVVTRPFAYEGKRVHVAQAG LEQLKEHVDSLIIIPNDKMLTALGEDVTMREAFRAADNVLRAVAGISEVVTCPSEIINLDFADVKTVMNNGIAM MGSGYAQGIDRARMATDQAISSPLDDVTLDGARGVLVNITAPGCLKMSSELSEVMKIVNQSAHPDLECKFGAED ETMSDAIRITIIATGLKEKGAVDFVPAREVEAVPSKQEQSHNVGEMIRTNRGIRTMNLTAADFQNSVLDDFEI PAILRRQHNSDK
50	0446	MSQTIDELLPHRNAIDTIDAEILRLNLNERAQHAHAIGELKGTGAVYRPEREVAVLRRIQDLNKGPLPDESVARLF REVMSECLAVERPLTIAYLGPQGTFTQQAIIKHFGHAAHTMACPTIDDCFKQVETROADYLVAIVENSTEGSVGRT LDLLAVTALQACGEIVLRIHNNLLRNKNGSTEGIAKVFSHAQALAQCNLDWLGRHLPNAERIAVSSNAEAARLVAES DDGTVAIAIAGRTAAEIIYGLDMVAECIEDEFNNTRFLVMGHGHETGASGSDKTSLAVSAPNRAGAVASLLQPLTESG ISMTKFESRPSKSVLWEYLFFIDIEGHRRAQIQTALERLGERASFVKVIGSYPTAVL
51	0462	MQAFSLYPPVGHFDSAKKRQNRADVFLPFWKQDNFLGKSVQYRFEFAQIYFTMPKPCAGVTMGRGDDFFSNLFHQE SARMKKSVALVLAALSACGGSEKNAVQPQADAASAANAEAAATDTLNIYNWSNYVDESTVEDFKKANLKLTYD LYENNETLEAKMLTGKSGYDLVPGIAFLPRQIEAGAYQVKNKDLIPNYKNIDPELLKMETADPGNQYAVPYFSG VNTIIATKAGKELLGGKLPENGWDLFKPEYTHKLKSCGIALWDTPEMFPIILNVLGKDPKGSNPEDLKAAAEVL KSIRPDVKRFSPSIIDELARGDCLAAGNGGDLNLAARSEEKVNNGVIEVLTPEKMGFWIESWLI PADAKNVANA HKYINYTLDPETIAAKNGIAVTFAPASKPAREKMPAELVNTRSIFFPNEQDMKDGFMVPMQSTDAKKLSVSLWQIKIV GTN
52	0466	MRTNYCGLISEQYLDQTVTVKGWVHRRRDHGGVIFIDLRDREGIVQVVIDPDTPEAFAAADSSRNEYVLSITGRVR NRPEGTNDKMSGKIEILAKEIEVLNAAATPPFQIDDENISENVLTRNVIDLRRPVMQRNLRLYQVAMGVRRY LDAQGFIDIEPMLTRSTPEGARDYLVPVRVHPGEFFALPQSPQLFKQLLMVAGFDRYQITKCFRDEDLRADRP EFTQIDLETSLNEDEIMDITEGMAKQVFKDALNVLDGDFPRMPYSEAMFYYSKDPKPMRINLKFTELTDLMKTEE FKVFRGAADMKGGRVVALRVNGAEFSRKEIDEYTKFVGIYAKGLAYIKVNDVSNLSNGEDSGLQSPIVKYLSN ALKEIIARTGAQNGDIIFFGADKAKVVNEAIGALRIKVLEHGKDNGYFTDEWKPLWVVDPMFEYDEEADRYVAV HHFPTAPKEGHEDLMVSDPANCLARAYDMVLNGWEIGGGSIRIHRADVQEKVFAALKISPEEQKEQKFFLLDNLFK GAPPHGGLAFLDRLVLTMTGAESIRDVIAFPKTKRAQCLLTNAPNSVDDKQLRELSRLRQKATETKEV
53	0477	MRENKIIFTGPVGKTTATAAISDEALVQTDASASDMTLDRKNTTVAMDYGAISLDEDTKVHLYGTGQERFNF

		MWEILSQSGSMGLVLLLDNARTNPLKDLFFLHSFRGLLEKAPVVVGITKMDIRSQPGIDVYHKYLAKHNLNVPVFE IDARKEDDVQQLVSAMLFSDPGLV
54	0530	MTVPHIPRGPVMADIAAFRLTEEEKQRLDPAVGGIILFRNRFQNIQLKTLTAEIKALRTPELIIVADHEGGRVQ RFIEGFTRLAMSTLGEIWDKDGASAAETAAGQVGRVLATELSACGIDLSFTPVLDLDWGNCPVIGNRSFHRNPEA VARLALALQKGLTKGGMKSCGKHFPGHGFVEGDSHLVLPEDWRSLSLELTADLAPFRIMSREGMAAVMPAHVVYPQ VDTKPAFSEIWLKQILRRDIGFKGVIFSDDLTMEGACGAGGIKERARISFEAGCDIVLCNRPDLVDELREDFRI PDNPTLAQRWQYMANLGSAAAQAVMQTADFQAAQAFVAGLASPDQTAGGVKVGEAF
55	0540	MFFKHI EAAPADPILGLGEAFKAETRPEKVNIGIVYKDSAGATPLVKAVKEAEKRLLESETTKNYLTIDGVADYN AQTQILLFGKDHEIIASRRAKTAQSLGGTGALRIAAEFKRLNAQTIWISNPTWPNHNAIAKAVGIQDKPYRYD AAKHGLDWDGMIEDLSQAQKGDIVLLHGCHNPTGIDPTPEQWETLAKLSAEKGWLPDFAYQGFNGLEEDAYG LRVFLKHNTTELLIASSYSKNFGMYNERVGAFTLVAEDEETAARAHSQVKTIIIRTLYSNPASHGANTIALVLKNDL KAQWIAELDEMGRKIKAMRQKFVGLLKAGASQNFDFIIKQNGMFSFSGLTPEQVDRLEKNEFAIYAVRSGRINVAG ITDNNIDYLCESIVKVL
56	0546	MKMQAVVNVKNVAGDVEVIEREVRPLEYGEALVEVEYCGVCHTDLHVAAGDYGEKPGRVLGHEGIGLVKEVADGVK NLKVGDRVSIAWLFQSCGSCYECNTGRETLCSVLNAGYTADGGMATHCIVSADYAVKVPEGLDPAQASSITCAGV TTYKAIKVSGVRPGQWIAIYGAGGLGNLGVQYAKVFGAHVVAIDINDDKLAFAKETGADLVVNAAKEDAARKVQE KTGGAAHAAVTAVSAAAFNSAVNCVRAGGRVVAIGLPPESMDLSIPLVLVDGIEVVGSVLGTRKDLLEAFQFGAEG LVVPKVLRLALDEAPAIQFQEMREGKITGRMVIDMKKECGCGHHH
57	0564	MEITLIGIVMFTVIVLVLALMILFAKSLVSEGDITIKVNGEKELTMPAGGKLLGALANEGIFIPSACGGGGSCGQC RVVVKSGGGDILPTELSHISKREAREGCLSCQVNVKTDMDIEVPEEVFGVKKWECTVISNDNKATFIKELKLAIP EGEEVPFRAGGYIQIEAPPHTVAYKDFDIPKEYHEDWDKYNLWQYVSKVDEPILRAYSMASYPEEKGIIMLNVRIA TPPPRPVDAPPQOMSSYIWSLPGDKVTISGPFGEFFAKDTDAEMVFIGGGAGMAPMRSHIFDQLKRLNSKRKITF WYGARSKREMFYVEDFDQLAAEFNFTHVALSDPLPEDNWDGYTGFIHNVVYENHLKNHEAPEDCEFYMCGPPIIM NQSVIKMLKDLGVEDENILLDDFGG
58	0589	MNLIQQLQEEIARLNKEIPEFAPGDTVVSVRVVEGTRSRQLQAYEGVVIARRNRGLNSNFIVRKISSGEGVERTF QLYSPTVEKIEVKRRGDVRRAKLYLRLGLTGKAARIKEKLPARKG
59	0595	MSRVLLVDDDALLTELEYLSAEGLNRSVPDGEAGVQEILSGQYDVVVLDSMMPKMNGLDVLKNVRARSTVPII MLTAKGDDIDRIIGLEMGADDYVPKPCPTRELLARINAILRRAQHSGEQNNAPNSISVSDVVLPAKRQASVKDMP LELTSTEFNLLEVLMRHAGQVVSKEITLSVEALDRKLAKFDRSIDVHISSIRHKLGDASLIQTVRGLGLYLFVK
60	0604	MKAARFYDKGDIRIEDIPEPTVAPGTGVINAWCGICGTDLHEFMEGPIFIPPCGHPHPISGESAPVTMGHEFSGV VYAVGEGVDDIKVGQHVVEPYIIRDDVPTGEGSNYHLSKDMNFIGLGGCGGLSEKIAVKRRVWHPISDKIPLDQ AALIEPLSVGHHAYVRSGAKEGDVALVGAGPIGLLLAAVLKAKGIKVIITELSKARKDKARESGVADYILDSEV DVVAEVKKLTNGEGVDVAFFECTSVNKLVDTLVEACKPAANLVIVSIWSPATINVHVSVMKELDVGRGTIAYCNDHA ETIKLVEEGKINLEPFITQRIKLDELVSKGFERLIHNNEASVKIIVSPNL
61	0610	MLPVRFTRVSDGIKRLTPASNQTAHYHFPENPFCCRYSSFYWSIAIMTATTASSAKPYLKIQGLVKKFGDNAYVDNI DLDIYQHEIFALLGSSGSGKSTLLRMLAGMESPNQGIILDGQDITKLAPYDRPINMMFQSYALFPHMTVEQNI AF GLKQDKMPKGEIARVEEMLRLVQMTKFAKRPKPHQLSGGQQQRIALARSLAKRPKILLDEPLGALDKKLRRQTQL ELVNTLEQVGVTICIMVTHDQEEAMTMATRIAIMSDGQLQVGTSPSDVYDYPNSRFTAEIFIGETNIFDGVVIEDHAD YAVIECEGLNHNRI DHGLGGPSEQDLWVSIRPEDIDLKEKPEYLGDNWAKGTVKEIAYLGSFAIYHIKLGNGR VVKSQVPAPYWYVRNITPPTWDETUYIISWPNQPTPLFR
62	0617	MHVSELQTLHISKLELAEHGIENANRFRKQDLVFAIVRQMMKKGEFTCSGTLEILPDGFGFLRSADTSYLAPG DDIYVSPTQIRRFNLHTGDTIEGSRVPKDNERYFALVRLDTINGDHEVCRHKILFENLTPLFPTEQLKLERDLK SEENLTGRAIDLISPIGQRALLVAPPKSGKTVMQNIHAHTANYPEVELIVLLIDERPEEVTMSRSVRGEVV SSTFDEPAQRHVQVAEMVLEKAKRMVEHKKDVVILLDSITRLARAYNTVVPTSGKILTGGVDANALHRPKRFFGAA RNVEEGSLTIATALVETGSRMDDVIYEEFKGTGNMELHLDRRMAEKRLFPAININKSGTRREELLVPNDQLQRM WLLRKFLHPMDEIEAAEFLLGKIKASKNNDDFFELMRGK
63	0618	MADNYVIVFENLRMTDVERVGGKNASLGEMISQLTEKGVRVPGGFATTAEAYRAFLAHNGLSERISAALAKLDVED VAELARVGKEIRQWILDTPFPEQLDAEIEAAWNKMVADAGGADISAVRSSATAEDLPASFAGQOETFLNINGLD NVKEAMHHVFASLYNDRAISYRVHKGFEHDIVALSAGVQRMVRSDSGASGVMFTLDTESGYDQVVFVTSSYGLGEN VVQGAVNPDPEFYVFKPTLKAGKPAILRKTMGSKHIKMIFTDKAEAGKSVTNVDVPEEDNRFSITDEEITELAHYA LTIEKHYGRPMDEIWRDGLDGKLYILQARPETVKSQEEGNRNLRRFAINGDKTVLCEGAIGQVKGQKVRLIKD ASEMDSVEAGDVLVTDMDTPDWEFVMKRASAIVTNRGGRTCHAAIARELGIPAVVGCNATELLKNGQEVTVSCA EGDTGFIYAGLLDVQITDVALDNMPKAPVKVMNVGNPELAFS FANLPSEGI GLARMEFI INRQIGIHPKALLEFD KQDELKAEITRRIAGYASPVDFYVDKIAEGVATLAASVYPRKTIVRMSDFKSNEYANLVGGNVYEPHEENPMLGF RGAARYVADNFKDCFALECKALKRVRDEMGLTNVEIMI PFVRTLGEAEAVKALKENGLERGKNGRLIMMCELPS NAVLAEQFLQYFDGFSIGSNDMTQLTLGLDRDGLVSESFDERNPAVKVMLHLAISACKRQNKYVIGICGQGPSDHP DEAKWLVEEGIESVSLNPDVTIETWLYLANELNK
64	0623	MKKTIVAAAILSLALTACGGGSDTAQTPSAKPEAEQSGKLNINWSDYVDPETVAAFEKETGIKTRSDYYDSNET LEAKVLTGKSGYDLTAPSIANVGRQIKAGAYQKIDKAQI PHYGNIDKDLLKMEAVDPGNEYAVPYFWGINTLAIN TQQVKKALGTDKLPENEWDLVKPEYTAKLKSGISYFDSAIEQIPLALHYLGKDPNSEN PEDIKAAVDMMAVRG DVKRFSSSGYIDDMAAGNLCAAI GYGGLNIAKTRAEAAANGVEIKVLT PKTGVGWVWDSFMI PRDAQN VANAHRY IDYTLRPEVAAKNGSFVTYAPASRPARELMDEKYTSDASIFPNKELMEKSFIVSPKSAESVKLVGKLVQGLKAGK

65	0631	MAKVLIVPVSAGLDASAAAQAFKALDAQIFQAVDATAETLLAQGKSDWFDALVGKVAALDAANLVIEGIAPDAD KIYLAGKNVELALSDDAAVFAVRSDNADADELANRVNLAKQFFAAAPGVLEGFVVDGAAASVAEAAAEKTLTFF GSSDALKDVSVLAGEAKRLSPAQFRYNLIDFARQADKRIVLPEGAEPRTVQAAAICHEKGIARCVLLAKREEVEA VAKERGISLPDSLEIIDPASLVEQYVEPMCELKRSKGLTPEDARKQLQDVTVLGTMMAQNDVDGLVSGAVHTTAN TIRPALQLIKTAPGASLVSSVFMLLPNQVLVFGDCAVNPNTAQQLADIAIQSADSAKAFGIDPKVAMISYSTVN SGSGPDVDTVIEATKLAREKRPDLAIDGPLQYDAATVPVGKSKAPGSPVAGQATVLVFPDLNTGNCTYKAVQRNA NVLSVGPLLQGLRKPVNDLSRGALVEDIVFTTIALTAVQAKQMEG
66	0634	MKTSIRYALAAALTAATPALADITVYNGQHKEAAQAVADAFTTRATGIKVKLNSAKGDQLAGQIKEGSRSPADVF YSEQIPALATLSAANLLEPLPASTINETRGKGVPAAKDOWVALSGRSRVVYDTRKLSEKDEKSVLNYATPKWK NRIGYAPTSAGFLEQVVAIVKLKGEAAALKWLKGLKEYGKPYAKNSVALQAVENGEIDAALINNYWHFAFAKEGV QNVHTRLNFVRHRDPGALVTYSGAAVLKSSQNKDEAKKFVAFLLASKEGQALTAVRAEYPLNPHVVSTFNLPIAK LEAPQVSATTVEKEHATRLLEQAGMK
67	0637	MHDKTWSGRFNEPVSELVKQYASIGFDRRLAEWDIQGSLAHAQMLKETGVLDGDLADIRRGMAEILEEIRSGKI EWSSDLEDVHMNIERRLTDKIGDAGKRLHTRSRNDQVATDIRLWLRDQITVIQSLIQSLQTLALDLAEQNAETVM PGFTHLQVAQPVSGHHMLAYVEMLGRDNERMADCRVRNRMPLGAAALAGTTPYIQRREITAEELGFEQICQNSLD AVSDRDFAIETFAAASLVMVHLSRLSEELILWMSPRFGFIDIADRFCTGSSIMPQKKNPDVPELVRGKSGRVIGHL IGLITLMKSQPLAYNKDNQEDKEPLFDTADTLIDTLRIYADMMRGVTVKPDNMRAAVMQGFATATDLADLYLVKKG PFRDAHEVVQAQVRHADQAGVDLSELPLEVLQGFSDLIADDVYGVLTPEGSLNARNHLGGTAPEQVRVQVWRREM LA
68	0641	MADFNQILTPGDVDGGIINVVNEIPAGSNHKEIWNRLAAAFQLDREPAIFAKPTNYGFIPTLDEGDGDELVDLLV TEQPLATGVFLEARVIGVMKFVDGGEVDDKIVCVPADDRNNGNAYKTLSDLPQQLIKQIEFHFNNHYKDLKAGTTK VESWGDAAEAKKVIKESIERWNKQA
69	0663	MKKALATLIALALPAAALAEAGSGFYVQADAAHAKASSLSGSAKGFSPRISAGYRINDLRFADVTRYKNYKAPST DFKLYSIGASAIYDFDTQSPVKPYLGARLSINRASVDLGGSDSFSQTSIGLGLTVGSYAVTPNVLDLAGYRYNI GKVNTVKNVRSSELSAGVRVKF
70	0697	MKEHKARRFRGQNFQDTRIISDIVNAVVRPQADDVIEIGPGLAAITEPLAKKLNRHLHVEIDRDIVCRLKTLPPFA DKLVIHEGDVLQDFNGIAGKKKIVGNLPYNIISTPLLEFKLAEVADDVDMHFMQLKEVEVERMVAAPKSN DYGR LGV MLQYFFDMEMLIDVPPESFDPAPKVD SAVVRMIPVKHRIKADDFEHFAKLVKLAFHQRRKTI RN NLKELAGDDDL QAVGINPDRAEHIAPEKYVALSNYLAGKV
71	0703	MKKILLTVSLGLALSACATQGTVDKDAQITQDWSVEKLYAEAAQDELNSSNYTRAVKLYEILESFRPTSRHAQSQSL DTAYAYYKDEKDKALAAIDRFRLHPQHPNMDYALYLRGLVLFNEDQSFLNKLASQDWSDRDPKANREAYQAFAE LVQRFPNSKYAADATARMVKLVDALGGNEMSVARYYMKRGAYIAAANRAQKIGSYQNTRYVEESLAILLEYKKL DKPRLAADTRRVLETNFPKSPFLKQPWRSDDMPWRYWH
72	0711	MSSGNIHHSMTGFANAAECGSKRINLDRAVNHRFLDIQIRMPDDLRYLESIGIREKISSHIARGKVECKIQIQD AENGQSLELNRDLVGQLAEINKDLRKHHDLAKLGVADILRFPGLVSLASQRENTTEELAKSITEKALKDFTAARK REGKKLGEHLLQRLAEAMEEIIDALSELFPTLLETHKEKIRARLVEAVGSDNDRLQQEFALFIQKSDIDEFSLR THIAEVRRIVTEHKSSGKRLDFLMQELNREANTLGSKSIAAECTQASVELKVLIEQMREQVQNI
73	0720	MLNITLPDGSVRQYESPVTVAQIAASIGAGLAKATVAGRVNGKLVADACDPIVEDSAVQIITPKDQEGIEIRHSCA HLVGHAVKQLYPNAKMVIGPVIEEGFYDIATEKFTPEDVAAIEARMKELIAQDYDVVKIMTPRAEAIKIFQERG EYKLRLLIDMPEVEAMGYHHQYVDMCRGPHVPNTREFLKNFKLTKLAGAYWRGDSNNEMLQRIYGTAWATKDEL KAYIQRIEEAEKDRHKLGLQDLDFHLQDEAPGMVFWHPKGLWQVIEQHMRELNAAGYKEVKTPTQIMDKTWE KSGHWDNYKDNMFVTSSEKREYAVKPMNCPGHVQIFNNGLSYRDLPMRLAEFGSCHRNEPSGALHGLMRVRGFGQ DDAHIFCTEDQIVSEARAFNELLIRIYKQFGFHDVSVKLSLRPEKRAGSDVDWDKAEQGLREALTACGVWEGELPG EGAFYGPKEIYHVRDALGRSWQCGTLQLDVFLPERLNAEYVTENNDRARPVMLHRAILGSLERFIGILIENHAGSF PLWLAPVOLVIMNITENQADYCREVAALKQAAGFRAELDLRNEKIGYKIRDNSQYRFPYQIVVGDKKEQENKVAVR RKAEDLGSLDLDDFIAQLQOEITDALVNH
74	0724	MENVNRIVAEGIAAVEAAQDFNALEQIKARYLGKTGELTGLLKTGLQMSPEERKTIGAHINECKNRFTAFNAKRE ALNEVKLQARLAAALDITLPGRAQEGGSLHPVTITLQRVVLFHGMGFVADGPEIEDDFHNFQALNIPANHPAR AMQDTFYVENGDLRTHTSPIQIRYMLDKKEPIRIIAPGRVYRVDSDATHSPMFHQAEGLWVEEGVTFADLKAVF TDFIRRRFFERDDLQVRFRPSFFPFTEPSAEIDIMGENGKWEVGGCGMVHPNVLKNVNIDPEKYTGFAFGIGLDRF AMLRYNVNDLRLFFDNDLNLKQFAK
75	0728	MQFSYSWLKTQADTELSSDKLEHLLTMSGLEVEEAETAAPAFAGVVAIEVKSVEKHPDADRLNVTRVDAGTGGLVQ IVCGAPNVKAGIKVPCSLPGAVLPGNFKIKPTKMRGEVSDGMLCSTDELGLPDDGVNGLHILPEDAPVGTNIREYL DLDDTLFTLKITPNRADCLSIKGIAREVSALTGCAFRQPEIHTAPITGSRKQPVQINAPADCGRFISRVIENVNAR ATTPDWMKQRLERSGIRISALVDIGNYVMLEIGQPMHVFDADKLSGSLHIRRAREGETLECLNEKTVSLSENTLV VADEKGVLSLAGLMGGAASAVSDGTQNVILEAAWFAPEIIAGKSROYGFGSDSSFRFERGVYRLQADAIERATEL VLQICGGAAGEMVEAQGELPEAKQVGLRLDRLKTVLGVDPAEQVETILOHLGLQPEKTAEGFRVTAPSFRFDIEI EADLIEEIGRVYGYENIPDDYTSGRCLKMELPETRRPRFAVYNEMAARGYREVVS YAFVDEQWEQDFAANADPIRL QNPLAAQYAVMRSTLIGLVEILQNNLNRKQNRVCVEIARVFSKSGSDGQFVQNERIGGLWYGAVMPEQWGGKTRN ADFYDIKADVENLLKNKAVEFVKTHGHPALHPGRAANIVSDGKVI GFV GELHPKWLQKYDLPQAPLVFEI DMAAVLE CGKTRYRVVSKFPVRRDLAFVMPEAMSHDLLLLVLKGAANKLVQEISVFDVYRGTLPEGMKSVAVKVILQDMEN TLTDEAVEPLIGKLIGAATAAGARLRS

76	0743	MGGQKTHFGSTVNEDEKAGKVAEVFHSVAKNYDIMNDVMSAGLHRVWKHFTINTAHLKKGDKVLDIAGGTGDLRSR GWAARVKGEGEWLTDINSSMLTVGRDRLLNEGMILPVSLADAELKPPFDNYFNLSVAFGLRNMTHKDAALKEMY RVLPKPGGTLVLVLEFSKIYKPLEGAYDFYSFKLLPVMGRLIAKDAESYQYLAESIRMHPDQETLQOMMLDAGFDSVD YHNMSAGIVALHKGVKF
77	0757	MSEIGLVKIYFGKVRDLYEIDDKRMLMVASDRLSAFDVLIDDPIPSKGEILTQISNFWFKLAHIMPNHFTGQTVY DVLPENEAKALEKRAVVAKKLTVPVKVEAIVRGYLAGSGWKDYQKTGSVCGIQLPEGMQEAQQLPEVIFTPSTKAAV GDHDENISFECEGRIIGKELAEVRAKAVRLYTEAAEYAKSRGIIICDTKFEFGLEDENGTLTLMDEVLTTPDSSRFW PADQYKVGTPPSPFDKQFVRDWLEQSGWNKKAPAPKVPADVIOKTVEKYREALTLTQD
78	0758	MMFDKHVKTFQYGNQTVTLETGEIARQAAAANKVSMGDTVVLVAVTTNKEVKEGQDFPLTVDYLERTYAAGKIPG GFFKREGKQSEKEILTSRLIDRPIRPLPEGFYHDIQIVAMVVSVDPEIDSDIPAMLGASAALVLSGVPPFAGPIGA ARVGYVNGVYVNLNPTKAELAKSQLDLVAGTSKAVLMVESEAKILPEDVMLGAVVYGHQDMQVAINAINEFADEVN PELWDWKAPETNEELVAKVRGIAGETIKEAFKIRQKQARSAKLDEAWSAVKEALITEETDTLAAANEIKGIFKHLEA DVRSQILDGQPRIDGRDTRTVRPLNIQTSVLPRTHGSALFTRGETQALAVATLGTSRDEQIIDALSGEYTRDFML HYNFPYSTGEVGRMGAPKRREIGHGRALAKRALLAVLPKPEDFSYTMRVVSEITESNGSSSMASVCGGCLSLLSAG VPLKAHVAGIAMGLILEGNKFAVLTDLGDEDHLGDMDFKVAGTTEGVLTALQMDIKIQGITKEIMQIALAQAKEAR LHILDQMKAAVAGPQELSAAHAPRLFTMKINQDKIREVIGKGETIRSITAETGTEINIAEDGTITIAATTQEAAGDA AKKRIEQITAEVEVGKVEYEGTVVKILDNNVGAIVSVMGKDGVLVHISQIAHERVRNVGDYLVQGVVNVKALEVDD RGRVRLSIKALLDAPAREENAAE
79	0763	MKIANSITELIGNTPLVKLNRLTEGLKAEVAVKLEFFNPSSVKDRIAEAMIEGAEKAGKINKNTVIVEATSGNTG VGLAMVCAARGYKLAITMPESMSKERKMLLRAFGAELILTPAAEGMAGAIKAKSLVDAHPTDYFMPRQFDNEANP EVHRKTTAEIWRDTDGKVDVVFVAGVGTGGTITGVGEVLKYYKPEVKVVAVEPEASVLSGGEKGPPIQIGIGAGF IPTVLNTKIYDSITKVSNEAAEFETARAIAEKEGILVGISSGAAVWSALQLAKQPENEGKLIVVLLPSYGERYLSTP LFADLA
80	0778	MPSETSSPRKENETEVHIPAAPFIVKQSGSNALAVCALVLAALGLTSGFLFVQGGQNVLKNQELAFNQKIDKAALG ESENAALLKDNLRQAAIQSELDRLDGNVKANGEQILEMQKSYRELTKGRADWLVDDETILNLAAQQLVLTGNIQ TAVGVLEHIDSRLSRFNQAELLPIKQAVSSDLAELKNRPYVDISGTALRLDRLETAVSGLPLMLDGVLPKPGVQVK EAASASWWQNVWEKSLGTLKGLVEIRRENNDAMLISPEQAYFVRENRLRLLDARTALMQRNSEVYQGDNLNAEA AVRQYFDAKSPATQSWLKELAEKALDVRMTADDGLKNSLNAVRAIRDGTMTAAENQEAQEAASEPANEXTASEP AAASDVKTIEAPSLPSERKPEQPAKKQTVPEKAGRSPSAKGERA
81	0791	MIILHTNKGDIKIELDFDKAPVTAKNFEQYVKDGYFDGVI FHRVIKGFMIQGGGMDENMNEKETRDP IQNEASNGL PNDKYTIAMARTSDPHSASAQFFINTADNAFLNFRSKELYGKTVVQDWGYAVFGKVVDGFDVDAIEGVSTKRHGY HDDVPSEPVVIAKAEV
82	0804	MTVLSKEQVLSAFKNRKRSCRHYDAARKISAEDFQFILELGRSPSSVQSEPWQFIVVQNPEIRQAIPFSWGMADA LDTASHLVFLAKKNARSDFPMLESKRRRGVTEPDAVAKSLARYAQFQADDIKILDDSRALFDWCCRQTYIALAN MMTGAAAGIDSCPVEGFNYAEMERILSGQFGLFDAAEWGVSAATFGYRVQEIATKARRPLEETVIWA
83	0814	MQTQWLPEHIADVLPNARQLESAREQLLALFRVHGYELVQPLMEYAHSLTLTHIDAGLSLKTILVTDRLSGRQLG IRADITPQVARIDAHLLSANQGINRLCYAGPVLHAQPDGLLNMREPLQAGAEMYGFADIRGDIELIDLMLKSMKIA DMGKVLSSLGHIGIFRALSAAHLDAQGSATLLALMQDKDTGAVEAQVKAWKLDGMWAKASLLPRLYGGREVLSD ARGRLPDL SAVGGALGELQAVCDADFPCIEHIDLSELVDNYHTGLLYAAYAADFHDVARGGRYDGLGGYFGRAR PATGFSFDLRSFIGRLPAIERQPAVLVDAEDAEAAHEAVEALREQQCVVIDYGIGHNVSEELAGRLKKTGQVQV VKR
84	0815	MAMAKNVVIGAQWDEGKGKIVDWLAEAGGVVRFGGHNAGHTLVVGGKKTILRLIPSGILHESLDCFIGSGVV VSPEALLGEIDELNAGVKNVEGRKLIAPTCLILPYHIALDQAREASRGKGIGTTGRGIGPAYEDKVARRAIRA ADLLHPEKLREKLDAVLAYNVQLQHLHNAEPVKAEDVMAVIEKVAPRIAPMITDVSRLVNEKNKNGEKLLEFEGAQ GALLDIDYGTYPFVTSSNCLAGAASAGAVGQMLDYVLGIVKAYTRVGSFPFTELFDEVGVGLAERGHEFGSV TGRARRCGWFDAAALKRSIQINGISGCITKLDVMDGVETINICVGYELPDGGKTDILPCGSDAVETCKPIYETMP GWRESTFGVKDYGALPENAKAYLKRIEVCAPVAIVSTGPDREETIVLHHPFA
85	0828	MTIIVTGAAGFIGSNIVKALNQRGITDIVAVDNLKSGEKFKNLAECETIAHYLDKHEFIRQVREHILPYQNI EAVFH QGACSDTMNHDGLYMDNNYQYTLDDLWDWCQDERIPFLYASSAAVYKGGEIFREERELEKPLNVYGYSKFLFDQVL RRRMKEGLTAQVVGFRYFNVYGOHEQHKGKRMASVAFHHFHQYREHGYVNLFGSNDGYNGEQTRDFVSVEDVAKVN LYFFDHPESGIYNLGTGRSQQFNELAAATVNACRAAEGKPEMSLKELVEEELIRYIPFPDALKGKYQSFTQADIT KLREAGYKEEFFDVKSGVDRYVVKWMLNLA
86	0854	MAQKIQSVKGMNDLLPVKQKDFKLTAAFWQAFEDTVGRWTRAYGYQQIRTPIVEQTGLFVRSIGEETDVVGKEMYT FSDSNDLSLSLRPEGTASCLRAVVEHLLYNSPQKLWYMGPMFRERPQKGRYRQFHQVGIEALGFEGPDIDAEI IAMSADLWEKLGIREYLTLEINSLGNREERAHRAALVEYLTREYEDKLEDESKRRLKTNPLRVLDTKNPDLQEI AAPRLVDYLGEDSQNHVYRFAKMLDGLGIQYIENPRLVRGLDYNNQTVFEWTTDKLGAQATVCGGGRYDGLIEELG GKPAPSIGFAMGIERLLLVSEYGSLEVNAAAPDVYAMHQEGADLQVMKYAQAALRAQGFNVMQHSGYQSLKAQMKK ADNSGARFALIVAQDELANGTVTLKMDMGAHQQTVAEEDLTPTTLQQWKNA
87	0875	MAAYDSLMVFTGNANPELAQRVVRHLDISLGNASVSKFSDEGAVELLENVRGRDVFILQPTCAPTNDNLMEILTM ADALKRASAGRITTAIPYFGYARQDRRPRSVRVPISAKLVANMLYSAGIDRVLTVDLHADQIQGFFDI PVDNIYAT PILNNDIKQRIENLTVVSPDIGGVVRAVAKSLNADLAIIDKRRPKANVAEVMNIIGDIQGRCLIVDDMIDTA NTLCKAAVALKERGAERVLA YASHAVFSGEAVSRIASSEIDQVVVTDIPLSEAANKCDRIQVTIAGLLAETVRR

		ISNEESVSYLFNEEVTGSM LLP
88	0876	MTYEIQASVREAQGTGASRRRLRREGQIPGILYEGOEPAVAIVDHTKTVFYALEKESFHTALIKLSLNGETKDVIVR DFQMHPFRREVQHIDFQAVKADQLVIRVPLHIVNAENSQAVKLQGGVSLNLSVEVVALPANI PAFILDLDCAEV VAGDILHLSDIKLPEGVESVSLKRNNLAVATVTGKKR
89	0878	MNTPLPYSDYLIRILTASVYDVAVETPLEPARSLSVRLKNNILLKREDLQPVFSFKIRGAYNKMSKLPKDALACGV IAASAGNHAQGVASQAQLGCRVAVIMPETTPKIKVDAVKSHGGEVVLRGVSYNDAYDYAMELAEKEGLTYIAPFD DPDVIAGQGTGMEIVSQHPDPIRAVFPVPIGGGGLAAGVAAFIKQVRPEIKVIGVQTNDSCCMQSVEAGEIVHLK DVGLFSDGTAVKVVGNETFRLCKELLDEIITVDTDAVCGAVKDI FDDTRSITEPAGALALAGLKAYIAREGAENQT LIAVTSGANMNFHRLRHVSESELGEGNEGIFAVTIPEERGSFLKFVNILGNRNITEFNRYRGDDEKAHIFVGLQA AGPQDLAVIGSRLDEAGLPNVDLTNNEIAKIHIRYVMVGGRTDKVENERLVSEFFPERPGALARFLNHMQGGWNITL FHYRHNAGADYGRILVGDVPPHDAADFGLFESLGSYHEETQNAAYKLFLA
90	0884	MEHKLPLQPYELDALSPHLSKETLEFHYGKHHTYITNLNNQIKGTEFENLPLEEIVKKSSGGVFNNAAQTWNHTF YWLGFTSKGGKPGAGELAAAI DAKWGSFEKQAEAFNACAAGTFGSGWAWLVKTPAGGLDLVSTSNAATPLTENTP LLTCDVWEHAYYIDYRNSRPNYLKGFWIWNWDEVAKRFAALS
91	0885	MNDYAAMPSEDREVGALSPPHSMEEQSVLGGMLLENPAWDRIADVSGEDFYRHEHRLIFRSIAKLINESRPAD VITVQEDLQRNEELEAAGGFEYLITLAQNTPSAANIRRYAEIVRERSIMRQLAEVGTETARSAYNPQGRDAGQLLD EAENKVFQIAESTAKSKQGFLEMPDLLKEVVQRIDMLYSRDNPDDEVTVPTGTFIDLDKKTSGLQPGDLIIVAGRPS MGKTAFSINIAEHVAVEGRLPVAVFSMEMGGAQLVMRMLGSVGRLDQSVLKTGRLEDEHWGRLEAVVKLSAPVY IDETPGLTALERARARRLARQFNKLGLIVIDYQLMAGSGSRSDNRASELGEISRSKLAKELQVPIIALSOLS RTVESRTDKRPMMSDLRESGAIEQDADLIMFYRDEYYNQDSPMKGLAEIIGKHRNGPVGKIFLTWTGQFTKFDN AAYIPPEAKIED
92	0894	MNTLLNQLKPYPFARLREAMQGISAPEGLEAVPLHIGEPKHPTPKVITDALTASHELEKYPLTAGLPELRQACAN WLKRRYDGLTVDADNEILPVLGSGREALFSFVQTVLNPVSDGKPAIVSPNPFYQIYEGATLLGGGEIHFANCPAPS FNPDWRSISEEVWKRTKLVFVCSPPNPSGSLDLGDKWEVFDLQDKYGFIIASDECYSEIYFDGNKPLGCLQAAQ LGRSRQKLLMFTSLSKRSNVPGLRSGFVAGDAELLKNFLLYRTYHGSAMSI PVQRASIAAWDDEQHVINDRRMYQE KFERVPILOQVFDVKLPDASFYIWLKVPDGDLLALARNLWQKAAIQVLPGRFLARDTEQGNPGEYVRIALVADV ATCVKAAETIVSLYR
93	0920	MTQKSTIVYTHTDEAPALATQSLLPVQAFARHADI DVKTSDISLSGRILAAFPPEYLTEAQRVPDALAELGELVKQ PDANVIKLPNISASVPQLTAAIKELQSKGFVDPYADPQTDDEKAVRERYDRIKGSAVNPVLRGNSDRRAPKAV KNFAKKNPHSMGAWTKDSKTHVATMQSGDFFHNEQSVIVPEATSVSIVFTDKQGNKKELEPVALKAGEIIDATVM SKKALLAFLAEQVKDAKAGVLFSLHMKATMMKVSDPIIFGHAVKVFFAPVFEKFGDKLAAAGVNVNNGFGNLLAN LDKLDADTPTTAVEAEIAAVYAANPDAMVDSKGITNLHVPSDVIVDASMPAMIRNSGRMWDKNGKAQDTKAVIPD SSYAGVYQATIDFCREHGAFTPTTMTGTVPNVGLMAQAAEEYGSNKTFEIEADGQVQVI DAAGKVLMOHDVEAGDI WRMCQTKDAPVKDWVQLAVNRARLSNTPAVFWLDENRPHDKSLAKVKAYLAELDTNGLDIRVLAPEEAAKFSLGR LKNGEDTISVTGNVLRDYLTDLPFPILELGTSAKMLSIVPLMNGGGMFETGAGGSAPKHVQQFLEENHLRWDLSLGEF LALAVSFEHLAQKTGNAKAQVLADTLDAATEKLLLNDSKPKRKAGELDNRGSHFYLTLYWAQELAAQDKDAELKAA FTPLAAALTADEAKIVAELSAVQGKAADIGGYAANPEKAAQVMRPSVTFNQALNAL
94	0944	MTTLHFGSGFPRVGAFFRELKFAQEKYWRKEISEQELLAVAKDLREKNWKHQAANADFVAVGDFTFYDHIIDLQVAT GAIPARFGFDSQNLSEQFFQLARGNKDQFAIEMTKWFDNTYHYLVPEFHADTEFKANAKHYVQQLQEAQALGLKA KPTVVGPLTLFWGKEKGAVEFDRLSLLPKLLPVYVEIILTALVEAGAEWI QIDEPALAVDLPKEWVEAYKDVYATL SKVASIKLLSTYFGSVAEHAALLKALPVDGLHIDLVRAPETQDAFADYDKVLSAGVIDGRNIWRANLKNVLETVEP LQAKLGDRLWISSCSLLHTPFDLSVEEKLKANKPDLYSWLAFTLQKTQELRVLKAALNEGRDSVAEELAASQAAA DSRANSSEIHRADVAKRLADLPANADQRKSPFADRIKAQAWLNLPLLPPTNIGSFQPTTEIRQARSAPKKGELSA ADYEAMKKEIALVVEEQEKLDLDVLVHGEAERNDMVEYFGELLSGFAFTQYGWVQSYGSRVCVKPPIIFGDVSRPE AMTVAWSTYAQSLTKRPMKMLTGPTILQWSFVRNDIPRSTVCKQIALALNDEVLDEKAGIKVIQIDEPAREG LPLKRAWDAYLWAGESFRLSSAGCEDSTQIHTMCEYFENDILPAIAAMDADVITIETSRSDMELLTAFGEFQY PNDIGPGVYDIHSPRVPTAEAEVHELLRKAIEVVPVERLWVNPDCGLKTRGWKETLEQLQVMMNVTRKLRAELAK
95	0946	MALQDRTGQKVPVSVFTRVGDVTKWDVSTDDLFGKKVVVFLSPGAFTPTCSSSHLPRYNELFGAFKENGVDIAYC VSVNDTFVMNAWAAEEESDNIYMPDNGEFTEGMGLVGKEDLGFGKRSWRYSMLVNDGVVEKMFIEPEEPGDPF KVSDADTMLQFVAPDWKAQESVAIFTKPGCQFCAKAKQALQDKGLSYEEI VLGKDATVTSVRAITGKMTAPQVFIG GKYIGGSEDL EAYLAKN
96	0947	MKKIQADVIVVIGGTAGMGAFRNARLHSDNVYLIENNVTGTTCARVGCMPSKLLIAAAEARHHLHTDPFGVHLDK DSIVNGEEVMQVRKSERDRFVGVVADVEEWPADKRIMGSAKFIDEHTVQIDEHTQITAKSFVIATGSRPVILPQ WQSLGNRLIINDDVFSWDTLPKRVAVFGPGVIGLELQALHRLGVKVEIFGLGGIIGGISDPVVSDEANAVFGEEL KLHLDAKTEVKLDADGNVEVHWEQDGEKGVFAEYMLAAVGRRPNVDNIGLENINIEKDARGVPVADPLTMQTSIP HIFIAGDASNQLPLLHEAADQGGKIAGDNAGRYPNIGGGLRSTIGVFTSPQIGFVGLKYAQAQAQYQADEFVIGE VSFKNQGRSRVMLVNKGHMLYAEKATGRFIGAEIVGPAAEHLAHLAWAHQMKMTVPQMLDMPFYHPVIEEGLRT ALRDADAKLKA
97	0955	MMGEKLNFSYLFSGSNAPYIEELYEAFLNPDAVDEKWKQYFTDLSKQPGTVAVDVAHTPIRESFVTLAKKKIASAV AGGADEAMLKKQSVLRLISAYRIQGVGAQLDPLKRIPPRDIEALDPKFHGLSDADMALQETNMGEGDFANRGKLP LSQIISNLKQTYCGHIALEYIYIPNTEERRWVRNYFESVLSSTPHYNADQKRRLKEMTAETLERYLHTKYVVGQR FGVEGGESAIAGLNYLIQNAKGDVVEVIIGMAHRGRLNVNLGKKPGDLFAEFEGRAEIKLPSGDVKYHMGFS

		SDIATPHGPMHVSALFNPSHLEIVNPVVEGSARAKQKRLGENGRDKVLPVLIHGDSAFI GLGVNQATFNLSKTRGY TTGGTVHIVINNQIGFTTSDIRDRSTVHCTDIAMKVSAPVHVNQDDPERVCFAIQAALDYRKKFKHDIVIDVVC YRKWGHNEGDDPTLTQPMYKVSQHPGARALYTEQLIAEGVVTQAEADGYI QAYRDALDKGEHVEQTTLNFORQ QIDWSKYQKDWREHIETGLPAADIERLTEKFTAVPEGFALHPTAKRVIEARKAMASGKQAI DWGMAETLAYASLV TKGHGVRISGEDSGRGTFSHRHAVLHDQKREKWDGTYVPLRHMGEGMGEFLVIDSILNEEAUMAFEYGFAC SAPD KLTIWEAQFGDFANGAQVTIDQFLSSGETKWGRLCGLTTILPHGYDQGPEHSSARVERWLQCSENNMQVIMPSE ASQMFHLLQRQVLGSYRKPLVIFMSKRLRLRFKGMSPLENFTEGSTFRPVI GDTAERASND SVKRVVLCAGQVYYD LEAGRAERKLEDDVAIVRVEQLYPPYDEVKAELAKY PNAKS VVWAQEEPKNQGA FYQIRHRIEDVISEEQKLSYA GRPSSASPAVGYSKXHIAQLKQLVEDALAL
98	0956	MIIDVKVPMLESVSEGTLEWKKKVGEAVARDEILIDIETDKVVLEVPSPQAGVLEIVAQDGETVVADQVLARV DTAATAAAEAPAAAPAAAPAAAPAAATQNNAMPAAAKLAAETGVDVNALQSGRDRGVLKEDVQNAAPAGAAA PAVALPAGARPEERVPMSRLRARVAERLLASQOENALITTFNEVNMKPIMDLRKYKEKFEKEHGVKLGMSFFVK AAVAALKKYPVNASVDGKDIVYHYGFDIGIAGSPRGLVVPILRDADQMSIADIEQAI VDYAKKAKDGKIAIEDL TGGTFSITNGGTFGSMSTPIINPPQSAILGMHATKERAVVENGVVVRPMMYLALSYDHRIIDGREAVLTLVAIK DALEDPARLLDL
99	0959	MNLHEYQAKELLASYGLPVQGGILAHNGEEAAAAYDKLGGKFAVVKAQVHAGGRGKAGGVKVKSRREEAKEVAESL IGTNLVTYQTDANGQPVNSVLVCEDMYPVQTELYLGAVVDRSTRITFMASTEGGEVIEKVAETPEKIFKVTVDP LVGLQPCQAREVAFQGLGKDKQINEFVKLMTGAYKAFVENDFALFEVNLAVRENGALACVDGKIGIDSNALYRLP KIAELRDKSQENERELKASEFDLNYVALEGNIGCMVNGAGLAMATMDI IKLKGGQFANFLDVGCGATKDRVVEAFK LILEDKSVQGVLINIFGGIVRCMDIAEAI VAAVKEINVNVVVRLEGNNAELGAKILNESGLKLT SADGLNDAAE KIVA AVNA
100	0960	MSVLINKDTKVLVQGGFTGKNGTFHSEQALAYGTKVVGVTTPGKGGQTHLNLVFNMTKEAVKETGADASVIYVPAP FVLDSIVEAVDSGVGLVVITTEGVPTLDMLKAKRYLETNGNGTRLVGPNC PGVITPGECKIGIMPGHIHTPGRIGI ISRSGLTYEAVAQTTKLGLGQSTCIGIGGDIPIGMNQIDALKLFQEDPDTDAIIMIGEIGGTAEAAA EYIQSNV SKPVVGYIAGVTAPKGRMGHAGAIISGGKGTAEKEFAFEKAGIAYTRSPAELGTTMLEVLKAKGLA
101	0983	MSSIKRALISLSDKTGAVEFAQTLHKLGEVILSTGGTAKLLADAGVPVIEVADYTGFP EMLDGRVKT LHPKIHGGI LGRDDLDEHVAKMEEHGIGNIDLVCVNLFLAATIAKPNCTLED A IENIDIGGPTMVRSAKNWKHVAIVTDTADF PAIAAELEANNALS DKTRFNLSRAKFSHTAQYDGMISNYLTSLSDDVLSGTPEIAGFPGRFNQSWIKVQDMRYGE NPHQRAAFYRIDPAAGSLAAYKQLQGKELSYNNIADADAWEAVKSFDPACVIVKHANPCGVAIASNTLDAYKL AYATDTTSAFGGIIAFNREVDGATVKQITDNQFMVEMAPKETA EAL EIAAAKKNVRVLEVPLEAGANRFELKRVG GGLLVQTPDIHRI SRADLKVVSKRQPT EQEWNDDLFWNVAKYVKSNAIVFGKGGQTYGIGAGQMSRVDSTRIAR KAQDAGLDLNGACAASDAFFPFRDGV D VIAEQGKAI IHPAGSMRDQEVFDAAD EHGIA MVVTGIRHFRH
102	0997	MSASQLLSRLTQTVEKEYIITDPAKTEQYRQGYRFGEGKALAVVRPGSILEMWKILOACVEADVIVITQAANTGLT GGSTPDGNDYDRDIVIVNTMRMNI IQTINNNEQVVC L PGSTLNQLELLKPLGREPHSVIGSSCIGASVLGGVCNN SGGALVQRGPAYTEMALFAQINEEGRLELVNHLGIDLGNTP EEILTNLQGHYQNKDITQDAGKGDHAYCEHVRQ VDEPTAARFNADPARHYEASGCAGKLMVFVRLDTFPOEKQTAVFYIGTNDINELTDIRRAALGEFESLPVSGEYI HRHAFDIADVCKDTFYVIKKFGTHQLPKLFDLKA RVD RF GKVSFLPKHFSKAMQFVSKFLPDHLPKSMRDYRD KYEHLILKMGKGVD EARAFLKEYFAHHGGAFFECNAETQAAMLHRFAVASAAIRYRAVHDDEVEDLVALDIAL RRDDRWDWEKLPPEIDNKI IHKLYYGHFMCHVFHQDYI IKKGNDCMALEHEMLHLLDQGAQYPAEHNVGHL YEAK PALQFYRKLDPTNSFNPGVGKTSKKKNWAE
103	1031	MTKHIAILRGDIGEPIVAETVRVLDKLI AQGLDAGYEYAPLGGEAYDEYGHYPPEFTQNLCKRADAVLLGAVGSP QYDNLDRPLRPERGLLAIRKDLNLFANLRPAVLYPELANASTLKPEIVAGLDI LIVRELTGDIYFGEPRGIRVLEN GEREGYNTMKYSESEIRRIAHVAFQSAQKRSKVKVSGKANVLETTELWREIFEEIGKEYPDVELSHMYVDNAAMQ LVRA PKQFDVIATGNIFGDILSDEASMLTGSIGMLPSASLDENGKGLYEP SHGSAPDIAGQNKANPLATILSLAML LRYSLNDEARAQQVENAVQKVLQQLRSTDIYEEGTKLVSCEMGDAVLAAL
104	1044	MAAFNTQKVL SVHHTDAYFTTCTRDESLRFENGQFVMVGLMVDGKPLMRAYSVASANWEEHLEFFSIK VQDGPL TSRLQHLKVGDDVLISKPTGTLVAGDLNPGKHL YLLSTGTGIAPFLSITKDPEIYEQFEKIILVHGVRYYKDLAY YDRFTKELPEHEYLGD LVKELIYYPIVSREEFEHHGR L TDLMVSGKLFEDIGLPKINPQDDRAMLCGSPAMLKDT CKVLDDFGLTVSPKTGVRGDYLI ERAFVDQ
105	1046	MKYISTRGETAHKPFSEVLLMGLAPDGGMLPEHPYQIGRETLDKWRGLAYPELAFEIMRLFVTDIPEDDLRDILN RTYTEAAFGTKEITPVRTLSDGIKI QALSNQPTLAFKDMAMQFLGNAFEYVLNKEGKKNILGATSGDTSAAEYA LRGKKG VNVFMLS PDGKMSAFQRAQMYSLQDENIHNI AVKGMFDDCQDIVKAVQNDAAFKEYHIGTVNSINWGRI VAQVVYYFAGYFNATSSNDETVSFCVPSGNFNGVCAGHIAKQMG LPIRRLIVATNENDVLEFFKTGAYRPRNSAH TYVTSSPSMDISKASNERFVFDLMDRDPAEINTLWAEVAAGKGFDLRFALDKVGGKYGFTSGKSTHADRLATIKQ VYEQDQELIDPHTADGVKVARVREEGEMVVCLETA LAAKFDATIREAVGDAAI PRPAALEGLENLPQRVQTVPN S ADAVKGIIEQTLA
106	1053	MKKTVFTCAMIALTGTA AAAQELQTAN EFTVHTDLSSISSTRAFLKEKHKA AKHISVRADIPFDANQGIRLEAGFG RSKKNIINLETDENKLGKTKNVKLPTGVPENRIDLYTGTYTQTLSDSL NFRVAGLGFESSKDSIKTTKHTLHSS RQSWLAKVHADLLSQLNGWYINPWSEVKFDLNSRYKLNTGVTNLKKDINQKTNGWGFLGANIGKKLGESASIEA GPFYKQRTYKESGEFSVTTKSGDVSLTIPKTSIREYGLRVGIK
107	1070	MTQTNRVII FDTTLRDGEQSPGAAMTKEEKIRVARQLEKLGVDIIEAGFAAASP GDFEAVNAIAKTITKSTVCSLS RAIERDIRQAGEAVAPAPKKRIHTFIATSPIHMEYKLMKPKQVIEAAVKAVKIAREYTD DVEFSCEDALRSEIDF

		LAEICGAVIEAGATTINIPDTVGYISIPYKTEEFFRELIAKTPNGGKVWVSAHCHNDLGLAVANSALALKGGARQVE CTVNLGERAGNASVEEIVMALKVRHDLFGLETGIDTTQIVPSSKLVSTITGYVPQPKAIVGANAFSHESGIHQD GVLKHRETYEIMSAESVGWATNRLSLGKLSGRNAFKTKLADLGIELESEALNAAFARFKELADKKREIFDEDLHA LVSDMGSMNAESYKFISQKISTETGEEPRADIVFSIKGEEKRASATGSGPVDIAFKAESVQAQSGAALQIYSVNA VTQGTESQGETSVRLARGNRVNVNGQADTDVLVATAKAYLSALSKEFSAAKPKAQSGGTI
108	1073	MIKISTRFDAGSVVVKDLTDPSNIRLALRPDNASDAQWFFRLOGAAYQNCIMHFENAEAAAYPKGWEGYQACAS YDRRNWFRVPTSYENGVLTVNHTPLSNSVYAYFEFYPSEEQHLNLLGDAQSGSLCRIDDLGSTVQGRDINLLTIGN QVESDLKIWITARQHPGETMAEWFIEGLLGRLLDPQDPTARALLDRATFYIVPNMNPDGSGALGNLRTNAAGANLNR EWENPTVEKSPVFFVREKMLETGVDLFDIHGDEGLPFVVFVAGTEGVPNYNPRIAALEAQFKNALLNASPDFQDE YGYEKDAPGEANMTLATNWVGNRFNCLAYTLEMPFKDNANLPDDDFGWNGQRSRLRGEAALSAILNVIGDLR
109	1127	MATLSDKTILVTGASQGLGEQVAKAYAAAGATVILVARHQKLEKVDATIVEAGYPEPFAICFDLISAEKEFEHF AATIAEATQGLDGIHVHCAGYFYALSPDFQTVAEWVNQYRINTVAPMGLTRALFPLLKQSPDASVIFVGESHGET PKAYWGGFGASKAALNYLCKVAADEWERFGNLRANVLVPGPINSQRIKSHPEAKSERKSYGDVLPFAFVWASAE SKGRSGEIVYL
110	1131	MALLQISEPGMSAAPHRRHLAAGIDLGTNSLVATVRSASAACLPDAEGRVTLPSVVRYLENGGIEVGKTALSAQK TDPLNTVSSAKRLIGRTLADLHQNTHYLPYRFGDNQVRIELHTRQGVKTPVEVSAEILKTLKSRAETLGGDLVGV VITVPAYFDDAQROATKDAARLAGLNVRLRLNEPTAAAIAYGLDNASEGTFFVVDLGGGTFDVSVLQTLKGLFEVK ATGGNSALGGDDFDRHLFCRLLEQNGLSQLNEQDSQLLSLVRAAKEQLTTQTEARIQATLSDMAIDTSSISRAEF HNLTQHLVMTLEPVTQALKDAGVGKNEVKGVIMVGGSTRMLHVQQAQVATFFGQTPLNNLNPDEVALGAATQANV LAGNKTDGEWLLDVTPLSLGLETYGGLAEKIIIPRNSTIPTARAQDFTTFKDGQTAMTIIHVQGERELVADCRSLA KFTLRGIPPMAGAAARIRVTFQIDADGLLSVSAEQSTGVQAQIEVKPSYGLDDDTITQMLKDSMSNAEADMAARA RAEAVVEAESLTDAVNAELELDSLLDAEELQQIRQGIADLQGRKDKGAEDIRAAAALGSIITDNFAAKRMNRNI QRALTGQSVDNI
111	1150	MPEYRSKTSTHGRNMAGARALWRATGVMETDFGKPIIAVANSETQFVPGHVHLHNMGQLVAREIEKAGAIKEFNT IAIDDGIAMGHSGMLYSLPSRDLIADSI EYMVNAHCADALVCISNCDKITPGMLIAAMRLNIPTIFVSGGPMEAGK VIGVANIQPERRDLIDAMIESADDNVSNRQVEEVEQNACPTCGSCSGMFTANSMNCLTEALGLSLPGNGSYLATH AGRKELFLEAGRMIVEITKRYEYQNDETVLPERSIATKKAFENAMTMDIAMGGSTNTILHLLAVANEAGVDFKMADI DRLSRVVPICKTAPNNHDYMEDVHRAGGIFAILKELDKAGKLHTDVHTIHAPTLKDAIEQWDVTNPENTRAIER FKAAPGGVRTTQAFSQNRMWKTLDLREKGCIRDVAHAYSQDGLAVLFGNIAERGCVVKTAGVDESILKFTGRAR VFESQEDAVEGILGNQIVAGDIVIIRYEGPKGGPGMQEMLYPTSYLSKSLGKACALLTDGRFSGGTSGLSIGHAS PEAAEGGAIGLVHEGDTVEIDIIPNSIHLAISDEELAARRAEMEARGSKAWKPKNRDRYVSAAALRAYGAMATSADK GAVRDVAQIER
112	1201	MRIVEKAYTFDDVLLVPAHSTVLPDRDVKLQTKLTREITLNLPLLSAAMDVTVEARLAISMAQEGGIGIIHKNPPE MQARAVSKVRHESGVVKDPVTVAPTTLIREVLEMRQQRKRKMSGLPVVENGKVVGIVTNRDLRFENRVDPVSAI MTPRERLVTVPEGTSIDEARELMHTHKVERVLVLEKDELKGLITVKDILKTTEFPNANKDSEGLRVGAAGVTGG DTEERVKALVEAGVDVIVVDTAHGHSQGVIDRVVRWKETYPHIQVIGGNIAATAKAALDLVAAGADAVKVGIGPGSI CTTRIVAGVGVPQLTAIHNVAEALKGTGVPLIADGGIRFSGDIAKALAGAYSVM LGGMFAGTEEAPGEIELYQGR SYKSYRGMGSLGAMSQGSADRYFQDKTDSTDKYVPEGIEGRVPYKGPVNIHQITGGLRSSMGYLGCANIAEMHE KAEFVEITSAGMSESHVHDVQITKEAPNYHR
113	1206	MKGDRLVIRELNKNLGLLLVTINQYFLHARILKNWGFEEELGEHFFKQSI VEMKAADDLIERILFLEGLPNLQELGK LLIGESTEEIIACDLTKEQEKHEALLAAIATAEAQDYVSRDLLEKQKDTNEEHIDWLETQQELIGKIGLPNYLQT AAQED
114	1228	MKPVNIGLLGLGTVGGGTAAVLRDNAEIEISRLGREIRISAVCDLSEEKARQTCPSAAFVKDPFELVAREDDVDDV ELFGGTGIAKDAVLKAIENGKHIVTANKLLAEYGNIEFPLAEQONVIVQFEAAVAGGIPIIKALREGLAANRIKS IAGIINGTSNFILSEMREKGSFADVLKEAQALGYAEADPTFDIEGNDAGHKITIMSALAFGTPMNFSA CYLEGIS KLDSRDIKYAEELGYRIKLLGITRKTGKGIELRVHPTLIPESRLLANVNGVMNAVVRNADMVGETLYYGAGAGALP TASAVVADIIDIARLVEADTAHRVPHLAFQPAQVQAQITLPMDEITSSYYLRVQAKDEPGTLGQIAALLAQENVSI EALIQKGVIDQTTAEIVILTHSTVEKHKISAAIAIEALDCVEKPITMIRMESLHD
115	1231	MTQKEKHFEYYAALATPLRDVVVPHMVLPLFVGRPKSIAALENAITREEPVFLAQTDAAVEEPIAADLYQTGT VAQVLQVLKLPDGTVKVLVEGLYRGRVLTIEDTGGLFVSHIETVVEEDTGNTDLEAVRRTLLAQFEQYAKLNKKI PAEIIIGSINGIAENSRLTDTVAHLQLKLAQRQOILEIPEIGKRMEFLLAQLESELDIMQAEKRIGRVRKQMEKS QREYYLNEQIKAIHKELGEEDENGELDALEADIKKAGMTKEAEKCLSELKLLKMPMSAESTVVRNYIDTLEL PWKKKSRVSKDIAKAGLVLDADHYGLEKVKERILEYLAVQKRMCKLKGPIILCLVGPVPGVGTSLGESIAKATGRKY VRMALGGVRDESEIRGHRRTYIGSMPGKILQNMAGAVKNPLFLLEIDKLGNDFRGDPASALLEVDPEQNNKFA DHYAEVDYDLSVDFIATSNLSNIPPLDRMEIIRLSGYTEDEKINIAMQYLVPKQMKRNGVKEGELAIIESAVR DIIRYYTREAGVRSLDREIAKICRKVVMQITLDEDKKRLSETKTSKAKPKAVKNEKNLHDYLGVRFDYGVAES ENRIGQVTGLAWTEVGGEELLTVEAALPGKGVIOCTGQLGDMKESVSAAWSVVRSAESVGLAPDFYEKKDIIH VPEGATPKDGPSAGIAMTLAAVSFTKIPVRADVAMTGEITLRGEVLPIGGLKEKLLAALRGGIKHVLIPKDNVKD LEEI PENVKTGLTIHPVKWIDEVLALEGLSQQEPWAEFSGAEAAAESASKPKPRSRATKH
116	1240	MISTNGITMQFGAKPLFENVSFVFGNGRYGLIANGSGKSTFMKILGGDLEQTAGEVAIENGVRIGKLRQDQFAY EDMRVLDVMMGHTEMWAAMTERDAIYANPEATEDDYMKAAELEAKFAEYDGYTAEARAELLSGVGISEDHNAK MAEVAPGFKLRVLLAQALFSKPDVLLLEPTNNLDINTIRWLEGVNLQYDSTMIISHDRHFLNEVCTHMADLDYN

		TTITYPGNYDDYMLASQAQSRERALKDNAKAKEKLQELQEFVARFSANKSKARQATSRLKQADKIKSEMVEVKPSTR QNPYIRFEADEKAKLHRQAVEVEKLAKRFETQLFKNLNFLEAGQRLAIGPNGAGKSTLLKLLAGAYNPEYSDGL LPDEGTIKWAEKASVGYYPQDHENDFDVMDLSEWMRWQOEGDDEQVIRGTLGRLLFGSNDVVKVVLSSGGEKG RMLYGKLLLLKPNVLMDEPTNHMDMESIESLNMALEKYNGTLIFVSHDRQFVSSLATQIIELDGKGGYEHYLG DY ESYLEKKGVA
117	1252	MSTSLSYRDAGVDIDAGDQLVENIKPFAKRTMRPEVLGDLGGFGALVEIGKKYQNPVLVSGTDVGVTGLKLAFDWD KHDTVGIDLVAMSVNDILVQGAEPFLFDYFACGKLDVPRATDVIKIGIAQGCESGICALIGGETAEMPGMYPVGEY DLAGFAVGVEKENVITGRSIGVGDVVLGLASNGAHSNGYSLIRKIIERDNPDLDAEFNGKTLREAVIAPTRLYV KPILAALAEKFTIKGMAHITGGGITENVPRVLPENTVAQIDAKSWELPKLFQWLQKAGNVETQEMYRTFNCGIGMVV IVAAEDADAVQGLLGEQGETVYRLGLIRERQGDHQTQVA
118	1301	MSMENFAQLLEESFTLQEMNPGEVITAEEVAIDQNFVTNAGLKSESLIDVAEFKNAQGEIEVKVGDVFTVTIESV ENGFGETKLSREKAKRAADWIALEAMENGDI LSIGINGKVKGGTLVMISSIRAFPGSLVDVPRVKDTSHFEGKE IEFKVIKLDDKRRNNVVSRRAVLEATLGEERKALLENLQEGSVIKGIVKNITDYGAFVDLGGIDGLLHITDLAWRR VKHPSEVLEVGQVEAKVLKFDQEKQVSLGKQGLGEDPWSGLTRYPQGTRLFVKVSNLTDYGAFFEIEQGIEGL VHVSEMDWTNKNVHPSKVVLGDEVEVMILEIDEGRRRISLGMKQCQANPWEFAANHNKGDKISGAVKSITDFGV FVGLPGGIDGLVHLSDSLWTESGEEAVRKYKKGEEVEAVVLADVEKERISLGIKQLEGDPFGNFISVNDKGSVLK GSVKSVDAGKAVIALSDEVEGYLPASEFAADRVEDLTTLKKEGDEVEAVIVTVDRKNRSIKLSVKAKDAKESREAL NSVNAANANAGTSLGDLKAKLSGEQE
119	1302	MTKSELMVRLAEVFAAKNGTHLLAKDVEYSVKVLVDTMTRSLARGQRIEIRGFGSFDLNHRPARIGRNPKTGERVE VPEKHVPHEFKPGKELRERVDLALKENAN
120	1313	MMSVTVETLENLERKVVLSLPSWEINAEETDKLKQTORRAKIDGFRPGKAPLKMIAMQYGASQNDVINELVQRRF YDVAVAQELKVAGFPRFEGVEEQDDKESFKVAIFEVFPEVVIGDLSAQEVEKVTASVGDAEVDQTEILRKQRT FNHVEREARNGDRVIDFEGKIDGEPFAGGASKNYAFVLGASQMLPEFEAGVVGKMGESKDVTVNFPEDYHGKDV AGKTAVFTITLNNVSEATLPEVDADFAKALGIADGDVAKMREEVQKNVSREVERRVNEQTKESVMNALLKAVELKA PVALVNEEAARLANEMKQNFVNQGMADAANLPLDMFKEQAERRVSLGLILAKLVDENKLEPTEEQIKAVVANFA ESYEDPQEVIDWYYADPSRLQAPTSLAVESNVVDFVLGKAKVNEKALSFDEVMGAQA
121	1320	MQIILLEKIGGLGNLGDIVTVKNGYARNFLIPAGKAKRATEANMKEFEARRAELEAKQAEILADARVRQEKLDGQT VTVAQKAGVDGRLEFGSVTNADIAAAI VAGIEAVKANVRLPNGPLKAVGEYEVEVALHTDAVAKITVAVVAATE
122	1323	MRHYEIVFIVHPDQSEQVPAMVERYKTMIAEANGKIHRLLEDWGRRLAYPINKIHKAHYVLMNIETTPVEVVELET AFFRNDAILRHLTIKTKHATVEASPLMGEEKAKNLLSGASEEAVAQ
123	1324	MSQHRKLIILGSGPAGYTAAYVAARANLNPVIITGIAQGGQMLTTTEVDNWPADADGVQGPFLMARFLAHAERFGT EIIDQINAVDLQKRPFTLKGDMGEYTCDALIVATGASAKYLGLPSEEFAGKGVSAACATCDGFFYKQNDVAVVGG GNTAVEEALYLANIAKTVTLIHRRSEFRAEKIMIDKLMKRVEEGKIIKLESNLQEVLDGDRGVNGALLKNNDGSE QQIAVSGIFIAIGHKPNTDIFKGQLEMDAEGYKTKGGTADNVGATNIEGVWAAGDVKDHTYRQAITSASGCGQAA LDAERWLGSQNI
124	1328	MTDTAENQTNWQAGHPRSIRSFVLRSQSHMTAAQORRAIDTLWDSFGIDYQATPADLDARFGSSRPKILEIGFGMG TATAEIAARRLPETDFLAIDVHGPGVGNLLKLI DENHLENIRVMRHDAVEVVENMLQDGLDGIHIFFPDPWHKKRH HKRRLIQAPFIAKLLPKLKTGGYIHLATDWEYAAQOMLEVLSSFDSLQNTAADYAPTDPYRPETKFEARGKRLGHG VWDLVFKRIG
125	1339	MKASQFFISTLKEAPAEALASHKLMIRAGLIKANASGLYTWMMPGLRVLRLKVENNVREEMARAGSVELLMPVVP AELWQESGRWEFYKELLRLKDRHDFCMGPTCEEVIADIVRKEINSYKQLPKNFYHIQTKRDEVRPRFGVMRA REFVMKDAYSFHADYASLQTTYQDMYDAYCRI FTRLGLAFRPAADTSGSIGTGSHEFQVLAESGEDVIAYS DTS YAANIELAPTLPLKGERAAQAELVKVHTPNVKTIDSLVDFLSIPIEKTLSIVVEGENEGELILLLRGDHEFND IKAELKLAGVKSPLTMASPAAVEQFGANGSLGPVGFAGKVYADFATEKGADWVIGANEDDYHTGFNFRDAEAP EFVDLRNVVEGDESPDQGRLLKLARGIEVGHVFLRDKYTQAMNVSFLDNNGKSQIMEMGCYIGITRVVAAAEQ NNDEKGIWTKAMAPFEVVI VPMNYKSDTVREAADKIYAEALLAAGADVLLDDRDERAGVLLNDSSELLGIPHRIVI GDRALKEGNVEYAERRDNEAQAQAIGEIVARVTASLNA
126	1341	MSTQLHDVDPIETQEWLDA LSSVLEYEGGERAQYLLNLVVKYCRDKGVRMPHGTTPYLTNTSVSENEKGI PGDQNI EHRIRAFVRWNAAI VLRAGKKDLELGGHIASFQSAATMYEVGFNFHFKARKEGEGDLVFFQGHVAPGIYARAFV EGRLTEDQLNNFRQEVGDHGLPSYPHPLLDFWQFPVTSMGLGPIMAIYQARFLKYLESRGLAKTKGRKVCFCG DGEMDEPESQGAIALAAREGLDNLI FVINCNLQRLDGPVRNGKIIQELEGNFAGAGWNVKVIWGRWRDRLAKD KDGI LRQRMEECLDGDYQTYKSKDGAYVREHFNTPPELKA LADMTDEQLWALNRGGHDPQKVYNAYDRAANHADG KPTVILAKTIKGYMGASGEGQNVAHQA KMDKASLKQFRDRFDI PVTDEQIESGDLPYLTFAPDTEEYKYLHARR DALGGYLPQRKPTQEVLEPELSAFDAQLKSSGEREFSTTMFVRILSTLLKDKKIGKRVVPIVPDESRTFGMEGM FRQYGIWNPKGQQYTPQDKDQLMFYKESVDGQILQEGINEPGAMADWIAAATSYANSNFAMIPFYIYYSMFGFORI GDLAWAAGDMHARGFLGGTAGRTTLNGEGLQHEDGHSIIQADLIPNCVSYDPTFQYEVAVIVQDGLRRMYANNED VFYITLMNENYTHPDMPEGAEQDILKGMYYLLKAGGKGDKKVQLMGSGTILQEVIAGAELLKADFGVEADIWSCPS FNLLHRDAVEVERFNRLHPLAEKVFPVTSQLQGHGDPVIAATDYIRSYADRIRAYIPNDYHVLGTDGFGRSDSRA NLRRFFEVDRYNVAVALAALAEQGVSKETVQQAIEKYGIKADSAPSWKR
127	1342	MSIVEIKVPDIGHENVNDI IAVEVKAGDTIAVDDTLITLETDKATMDVPADAAGVVKEVKVKGDKISEGGVILT ETGAAAAEAAPAAAEQA PAAAAAAGGATVQVAVPDIGGHTDVDVIAVEIKVGDVVAEDDTLITLETDKATMDV PCTAAGVVKAVFLKVGDKVSEGSIIIEVETVGSAAAAPAAQAAAPAAAPPTAAAAAPAAAPAPSAPAAAKIDEA

		AFAKAHAGPSARKLARELGVDLGQVKGTGLKGRIMGDDIKAFVKSVMQGGAAKPAASASISGGLDLPWPVKVDFS KFGNVEVKELSRIKKISGQNLRSRNVVIPHVTVEEADMTELEFRKQLNKEWEREGVKLSPLAFIIKASVSALKAF FPEFNASLDGDNLVLNKYNIGFAADTPNGLVVPVVKIDVDQKGLKQISQELTELSKKAREGKLPQEMQACFTIS SLGGIGGTGFTPIVNAPEVAILGVCKSQIKPVWNGKEFAPRLMCPLSLSFDRVIDGAAGMRFTVFLAKLLKDFRR ITL
128	1343	MGNFLYRGISCCQDEQNNQQLKPKGNKAEVAIRYDGFKYDGKATHGPSVKNVAYAHQIETGLYDGCYISTTTDKE IAKKFATSSGIENGYIYVLNRDLFGQYSIFEYEVEHPENPNEKEVTIRAEDCGCIPEEVIIAKELIEIN
129	1344	MALVELKVPDIGHENVDI IAVEVNVGDTIAVDTLITLETDKATMDVPAEVAGVVKEVKVVGDKISEGGLIVVV EAEGTAAAPKAEEAAAPAEAPKAAAPAPQAAQFGGSADAEDVVLVGGGPGGYSAAFAAADEGLKVAIVERYKTL GGVCLNVGCI PSKALLHNAAVIDEVRHLAANGIKYPEPELIDMLRAYKDGVSRLTGGLAGMAKSRKVDVIOGDG QFLDPHHLEVSLTAGDAYEQAPTGEKKIVAFKNCIIAAGSRVTKLPFIPEDPRIIDSSGALALKEVPKLLIIG GIIGLEMGTVYSTLGSRLDVEMMDGLMQGADRDLVKVWQKQNEYRFDNIMVNTKTVAPEKEDGVYVTFEGANAP KEPQRYDAVLVAAGRPNGLISAEKAGVAVTDRGFIEVDQMRTNVPHIYAIGDIVGQPMALAHKAVHEGHVAEN CAGHKAYFARVIPGVAYTSPEVAWVGETELSAKASGRKITKANFPWAASGRAIANGCDNGFTKLI FDAETGRIIG GGIVCPNGGDMIGEVLAIEMGCDADIGKTIHPHTLGE SIGMAAEVALGTCTDLPPQKKK
130	1347	MNPFNTAFKAARRAGQMMIRAGNLDVKTDSKAFNDFVSDVDRNSEIILVEALKEAYPHHKITCEESGSHGKAA AEYEWIIDPLDGTTFNLHGHPQYAI SMALLHKGVLQEALVYAPERNDVYMASRGKALLNDRRI RVSNRIELNRCL IGTGFPVVDQSMMDKYLA ILKDFLAKTAGGRREGAASLDLCAVATGRFDGFFEFLNKPWDIAAGALIVQEAGGIVT DMSGEDGWLESGDIVAANPKVLAQMLKII SAHV
131	1356	MTQYTLKQASVLLQSKQISAVELASAYLAAIAEKNPALNGYITIDQDKTLAEARAADERIAQGNASALTGPVYAYK DIFCQTGWSACASKMLDNFISPYTATVVQNLLDEGMVTLGRTNMDEFAMGSTNENSFYGAAKNPWNLEHVPGGSS GGSAADVAAARLAPAALGSDTGGSIRQPASHCGITGIKTYGTVSFRGMVAYASSFDQTGPMAQTAEDCAILLNAMA GFDPKDSTSLEREKEDYTRDLNQLKGLKIGLPKEYFTEGNSADVLTALQNTIDLLKAQPALEHVLPLQTKLSIP AYYVLASAEASTNLSRYDGVRYGHRAAQFADLEEMYGKTRAEGFGSEVKRRIMIGTYVLSHGYDAYYLKKAQKLRR LVADDFQTA FARCDLI LAPTAAPKIGADASPVEYLSDIYTI AVNLAGLPALTLPAGFSGGGLPVGVQLVGNV FAEAKILGAHQIQLNSDWHGKRPE
132	1358	MTWETVIGLEIHVQLNTKSKI FSGASTAFGAEPNAHASVVECALPGVLPVMNREVVEKAIKGLGLADAKINQKNVF DRKNFYFPLPKGYQISQLDLPIVEHGKLEIVVGDDVKTI NVTRAHMEEDAGKSVHEGLNGATGIDLNRAGTPLLE VVSEPEMRSAAEAVAYAKALHSLVTWLDICDGNMAEGSFRVDANVSVRPKQEEFGTRREIKNLNSFRFLEQAINV EAEAQIEILEDGGKVQQTMLFDPEKGETRVMRLKEDAHDYRYFPDPLLPV IISDAQMOKAKAEMPPEPKEMAAR FVADYGVSEYDARLLTASRAQAAFYEEAAKESGQKLTANWMNGELAAALNKEGMELADSPITAPRLAALVGKIAD GTLSSKLAKKAFEA MWAEPEATIAEII EKHGLQQMTDTGEI EAMVDEVLANNAKAVEQFKSGNEKALNAIVGQVMK ASKGKANPAQVQELIKAKLA
133	1372	MSNENRTCSFCGKSKSHVKHLIEGENAFICDECVSNCIEILHEDGNDGTPSESAGGEPEESGKLPPTAEIVANLND HVIGQEQA KALAVSVYNHYKRLRHPKAGANVELSKSNILLIGPTGSGKTLAQSLARKLDVFFVMADATTLTEAG YVGEDVEQIITKLKGKCDFVEKAQRGIVYIDEIDKISRKSDNPSITRDVSGEGVQALLKLI EGTVASVPPQGG KHPNQEFINVDTTNIFICGGAFAGLEKVIQRTEKGGIGFGASVHSDENADITKLF GIVEPEDLIKFGLIPELI GRLPVIATLEELDEDALINILTEPKNALVKYQALFGMENVELEFEEGALRSIARQAMERTGARGLR SIVERCLL DTMYRLPDLKGLKKVVVGKAVIEEGREPELVFES
134	1379	MTVKTVPVYLDYAATPPVDKRAEKMI PYLTETFGNPASNHSFGWEAEAEVEKARADIAALINADSKEIVFTSGAT ESNNLAIGKAAHFYKSKGNHLITVKTEHKAVLDTMRELRQGYEVTYLDVQENGLVDLDVLA AIREDTILVSVMW VNNIEGVQDIPAI GEICREKIIIFHDVAAQACGKVPDVDEAAKVDLLSMSGHKVYGPKGICALYVRKPRVRL QMHGGGHERGFRSGTLPTHQIVGMGEAFRIAKEELAQDTAHYKLRLDIFLKGIEGIEEVYINGDLEHRVPNNLVNVS FNFVEGESLIMAVKELAVSSGSACTSASLEPSYVLRALGRNDELAHSSLRITFGRMTTEEEVQFAELIKSKIGKL RELSPLWEMFKDGI DLNSIEWAAH
135	1390	MSSTPNKQAGYPRLVADIGGTNARFALETAPRVIEKAAVLPCKDYDTVTD A VRAYLNQSGATAVRHAAFAIANPIL GDWVQMTNHHWAFS IETTRQTLGLDTLILLNDFTAQALAVTQTSSKDLMQVGGQKPV EFAPKAVIGPGTGLGVSGL VHSHAGWVALAGEGGHTSFPPFDMEVLIWQYAKNKYGHVSAERFLSGAGLSLVYEALAAKQAKPAKMPSEITE KALSGASPLCRQTLDFCAMLGTVASNLALT LGARGGVYLCGGI IPRVLEYFKTSPFRSRFENKGRFEAYLAAIPV YVVLSEFPGISGAAAALDNHLRNV
136	1392	MSTQTNFDLVLF GATGDLAMRKLPCLYQAHVAGLLHPEGRILGVSRSSELDTEGFLAKVETSSKIHVKENFSDEAW ASFVERFAYLKVDVTQPDFAALGDLVKARKETDNVVI YLSTAPKFFAQACENLAAIGLNADNVRVLEKPLGTDL ASSQQINTDVARYFKEGQIYRIDHYLGKESLQNLALRANVMFELWNNKYIESVQLTIAEQLGVEERGEFYDIT GALRDMVQNHLMQMLCMTAMEAPASLDADAVRDEKVKVIKSLKPLTVESVNNENVVRGQYTAARGMNGYLEEINVPQ DSFTETYYAIAKAEIENERWKGVFPYLR TGKRMAGKVAEIVLNFKDLNSHIFEGSRTAPNRLVIELQPYESVRLYTQ MKTPGAGNKVETVPLATDLGKALEGRRAEAYERLLLDVINGKLALFNRRDELEAAWEYVMPILENWTNNTTPPHGY GAHSWGPEAAARELLARDGHKWHEEQ
137	1425	MSEQNHQPTEPQLDENQII ALRREKLNIRQQRNAYPNDFKRDSFAADLHAQYGEIGKEELDPOGIPVKVAGRMMML KRQMGKASFATIQDVSGQIQLYLNNKGVSQEVLDDFNHWDLGDIVGAEGTLFKNHNGELTVRVSGIRLLSKSLRPL PDKHKGLSDQETKYRQRYVDLIANEESRNTFIKRSQIIQSVRNFMVGEHYLEVETPMMHPIPGGATAKFPVTHHNA LDIPLYLRIAPELYLKRLLVGGLERVFEINRSFRNEGMSVRHNPEFTMIEFYEAFSDYERMMQMAEDIIRNASRTV NGTANITYNGREVDLESFFERLTILEAIKKYNPHYTDEQLNDAEWLKEIVKHGESLPPSPGISGLQALFEGCAE

		<p> GKLWNPTFIVDYPVEVSPLARASDTKQGLTERFELFVVGRELANGYSELNDPEDQAERFKAQVQKDGADDEAMHY DADYIRAMEFGLPPTGGCGIGIDRLVMLLTDSQTIRDVILFPQMRPE </p>
138	1429	<p> MRKKLTALVLSALPLAAVADVSLYGEIKAGVEGRNYQLQLTEQAANGGASQVKVTKVTKAKSRIRTKISDFGSF IGFKGSEDLGDGLKAVWQLEQDVSVAGGATQWGNRESFIGLAGEFGTLRAGRANQFDDASQAIDPWDSNNDVAS QLGIFKRHDDMPVSVRYDSPEFSGSGSVQFVPIQNSKSAITPAYTKNTNNLTLVPAVVGKPGSDVYAGLNYK NGGFAGNYAFKYARHANVGRNAFELFIGSGSDQAKGTDPLKNHQBHRITGGYEEGGLNLALAAQLDLSSENGDKTK NSTTEIAATASYRFGNAVPRISYAHGDFDIERGKKGENTSYPDQIAGVDYDFSKRTSAIVSGAWLKRNTGIGNYTO INAASVGLRHKF </p>
139	1445	<p> MSDDKSKALAAALAEIKESFGKGAIMKMDGSQQEENLEVISTGSLGLDLALGVGGLPRGRIVEIFGPESSEKTTLC LEAVAQCCQKNGGVCFAFVDAEHAFDPVYARKLVGKVEELYLSQPDTEQALEICDTLVRSGGIDMVVDSVAALVPK AEIEGDMGDSHVGLQARLMSQALRKLTHIKKTNTLVVFINQIRMKIGVMFGSPETTTGGNALKFYSSVRLDIRRT GSIKKGEVLGNETRUVKVIKNKVAPPFRQAEFDILYEGEGISWEGELIDIGVKNDIINKSGAWSYNGAKIGQGGKN VRVWLKENPEVANEIDAKIRALNGVEMHITTEGTQDETDERPEE </p>
140	1452	<p> MQNIFDPLVIRGKSLTPVQGGMGVGSASGLSSAVARENGIGTASVDLRHLHEDLLAESQINPSEEKYTSLNCT ALDREIQKAKSASEGKGLIANNVMKAVKDHAAVYRQACESGADAVVMGAGLPLDLPETEGYHKDVALLPILSES GINIVLKRWMKGLIPDAIVVEHPAHAAGHLGASTVEGVNDAKDFDKRVIETFEVFKSLGLESEKIPILLAGGMA NFEKVKTALKNWGASAVQIGTAFVTEEGDAHLNFKKTLAGAETEKVVEFMSVAGLPARGVRTKFLDSYIKRESKL QTNAKADPRRCTQGLNCLTSCGLRDGLSKAGQFCIDIQLAAAFERGEVDKGLFFRGKDRCPSSAPSSARRYNIC </p>
141	1457	<p> MSOLANAIRFLSADAVQKANSCHPGAPMGMAEMAETLWTKFLNHNPNANPKFYNRDRFVLSNGHASMLLYSLHLTG YNLSIEDLKNFRQLHSHKTPGHPEYGYTDGVETTTGPLGQGIANAVGMALAEKILAAEFNKDGLNVDHYTYVFMGD GCLMEGVSHACSLAGTLGLGLKILVLYDDNNSIDGKVDGWFTENIPORFESYGHVVPVNVNGHDTAAIQAAIEAA RAETGKPSIICCKTLIGKGSANKEGSHKTHGAPLGADEIETARKHLGWTYPAFEIPQEIYDAWNAKEQGAKLEADW NELFAQYQAKYPAEAAEFVRMDKLPDNFDEYVQAALKEVCAKAETIATRKASQNSIEILAKELPELVGGSADLT PSNLTDSNSVSVTRDKGGNYIHYGVREFGMAIMNGLVLHGGVKPFGATFLMFSEYERNALRMAALMKINPVFVF THDSIGLGEDGPTHQPIEQATLRLIPNMDVWRPCDTAESLVAWAEAVKAADHPSCLIIFSQNLKFQARSEQQIND IKRGGYVISEAQGNAQAVIATGSEVELALEAQKALAAQNIIVRVVSMSTNVFDRQDAAYQAAVLPEGLPRIAVE AGHADGWYKYVGLNGAVVGINRFGESAPADLLFKAFGFTVDNVVDTVKSVL </p>
142	1471	<p> MSKKRVLTVGTTTGPILGNVYGAIRPAVRAAQNLTDESFLADYHGIKCHEPEMIHQSTQAVAAATWLACGLDP ERTTFYRQSDTPEVMELNWLTCITAKGLMNAHAYKAQVANAENGQEDDPDFGVEMGLFSYPILMTADILMFNAN EVPVGRDQIQHVEMARDIAGRFNHRFRELFTLPEVKIDENVELLVGLDGRKMSKSYGNTIPLWENDKKTQKSVNKI ITNMKEPGEKQPDDESPLFEIYKAFSTPSETVEFTKMLADGLAWGEAKKLLAAKINAELAEPRERYNELTADPSQI EEILQAGAAKARKEARELLDKVRDAVGIRPLK </p>
143	1472	<p> MRYDKLTAKFQQAALAEQSLALAADGSYLEAGFVLKALLDDQNSGAAALLAHAGVNVQVKQRLQOHLNLSLKVSG QGGDILPSRELQAVLNLMDKAATKRSDAYIASELFLLALVQONDATGKILKEAGATEQINAAIDAVRGGQNVNDA NAEQORDALKKYTLDLTORARDGKLDPVIGRDEIRRAIQVLQRRTKNPNVLIGEPGVGKTAIVEGLAQRIVNGEV PESLRNKRLLVLDLALLAGAKYRGEFEERLKGVLNLDLAKDDGNTLIFIDEIHTLVGAGKTDGAMDAGNMLKPALA RGELHCIGATTLDEYRQYIEKDAALERRFQKVLVGEPSVEDTIALRGLQERYEIIHHGIDITDPAIVAAAELESDRY ITDRFLPKAIDLIDEAASRVMEKETKPEAMDKIDRRLIQLRMEKAHVEKEKDDASKRLELIDEEINGLQKEYA DLDEIWKAEKASIDGAANIKKQIDEVKIKIEQAKRQGDALALASKLMEYEDLEHLEKQRAAERADTDSTKPANKLLR NNVGAEIEAEVVRMTGIPVSKMMEGERDKLLKMEVLRHVVVGQDEAVRAVSDAIRRSRGLADPNKPGSFLFL GPTGVGKTELCKALAGFLFDSEDHLIRIDMSEYMEKHAVARLIGAPPGYVGYEEGGYLTEQVRRKPYSVILLDEVE KAHDPVFNILLQVLDDGRLTDGQGRTVDFKNTVIMTSNIGSQHIQQMGIQDYEAUVKEVVMEDVKEHFRPEMINRI DEVVVFHGLDQDNIRNIAKIQKLEKRLKQNLRLAVSDAALDIKAGFDPYIYGARPLKRAIQSEIENPLAKAL LAGNYAPESEIRVEADGDRKFA </p>
144	1506	<p> MNLHQTVEHEAAAAFAAGIADSFIVLOPTKNAEHGDFQINGVMGAACKAKQNPRLAQKVAEALADNAVIESAEV AGPGFINLRLEFLAQNIQTALNDRFGVAKTDKPTVVIDYSSPNLAKEMHVGLRSSIIIGDSISRVLAFMGNT VIRQNHVGDWGTQFGMLVAYLVEQQKDNAAFELADLEQFYRAAKVRFEDDPAFADTAREYVVKLQGGDETVALWK QFVDISLSHAQAVYDTLGLKLRPEDVAGESKYNDLQPVVDDLVQKGLAVEDDGAKVFLDEFKNKEGEPAAFIQ KQGGGFLYASTDLACLRYRIGRLKADRLLYVVDHRQALHFEQLFTTSRKAGYLPENVGAAGIFGFTMMGKDGKPFK TRSGDTVKLVDLLTEAVERATALVKEKNPELGADAEEKIGKTVGIGAVKYADLSKNRTSDYVDFWDAMLSFEGNTA PYLQYAYTRVQSVFRKAGEWDANAPTVLTEPLEKQLAAELKLFEDVLQSVADTAYPHYLAAYLYQIATLFSRFYEA CPIKAEAGASRNSRLQAKLTGDTLKQGLDLLGIDVLDVM </p>
145	1518	<p> MSQKLILVLNCGSSSLKGAVLNDSGEVLLSCLAEKLNLPDAYITFKVNGEKHKVDLSAHPDHTGAVEALMEELKA HGLDSRIGAIGHRVVSGGELYSESILVDEVIAGIEKCIPLAPLHNPALHLLGLRAAQSIKGLPNVVVFDTSFHQT MPEVAYKYAVPQELYEYGLRRYGAHGTSYRVADETARFLGKDKDLRMVIAHLNGASITAVANGESRDTSMGL TPLEGLVMGTRSGDIDPSVFGFLAENAMTIAQITEMLNKKSGLLGISGLSNDCRTIEEEAAKHGKAKLALDMFI YRLAKYIGSMAVAAGGLDALVFTGGIGENSIIIRERVIGYLGFLGLNIDQEANLKARFGNAGVITTADSKAVAVVI PTNEELMIAHDTARLSGL </p>
146	1533	<p> MKAYLALISAAGVIGLAACSQEPAPAAEATPAEAPASEAPAAEAPADAAEAPAGNCAATVESNDNMQFNTKDI QVSKACKEFTITLKHGTQPKASMGHNLVIAKAEDMDGVFKDGVGAADTDYVKPDDARVVAHTKLIGGGEASLT DPAKLADGEYKFACTFPFGHGLMNGKVTLVD </p>
147	1536	<p> MLTNIAKKIFGSRNDRLLKQYRKSARINALEEQMALSDADLQAKTAEFKQRLADGQTLGDGILPEAFVCREASR </p>

		<p>RTLGMRFHDVQLIGGMVLHDGKIAEMRTGEGKTLVATLAVYLNALAGKGVHVVTVDYLASRDAGIMEPLYNFLGL TVGVIIISDMQPFDRQNAAYAADITYGTNNEFGFDYLRDNMVTDOYDKVQRELNFAVVEVDSILIDEARTPLIISGQ ADDNIQLYQIMNTVPHLRQETEEGEGDYVWDEKAHQVILSEAGHEHAEQILTQMGLLAENDSLYSAANIALMH LMAALRAHSLFHKDQHYVIQDGEIIVDEFTGRLMSGRWSEGLHQAVEAKEGVEIKRENQTLASITFQNYFRLYT KLSGMTGTADTEAFEFQSIYNLETVIPTNRPVQRKDFNDQIFRSAAEKFEAVVKDIEECHKRGQPVLVGTTSIEN SELVSKLLTQAGLPHNVLNAKEHEREALIVAQAGKVGAITVATNMAGRGTDIVLGGNLKHQTDAIRADETLSDEEK QAQIAALEDGWQAEHDKVMEAGGLHIIGTERHESRRIDNQLRGRSGRQGDPSRRFYLSFEDPLRLFLDRAAAI LNRLAPERGVAIEHNLLTRQIEGAQRKVEGRNFMKQVLEYDDVANEQRKVIYSQRNEILTSKDISDLMQEIERSD VVSDDLVDTYMPPDSMEEQWDIPTLENRLAAEFRLHEDIQSWLKADNAIDGQDIKERLIERIENEYAAKTELVGKQA MADFERNVMLQVIDNQWREHLAAMDYLROGIHLRSYAQKNPKQYKREAFMTFQDLWNGIKFHASLLTSVQIEQN PVAVVEEQPIGNIQSIHSESPDMEELGQSQTDLVTEAFNPDGTDFSPEALEARGQIVHRNDPCPGSGGLKYKQCH GKLA</p>
148	1560	<p>MLNKDQFADNHFIPTIIEEDLESKHTAVQTRFPPEPNGLYHIGHAKSICLNFGLAYIYDGLCNLRFDDTNPEKEN DEYVNAIKEDVEWLGFWHAGEPRFASNYFDQLYDYAVGLIKDGKAYVDDLTPPEMREYRGTLTTEAGKNSPYRDRSV EENLDLFTRMKNGEFPDGSKTLLRLKIDMASGNINMRDPVIYRIRRAHHNTGDKWCYIPMYDYTHCISDAIEGITH SLCTLEFEAHRPLYDCVLNIPAPHATRPRQYEFSTRLELLYTTITSKRKLNLQVVEKHVSGWDDPRMPTISGMRRRG YTPPEGLRLFAKRAGISKSENIIVDMSVLEGAIREELENSAPRLMAVLNPLKVTLTNFETGRTQSRRAAFHPNHEEMG EREVPISQTIYIEADDFAEENPPKGFRLIPGGEVRLRHGYVIKCDDEVVKDEAGNVVELKCSIDHDTLGKNPEGRKV KGVHWWSAEHAAEIKVRLYDRLFTVERPDVARGEDGEYLPFTDFLNPESVKEITAYAEPAAKDLPAESRWQFERI GYFTVDRKDHGKDTVPVFNRTVTLKDSWQPK</p>
149	1572	<p>MLEAYRKAARAALGIPALPLNAQQTADLVELLKSPPAGEGEFLVELLAHRVPPGVDDAAKVKASFLAAVAEGSA SSPLISPEYATELLGTMLGGYNIHALIELLDDDKLASIAAKGLKHTLLMFDSDHVDQEKAEKGNKYAQEVLQSWAD AEWFASRAKVPEKITVTVFVKVDGETNTDDLSPAPDAWSRPDIPLHALAMLKNPRDGIPTDKPGEVGPVKLLEELKA KGHPVAVYGDVVGTGSSRSATNSVIWHTGEDIPFVFNKRFGGVCLGGKIAPIFFNTQEDSGALPIEVDVSALKMG DVVDILPYEGKIVKNGETVAEFELKSQVLLDEVQAGGRINLIIGRGLTAKAREALKLPASTAFRLPQAPAESKAGF TLAQKMVGRACGLPEGQGVPRGTGYCEPRMTTVGSQDTPGPMTRDELKDLACLGFSAADMVMQSFCHTAAYPKPVDVK THKELPAFISTRGGVSLRPGDGVHISWLNRLLLPDTVGTGGDSHTRFPIGISFPAGSGLVAFAAATGVMPDLMPES VLVRFSGKLQPGVTLRDLVNAIPLYAIKQGLLTVAKAGKNIFSGRILEIEGLPDLKVEQAFELTDASAERSAAGC TVKLNKEPIIEYMKSNVVLKNNMIANGYQDPRTLEERRIKAMEKWLANPELLEADKDAEYAAVIEINMDDIKEPIIA CPNDPDDVCFMSERSGKIDDEVFIGSCMTNIGHFRAASKLLEGKADTPVRLWIAPPTKMDAKQLSDEGHYVGLGRA GARMEMPGCSLCMGNQAQVREGATVMSTSTRNFPNRLGKNTFVYLGSAELAAICSKLGKIPTVEEYQANIGIINEQ GDKIYRYMNFNEIDSYNEVAETVNV</p>
150	1574	<p>MQVYYDKDADLSLIKGTVAIIGYGSQGHAAANLKDSGVNVVIGLRQGSWKKAEAAAGHVVKTVAEATKEADVVM LLLDPDETMPAVYHAEVTANLKEGATLAFAGHFNHYNQIIPRADLDVIMVAPKPGHGTVRSEYKRGGGVPSLIAVY QDNSGKAKDIALSYAAANGGTKGGVIEFTFRETTETDLFGEQAVLCGGVVELIKAGFETLTEAGYAPEMAYFECLH EMKLIVDLIFEGGIANMYSISNNAEYGEYVTGPEVVNASSKEAMRNALKRIQTGEYAKMFIQEGNVNYASMTARR RLNADHQVEKVGAQLRAMPPWITANKLVDDQKN</p>
151	1577	<p>MLSGAQIIVQSLKAEVVEYFGYPGGAVIEIYDALFQNLKFKHILTRHEQAAVHAADAYARVSGKVGVALVTSGP GVTNALTGIATAYTDSIPMVVISGQVNSLIGTDAFQGEVDTVGITRCPVKHNFVLTIDINELAETIKKAFQIAASGR PGPVVVDVDPKDVTPQAMAKFSYPOEDI FIRSYQPVVQGHIGQIKKAVQMLASAKRPVVYFGGGVVLGNASEELTRFV RMTGAPCTGTLMGLGAYPSGDRQFLGMLGMHGTYEANLHAMQNAADVLAVGARFDDRVVSVPSKFEEKAKKVIHIDV DPSSIAKRVKVDIPIVGDVKNVLSMVALWQKQESVPSDALGKWWKTIEEWRSDCLWFDNGSEIIPQYVVIQKL AEITGNSAIITSDVGQHQMFQYYPFERPRQWLNSGGLTGMVGLPYAIGAKLAAPQDVFCITGDGSIQMNIE LSTCFQYRIPVNVITLNNGYLGMVRQWQEIYYGRESEYTFDSLDPFVKLAEAYGHIGIRVDKKSDEGALLEALN QKDLRFVDFLTDQKQNVMPVGVNGKGLDEMVLPPHMRADGKA</p>
152	1581	<p>MKKLNTQSPDFQAGLKALLAFETAQNPEITERIVADICADVQKRGDAALIEYTNKFDQTNAKSIDDILITQADLNAA FERIPNDVQATALQTAARRVESYHQRQKMSWSYTDDEGTLGQQTITPLDRVGIYVPGGKAAYPSSVIMNAMPAPHA GVKEIIMVVPPTPKGERNDIVLAAAYVAGVTKVFTVGAQVAALAYGTETIPQVDKITGPGNAFVAAAKRRVFGVV GIDMVAGPSEILVIADGTTADWVAMDLSQAHEDEIAQAILIGTSQAYLDEVEAAMDRLIETMPRRDIEASLGN RGAMILAKDLDEACEIANYSISPEHLELSVENPQEWAKKIRHAGAIMFGRYTGESLGDYCAPGNHVLPTSRTARFSS PLGTYDFQKRSSLIQVSEQQAQKLGETASVLAHGESLTAHARAAEFMRK</p>
153	1583	<p>MNLTKTQRQLHNFLLTAEAGSLSKLAKLCGYRTPVALYKLRLEKQAEDEPDARGIRPSLMAKLEKHTGKPKGWL DRKHRETVPETAAESTGTAEQIAETASAAGCRSVTVNRNTCETQITVSINLDGSGKSRLDTGVPFLEHMIDQIA RHGMIDIDISCKGDLHIDHHTAEDIGITLQAIQALGDKKGIIRRYGHSYVPLDEALSRVIDLSGRPLVYNIE FTRALIGRFDVDFEEFFHGI VNHSMMLHIDNLSGKNAHQAEVTFKAFGRALRMAVEHDPDMAGQTPSTKGTLT A</p>
154	1595	<p>MKTSELRQKFLKFFETKGHTVVRSSSLVPHDDPTLLFTNAGMNQFKDVFLGFDKRPYSRATTAQKCVRAGGKHNDL ENVGYTARHHTFFEMMGNFSFGDYFKRAIHFAWEFLTSPEWLNIPKDKLLATVYAEDEAYNIWLNEIGMPSERI VRIGDNKGAKYASDNFWQMGTGPGCPCEIIFYDHGEEIWGGIPGSPEEDGDRWIEIWNCFVMQFNRDEQGNMNP PKPSVDTGMGLERIAAVMQHVHSNYEIDLQDLKAVARETGAFFRMEEPSLKVIADHIRSCSLIADGVLPSPNEG RGYVLRRIIRRAVRHGYKLGQSKPFFHKLVLADLVKEMGGAYPELKEKQAQIEEALKNEESRFAQTLETGMALLENA LVKGGKTLGGEIIFKLYDTYGFYDLTADICRERNIEPDEAGFEREMEAQRARARAAQSFKANAQLPYDGDQDETFK</p>

		GYSERQTESKVLALYKDEQVNELENEGDSGAVVIDFTPFYAESGGQVGDVGYIFSGENRFEVRDQKIKAAVFGQF GVQTSGRLLKVGDSVTAKVDDEIRNANMRNHSATHLMHKALRDVLGRHVEQKGSIVTAESTRFDISHPQAVTAEIEIA EVERRVNEAILANAVNAAIMSMEDAQKTGAMMLFGEKYGEVVRVLQMGGFSTELCGGTHVSRTGDI GLFKI I SEG GIAAGVRRIEAITGLNALKWAQEQERLVKDI I AETKAQTEKDVLAQIQAHAHAKALEKELARAKAELAVHAGAKL LDDAKDLGAALVAAQIEADAAALREIVTDLTGKSDNAVILLAAVNDGKVSILCAGVSKPLTGKVKAGDLVKFAAEQ VGGKGGGRPDLAQAGGTADKLPVLDVSKDWVGAKL
155	1604	MELVFIRHQSEWNAKNLFTGWRDVKLEQGLAEAAAAGKKLKENG YEFDI AFTSVLTRAIKTCNI VLEESDQLFV PQIKTWRLNERHYGQLQGLDKKQTAEQYGEQVRIWRRSYDTLPPLLDKDDFSAHKDRRYAHL PADVVPDGENLK VTLEVRVLPFWEDQIAPAILSGKRVLVAAHGNSLRALAKHIEGISEDIMGLEIPTGQPLVYKLDNLIKVIEKFYL
156	1621	MGIYDFQMKDAEGNAVDLSGYRGKVLIVNTATRCGLTPQYEAQKLYAQYTAEGLEILDFPCNQFREQAESSGE IAQVCMKFGTKFKIFDKIEVNGANTAPLYAYLKSVPQDKGNHFLKDFVLKLAALGEKRDEGDIKWNFTKFLVNR DGEVVERFAPSVTPEEIEADIRALL
157	1636	LLFSSLLFSSLLFSSLLFSSAAQASESSRSPYYQADLAYAAERITHDYKPTGTDKDKISTVSDYFRNIRAH YHPRVSVGYDFGGWRIAADYASRKWNKNKYSVNIKKGRETQDNREELKTENQENG SFHAASSLGLSAIYDFKLN KFDKFKPYIGARVAYGHVKHQSVEKTTITVSKPAATSPQGGPIET
158	1640	MSLYPIYNFSAGPAVLPEAVLETARQEMLDYNGTGFFVMAMSHRSEMFLSILHHAEQDLRQLLKVPDNYKILFQ GATTQFNMAAMNLAHGFRTADAVVTGNWSRIAYEQMSRLTDTEIRLAHGGEQFDYLDLPPVETWDVADPSAFVHF AVNETVNGLYREVPCISEGMPPLVCDMSSEILSREFDVADYGLIYAGAQNIGPAGVTVVIVREDLLERCNDIP DVFNYSRSHINRDGMNTPTSTYAIYMSGLVFRWLQAQGGVKIEAVNRLKAQTLYETIDGSDGFYINRIRPNARSKM NVVFQTGDEELDRRFVLEAELQGLCLLKGYKTVGGMRAIYNAMPLEGVRALADFMDFQRRYG
159	1642	MSREMLQALAEALAEKNVDAEVVQALEFALSTAACKKADREHMDVRVQINRDTGEYQTFRRWLIVADEDYTPDV EKTIEEIQEEIPGTTTIQIEYEEQLPNEGFGROAAQTAKQIILQRI DAEREQNLNEFLAVKEDI VSGTVKRVER HGIIIEVVAGKLDALIPRDQMIPRENFRSGDRIRALFLRVEEIGNTRKQVILSRTSGDFVLKLYANEVPEIADGM LEIRAVARDPGQRAKVAVKANDQRIDPQGTGIGVRGSRVNAVSNELSGERIDVVLWSPEPAQFVMSALSPEVSR VIDEDKHADVIVAEDQLALAI GRGGQNVRLASDLTGWQLNIMTSAEADERNAAEDAAIRRLFMDHLNVDEETADV LVQEGFATLEVAVYPAAELLAIEGFDEEIVDMLNRNARDAILTMAIAAEKLGESDDMRNLEGIDADMLRSLAE AGITTRDDLAEALAVDELEITGVNEETAKAVILTAREHWFTEK
160	1655	MVHIMFNQAAQELTTIRDIRLFAVSRFNEAGLFFGHGTNAHDEAAYLILHTNLPLDMLAPYLDKLLAEKEEV LAVIERRAVEHIPAAYLTHQAWQGEFDFYVDERVIIPRSFYELLDGLRPWIEYDELVHNALDLCTGSGCLAIQM AHHPDAQIDAVDVSLDALEVAGINVEDYGLEERILIHDTLFELEGTYDLIVSNPPYVDAESVELLPEEYLHEP ELALGSGDGLDATRQILLNAAKFLNPKGVLLVEIGHNRDVLEAAYPELPFTWLETSGDGFVFLLTREQLLGE
161	1684	MLDIQLLRNSNTAAVAERLARRGYDFDTARFDTLEERRKSQVQKTEELQASRNSISKQIGALKGQKHEEAQAAMNQ VAQIKTDLEQAAADLDAVQKELDAWLLSIIPNLPHESVPAGKDETENVEVRKVGTPREFDFEIKDHVDLGEPLGLDF EGGAKLSGARFTVMRQIARLHRAALQFMDLTHTLQHGYTEHYTPYIVDDTTLQGTGQLPKFAEDLFHVTRGGDET KTTQYLIPTAEVTLTNTVADSIIPSEQLPLKLTASPCFRSEAGSYGKDRGLIRQHOFDKVEMVQIVHPEKSYET LEEMVGHAENILKALELPYRVITLCTGDMGFGAAKTYDLEVWVPAQNTYREISSCSNCEDFQARRLKARFKDENGK NRLVHTLNGSGGLAVGRTLAVAVLENHQNADGSINI PAALQPYMGGVAKLEV
162	1691	MARHVWQAGREFEIGLDPKIMGINLT PDSFSDGGVYSQNAQTALAHAEQLLKEGADILDIGGESTRSGADYVSP EEWARVEPVLAEVAGVGPISLDTTRTVIMEKALALGGIDIINDVAALNDEGAVELLARQADTGICLMHMQGLPKT MQINPKYQDVVGEVARYLKARSAECIAAGIAPQRIILDPGFGSGFGKPLQHNIALMRHLPELMAETGFPPLIGVSR KSTIGELTGEANAERVHGVSAAALASVARGAQIVRVHVKATADALKVWEALGINL
163	1710	MTDLNTLFLANKQRNPQEPFHQAVEEVFMSLDPLAKNPKYTQSSLLERIVEPERVVMFRVTWQDDKGQVQVNRG YRVQMSSAIGPYKGLRFHPTVDLGLVKFLAFEGVFNALTTLPMMGGKGGSDFPKGSKDAEVMRFCQAFMTELY RHIGADTDVPAGDIGVGGREIGYLFQYKIRNEFSSVLTGKLEWGGSLIRPEATGYGCYVFAQAMLQTRNDSFE GKRVLISGSGNVAQYAAEKAIQLGAKVLTVSDSNGFVLPDSGMTAQLAALIELKEVRRERVATYAKEQGLQYFE KQKPWGVAEIALPCATQNELDEEAATLLANGCYVVAEGANMPSTLGAVEQFIKAGILYAPGKASNAGGVATSG EMSONAIRLSWTREEDVQRLFGIMQSIHESCLKYGKVGDTVNYVNGANIAGFVKVADAMLAQGF
164	1716	MAFYAFKAMRAAALAAVALVSSCGKGDDAAQGGQAPAGREAPAPVGVTVHPQTVALTVELPGRLESRLTADVR AQVGGIIQKRLFQEGSYVRAGQPLYQIDSSTYEAGLESARAQLATAQATLAKADADLARYKPLVAAEAVSRQEYDA AVTAKRSAEAGVKAQAIAKSAGISLNRSRITAPISGFIGQSKVSEGTLLNAGDATVLATIRQTNPMYVNVNQSAS EVMKLRRIAEGKLLAADGVIAVGKIFDDGTVPYKEGRLLFADPAVNESTGQITLRAAVPNDQNIIMPGLYVRVLM DQVAVDNFVVPQAVTRGAKDTVMIVNAQGGMEPREVTVAQQQGTNWIVTSGLDKGDGVVVEGISIAGITGAKKV TPKEWASSENQAAAPQSGVQTASEAKPASEAK
165	1796	MIMAKKISILVGLSRASFAKVALNAAEMFPEGWQAEIVEIGHLPLYNFDYDDPAVEDVPLPESYTAFRETIKAS DGILFVTSENNRTIPACLKNAVDIGSKPNADVWKNPKAGIISHSVGKMGGYSSQKNRLALSIFYDMPVTGQPEVF LGNSPTLFDENGKLIDSARDFVQSYINQFVGLIERNAK
166	1809	MNNLIKINLLPYREEMNRKQKQFQKTLMYGAVLTGVAAVAATYLFIDNMINNQSERNTLLETSLIAHLDTSELQK LKQEKDAFLIKKNKIEELQLKRLQAALDLSLNEAVPGSTYLTSLDAVTADSYRLSGRTSSDNRVAAMMRAMPNTG IFKQPELLSIKKNNSHQEFTLQATLQPIVKAESKENPASGNAQEAN
167	1810	MASKSSKTNLDLNNLHLLNLPARLFIALLAVALGLGYAGLFSQMESLEEYEAKETELKNYKQKSIDAASLNN LRDELASIRSAFDIMLKQLPTDAEIPNLVQELHQAGSSNGLRLDSVMPQPPVDDGPILKPLYSISITGNYEQISQF TRDVGSLSRITITLESKIAQSPENGGNPDGKSSILNLSAIATTYQAKSVEELAAEAQNAEQK

168	1811	MKHYALLISFLALSACSQGSSEDLNEWMAQTRREAKAEIIPFOAPTLPVAPVYSPQLTGPNAFDFFRMETDKKGEN APDTKRIKETLEKFSLENMRVYVILKSGQKVSFIEAEGYVYTVGVGNLQNYGRIESITDDSIVLNELIEDSTG NWVSRKAELLNLSKDNTEQAAAPAAEQN
169	1812	MNTKLTIIISGLFVATAAFQTASAGNITDIKVSSLPNKQKIVKVSFDKEIVNPTGFTVSSPARIALDFEQTGISM QQVLEYADPLLSKISAAQNSSRARLVNLNPKGQYNTVEVRGNKVWIFINESDDTVSAPARPAVKAAPAAAPAKQQA APSTKSASVSEPFPAKQQAAPFTESVSVSAPFSPAKQQAASAKQQAAPAKQQAAPAKQQAAPAKQTN DFRKDGKNAGIIEALGAGFAGQPDISQQHDIIVTLKNHTLPTTLQRSLDVADFKTPVQKVTLKRLNNDTQLIITT AGNWELVNKSAAPGYFTFQVLPKKQNLSEGGVNNAPKFTTGRKISLDFQDVEIRTLQILAKESGMNIVASDSVNG KMTLSLKDVWDQALDLMQARNLDMRQQGNIVNIAPRDELLAKDKALLQAEKDIADLGALYSQNFQKLYKNVEEF RSILRLDNADTTGNRNTLISGRGSLIDPATNTLIVTDTRSVIEKFRKLIDELDVPAQQVMIEARIVEAADGFSRD LGVKFGATGKKKLKNDTSAFGWGVNSGFGGDDKWAETKINLPITAAANSISLVRAISSGALNLELSASELSKTK TLANPRVLTQNRKEAKIESGYEIPFTVTSIANGSSSTNTLKKAVLGLTVTPNITPDGQIMTVKINKDSAPQAS GNQITLCISTKNLNTQAMVENGGLIVGGIYEEDNGNTLTKVPLLDIPVIGNLFKTRGKKTDRRELLIFITPRIM GTAGNSLRY
170	1835	MSVIQDLQSRGLIAQTTDIEALDALLNEQKIALYCGFDPTADSLHIGHLLPVLALRRFQQAQAGHTPIALVGGATGMI GDPSFKAERSLSNAETVAGWVESIRNQLTPFLSFEQGNAAIMANNADWFGSMNCLDFLRDIGKHSVNAMLNKES VKQRIDRDGAGISFTEFAYSLQGYDFAELNKRHGALEIGGSDQWGNITAGIDLTRRLHQKQVFGTLPLVTKSD GTFKFGKEGGAVWLNAKKTSPIYQYQFWLVADADVYKFLKYFTFLSIEIDAIEAKDKASGSKPEAQRIAEEMT RLIHGEEALAAQRISESLEAEDQSSLTESDFEQALDGLPAFEVSDGINVVEALVKTGLASSNKEARGFVNSKAV LLNGKPAEANNPNHAAERPDACLLNGEHKRFKYITLRRGKRNHALLVWK
171	1838	MSLKCGIVGLPNVGKSTLNFALTQSGIEAANYPFCTIEPNVGIVEVDPDMAELAKIVNPQKMPAIVEFVDIAGL VAGASKGEGGLGNQFLANIRETDAIVNVVRCFDDDNIVHVAGRVDPADIETIGTELALADLASVEKAVREKRAR SGDKDAQKLVLDCKLLPHLDEGKPVRSFGLDAERAMLKPLFLTAKPAMYVGNVAEDGFENNPHLDRLKELAAK ENAPVAVCAAMESEIAELEDEKAEFLAEMGLEEPGLNRLIRAGYDLDGLQTYFTAGVKEVRAWTIHKGDTAPQA AGVIHTDFERGFIRAQVISYDDFVSLGGEAKAKEAGKMRVEGKEYVVDGDVDMHFLFNV
172	1843	MPTQSKHASINIGLIQAREALMTQFRPILNQANITDQQWRIIRLLAENGTLDFQDLANQACILRPSLTGILTRLEK AGLVRLKPSNDQRRVFLKLTAEGEKLYEEIGEEVDERYDAIEEVLGREKMLLLKDLALAEAKIEDALNS
173	1849	MSTPALLVLADGSVFHGTISIGYEGSTSGEVVFNMTSGYQEIILTPSYCKQIVTLTYPHIGNTGTNAEDESRSVY AAGLIIRDPLLSNFRASESLHDYLVNRKTVAIADIDTRRLTLLREKGAQGGAILTGADATIEKAQELIAAFGS MVGKDLAKEVSTETETEWTEGEWALGKGFVTPDEQPYHVVAIDFGVKTNILRMLASRGRLTVVPAQTSADVLAL NPDGVFLSNGPGDPECTYAIKAVQKLIESGKPIFGICLGHQLISLAIGAKTLKMRFSHHGANHPVQDLDSGKVI TSQNHGFAVDADTLPANARITHKSLFDNTLQGIELTDKPVFCFQGHPEASPGPDVGYLDFKFIGNMKAakra
174	1854	MSIPINFNNKYLNDMRNKNRIIEAFPFNYNQRYAVILTRYKPDPRPDDYAQAKLEFFNLNSSENSIFAYADFY EVHFKSATDFINFKINVQAGAAKIREIFSFSNLFADFIPTQTKDLDDIYKKIVATRELNPSPNTIYCYDVRN GKDKAGKPNRRSVENSEKAKILRPELYEKFKADSNYSFFSDNPSDEKTDAEIIREVTNRN
175	1855	MPKRTDLKSILIIAGPIVIGQACEFDYSGAQACKALREEGYKVLVNSNPATIMTDPEDADVTYIEPIMWQTEK IIAKERPDAILPTMGQTALNCALDLARNGVLAKYNVELIGATEDAIDKAEDRGRFKEAMEKIGLSCPKSFVCHTM NEALAAQEQVGFTLIRPSFTMGSGGGIAYNKDEFIAICERGFASPTHELLIEQSVLGWKEYEMEVRDKNDC IIICSIENFDPMGVHTGDSITVAPAQTLTDKEYQIMRNASLAVLREIGVDTGGSNVQFAVNPANGEMIVIEPNRV SRSSALASKATGFPIAKVAKLAVGFTLDELNDITGGKTPASEPSIDYVVTKIPRFAFEKFPAADDRLLTQMS VGEVMAMGRTIQESFQKALRGLETGLCGFNPRSEDKAEIRRELANPGPERMLFVADAFAFRAGFTLEEIHEICAIDPW FLAQIEDLMKEEKAVSDGILSDLDFAALRRLKRKGFSDKRLAQLLNVSKEVREHRYALKLHPVYKRVDTCAEFA TETAYLYSTYEECESRPSDRKKVMILGGGPNRIGQIEFDYCCVHAALALRESGFETIMVNCNPEFTVSTDFDTS RLYFEPLTLEDVLEIVRTENPWGVIHYGGQTPKLKLANALVENGVIIGTSADSIDAAEDRERFQKVLNDLGLRQ PNRIAHNEEALVKAEEIGYPLVVRPSYVLGGRAMQVVSAAELQKYMREAVQVSEDSVLLDDFFLNNAIEVDVDC VSDGKDVVIGGIMQHQVQAGIHSGDSCSLPPYSLSEEIQDEIRRTKAMAYALGVVGLMNVQFAVQDGVVFLV NPRASRTVPFVSKATGVPLAKVGARCMAGISLKEQGEKEVVPDFYAVKEAVFPFIKFPGVDTILGPEMRSTGEVM GVGASFGAAYKAQLGAGERLNPTGKIFLSVREEDKERVIKTAKNFQVLGYGICATRGTAQYLTEHGLIVQTINKV PEGRPHIGDALKNGEIALVVNTVSSDPQSVSDSHIIRQSALQQRVPQYTTTAGGEAMSEGAksrdhlgvysvqelH GRLKNRN
176	1859	MDISDFDTLPEKLIHQHPPEVRGSSRLVALPDMPLQDRVFGDLDPDYVEAGDVLVFNNTKVMKARLFGQKDSGGR IEALIERVLDNHTALAHIRSSKSPKPGMGLVFEGGIRAVTVGREGELFCLRFEGGETVYELLEQNGHLPLPPYIER AADADDDSRQTVYAKYQGAAPTAGLHFTTEELLHRLKDKGAVTAEVTLHVAGAGTFQPVVDKIEEHKMHEWFE VPSETAAAVEAAKARGNKVAVGTTSMRALESAAARATGRLLKAGQGDITFITPGYRFNVVDRLVTNFHLPKSTLLM LVSAFSGMGHIRAAYRHAVEREYRFFSYGDAMVLGRNEGVR
177	1861	MLKKVLIANRGEIALRVLACREMGIATVAHSEADKDSLHVKLADESVCIGPAASAQSYLNPVPAIAAAEVSCAD AVHPGYGFLAENADFAEQVEQSFTFIGPKPDTIRLMDGKVSASHAMIAAGVPCVPGSDGALPDDGEEILKIADKV GYPVIIKASGGGGGRMRVVEKKEDLLQSVEMTKAEAGAAFGNPMVMERYLQRPVHVEIQVIADEHGNAYLAER DCSLQRRHQKVIIEAPAPFITEKERAKIGNACADACKRIGYRGAGTFEFLYEDGEFFFIEMNTRVQVEHPVTELT GVDIVQEQLRIAAGLPLOYKQKDIQVEGHAFECRINAEDPYNFIPSPGLIESCHLPGGFGIRVDSHIYQGYRIPPY YDSLIGKICVHGKTREQAMAKMRVALAELAVTGIKTNTPLHRDLFADAGFQKGGVSIHYLEHWLEDRKAKQDK
178	1862	MPYQOITVNVNDAVAERLADALMEHGALSAIEDAYAGTQNEQAFGEFGMPAEQIQWQSKVIALFGEHDEAAAI

		QTATQECGLKDLAYTGETIEDQDWVRLTQSQFDPDIRISDRLWITPSWHEVPEGSAVNLRDPLGAFGTGSHPTTRL CLKWLDLTQLKNGESVLDYCGSGILTIAALKLGAGFAVGVDIDEQAVRAGKDNAQAQNVDAQFFLPDGLPQGGQFDV VVANILANPLRMLGEMLAARTKQGGRIVLSGLLDEQAEELGGIYSQWFDLPAETEEGWARLSGVKR
179	1864	MNRNEILFDRAKAIIPGGVNSPVRAFSGVGVPRFIKKAEGAYVWDENGTRYTDYVGSWGAIVGHAPPEVETVC EAALGGLSFGAPTEGEIVIAEEIAKIMPSVERLRVSSGTEATMTAIRLARGFTGRDKIKFEGCYHGHSDSLLVK AGSGLLTFGNPSSAGVPADFTKHTLVLEYNNIAQLEEAFAQSGNEIACVIVEFFVGNMNLVRPTEAFVKALRGLTE KYGAVLIYDEVMTGFRVALGGAQSLHGITPDLTMTGKVIIGGMPLAFAFGGRKDIMECISPLGGVYQAGTSLGNPIA VAAGLKTLEIIQREGFYENLTARTEQLVQGFRTAADAAGIEFTADSVGGMFGLYFAAHAPRNYADMARSNIEGFKQ FFHGMLDNRNVAFGPSAYEAGFVSAHTPELIDTVAVAVEVFKAMAE
180	1903	MTLAEFWPLCLRRLDHMLPQGGQFAQWIAPLTVGEEGVVVYVYGNQFACNMLKSQFAGKIEAVREELAAGRSFAVF KPEGVRYEMAAVEGAVEPAEPSLHAVSEGMPVQVLELDELPEEPVKPAASKTAADILAERMKNLPHEPRQAAGS ASRPESVAVAKARTDVQRDAEEARYEQTNLSPDYTFDTLVEGKGNRLAAAAQAIAESPGQSYNFFLYGSTGLGK THLVQAVGNELLKNRPDAKVRVMHSDDYIRSFMAVRNNTYDVFKQYKQYDLLIIDDIQFIKGRDRTMEEFFYLY NHFHNEKKQLILTCVLPKIEGMDRLKSRFSWGLTLEPEPELEMRIAILQKKAEEAGISIEDEAALFIANLIR SNVRELEGAFNVRGASSRFRMNPVIDIDLARTALQDIIAEKHKVITADIIIDAVAKYRIKISDVLGKKRFRNIAR PRQVAMSLTKELTTLSPSIGDSFGGRDHTTVMHGIRAVAKLREEDPELAQDYEKLLILIQN
181	1920	MTQDKILILDFGSQVTQLIARRVREAHVYCELSHSDMPLDEIKAFNPKGIILSGGPNVSYESDYQADTGIFDLGIP VLGICYGMQFMAHHLGGEVQPGNQREFGYAQVKTIDSELTRGIQDGEPTLDDVWMSHGDKVSKLPDGFVIGNTPS CPIAMMENAEKQFYGIQFHEVTHTKQGRALLNRFVLDICGAQPGWTPMNYIEEAVAKIREQVGSDEVILGLSGGV DSSVAAALIHRAIGDQLTCVFDHGLLRNLSKVMMDMFARNLGKVIHVDAEQGFMAKLAGVTDPEKKRKIIIGAE FIEVFDAEEKKLTNAKWLQGTIYPDVIESAGAKTKKAHAKSHHNVGGLPENMKLKLLEPLRDLFKDEVRELGVA LGLPREMVRHPPFGPGLGVRLGEVKKEYADLLRQADDIFIQELRNTTDENGTSWYDLTSQAFVFLPVKSVGVM GDGRTYDYVIALRAVITSDFMTAHWAELPYSLLGKVSRIINEVKGINRVYDVSGKPPATIEWE
182	1921	MSTQDLNGKIALVTGASRGIGAAIADTLAAAGAKVIGTATSESGAAISERLAQWGGEGRVLNSAEPETIESLIAD IEKAFGKLDILVNAGITRDNLLMRMKEEEDDQMVNLSVFRASKAVLRGMMKQRSRIINITSVVGMGNAGQ TNYAAAKAGLIGFSKSMAREVGSRGITVNCVAPGFIDTDMTRALPEETRQTFTAQTALGRFGDAQDIADAVLFLAS DQAKYITGQTLHVNGGMLMP
183	1930	MMTQTLLELLELPPKALNNLGNHFAASVAEGLEKAQLVDGAEFTAYASPRRLAVQVKNVAVQADQKIVKKG PAVANAMKDGAPTKALEGFARGAGAKIEDLTIHVDGKQDVYAYEYVQIGKPLGGLEDIIINQAVKKLPKVMRWG SSTFTFVRPVHGLVVLHGGDIVNVSVLGLQSGNKTGLHRFLSDGEITENADSYAAQMREQQKVVASFAERKAAIQ TVLEGQARRLNATAAADEALLDEVLTALVEWPVLEAGFEHFLAVPQECILITMOQNQKYFPLLDQNGKLMNRFL VSNLQTEDPHSIIQGNERNVLRARLSDAEFFYKQDQKATLESRLPKLTNVVYHNKIGSQAERIERLQSIAAHIAKAL GADAAAERAARLAKADLVTEMVGEFPELQGTMGKYIARLDGETEEITEAVEQHYQPRFAGDNLPEGKIAAVALA DKLETLVGIWGLIPTGDKDPYALRRAALGILRMLMQYGLDVNELIQTAFNSSFQGLLNEKTPSETADFMQARLA VLLQNDYPQDIVAAVLAKQPRRLDDLAKLQAVAAFKQLPEAAALAAANKRVQNLKKADAELGAVNESLLQQDEE KALFAAQGLQPKIAAABAEGNFQTALSELASVKPQVDAFFDGMVMAEDA AVKQNRNLNLLRLAEQMNNAVADIAL LGE
184	1934	MSQKIVQIIGAVVDVEFPRDMI PRVYDALKDENGTLLEVQQLLGDGVVRAIAMGSSDGLKRGMTVSNTGAPITV PVGKGTGLGRIVDLGTVPVDEAGPIDTKSRAIHQAAPKFDELSTTELETGKVIDLLCPFAKGGKVLFGGAGV GKTVNMELINNIKAHSGLSVFAGVGERTREGNDFYHEMKDSNVLDKVAMVYGMNEPPGNRLRVALTGLTMAEY FRDEKDENGKGRDVLFFVDNIYRYTLAGTEVSALLGRMPSAVGYQPTLAEEMGRQERITSTQTSITSIQAVYVP ADDLTDPSPATTF AHL DATVVL SRDIASLGIYPAVDPLDSTSRQLDPMVLGQEHYDVARGVQSTLQYKELRDI ILGMDLSDEDKLTVMRARKIQRFLSQPFHVAEVFTGSPGKYVALRDTIAGFKAILNGEYDHLPEQAFYMGVSIEE AVEKAKTLN
185	1936	MQLNPAEISDLIAKAKIENLSVNAEVRTCGTVISVTDGIVRIHGLSDAMQGELEFPNGTFLGLAMNLERDSVGA VVL GEYEHKEGDTVTCTGRILEVPVGRVLDVGRVVDALGRPIDGKGPINTTLTAPIEKIAPGVIARKSVDPQMOTGLKA IDSMVPVGRGQRELIIGDRQTGKTAVALDAIVNQKGTGVICIIYAIGQKASSIANVVRKLEEHGAMEHTIVVAATA SEAAALQYIAPYSGCTMGEFFRDRGEDALIVYDLSKQAVAYRQISLLLRPPGREAYPGDVLYLHSLRLERAARV NEHEVEKLTNGEVKGTGSLTALPIIETQAGDVSAFVPTNVISITDGQIFLETDLFNAGIRPAINAGISVSRVGGGA AQTKVVIKLGGGIRLALAQYRELAASFQFASDLDEATRKQLEHGEVTELMKQKQFSTLNTAEMALTLWAINNGSY SDVPVAKALAFESEFLSFVRTQHPEVLEAVNASGAMSDESEKLEAMKSFKSSYAYQA
186	1937	MAEFATIPYAKALFGLAQEKQIESWLGGLEKLAADVQEGKVASLIDRPETNASEKADILIDLVLKDKELKNF VIVLAGQKRLSILPEVYAYQYQDLTSLFNHIKSAVIYSAYPLTDKQVGELVQMLNKRFDSELKISVEIEPELIGGIK VEVGQVLDLSVQGKLSALYTTMTN
187	1938	MNINATLFAQII VFFGLVWFTMKFVWPPIAKALDERAAKVAEGLAAAEGRKSDFEQAEEKVAELLAEGRNQVSEMV ANAEKRAAKIVEEAKEQASSEAAARIAAQAKADVEQELFRARESLEQVAVLAVKGAESILRSEVDASKHAKLLDTL KQEL
188	1953	MMTLYSGITCPFSHRCRFVLYEKGMDFEIKDVIDIYNKPEDLAVMNPYNQVPVLVERDLVLHESNINEYIDERFPH PQLMPGDPVMRGRRLVLYRMEKELFNHVQVLENPAATNKEQAKAREAI GNGLTMLAPSFSKSKYILGEDFSMIDV ALAPLLWRLDHYDVKLKGSAAPLLKYAERIFQREAFIEALTPAEKAMRK
189	1966	MSPSPFIEMKDVAFAYGDRPILKNINFSIPQGNFAAVMGSGSGKTTLMRLITGQIRPQSGQVLI EGRDLAGFSAD ELYEHRRRMGVL FQH GALFTDLSVFDNTAFPMRELTRLPEAVIRDLVLLKLNAGVLRGVENLMPSELSGGMSRRVA

		LARTIALDPEIMLYDEPFTGLDPIISLGVIAHLISRVNKLARSTSIMVTHDIEKSLEIVDQVIFLANGEIMFSGSPQ EMRELDSPWVRQFVGGADGPVAYRPAQTSLOQDILLG
190	1968	MKQLAMYINGRFENDFNGEWRDVLNPFSTEEAIAREPKGKADVDRAVAAARAAQPAWERLPAVERGAYLRKIAQGI RERADELTDITVAEGGKTDLARVEVMFTADYLDYQAEWARRYEGEIIQSDRPRENILLFKRPLGVIAIGILPWNFP FFLIARKMGPALVTGNTIVVKPSSVTPINCHIFAEIVDAVGLPAGVFNVNPGAEIGNALSAPQVDMVSLTGSV EAGRQVMEASANITKVSLELGGKAPAIVLKDADLDLAVKSILASRVGNTGQICNCAERVYVHSSSLKDAFIEKMTA AMKGVRYGNPAEAEAGALEMGPLIEERAVKAVAVERAVKQAKLVCCKRAEGRGYFFETLLTDTDNSMDIMK EETFGPVLVPSAFDTLDQVIALANDCEFLTSSVYTTNLNEAFYVTRRLQFGETYINRENFEAMQGFHAGWKSGI GGADGKHGLEEYLQTVVYLETDI
191	1982	MSNRPTLLLVGDSSYLRYAHAMQNLTPADGAPTALYGVNLMLRRLRSEYPHYCAVVFDAKGKNNFRHQMFEY KATRPMPDDLRPQAEALPDLVRLTGWPVLVIGQVEADDVIGTLAKQGAHGLRVIIVSTGDKDMAQLVDERVTLVN TMSSETLDIEGVKAKFGVRPDQIRDYDALMGDKVDNVPVGEKCGPKTAVKWLEAYGSLAGVMEHASEIKGVGENL QAALPQLPLSYDLVTIKTDVDLHAELSDGIESLRRTTPKWAQLVDFKRWGFRWLKEAESNMNTGSTDDLFGSDS IGEQAALNAEMPFEKQAEKATAPEKLDYQAVTTEAQFAALLDKLSRADTIGIDTETSLDAMNASLVGISIATFQAG EAVYIPVGHSLTAAPQLDLQDVLGRKLPHLGNPALKKIGQNLKYDQHVAFANYGIALNGIAGDAMLASYIIIESHLG HGLDELSEWLGLTITYESLCGKGAQIGFADVAIGQATEYAAQDADFALREAHRAQMDEKQLEMYEKMELPV AQVLFEMERNVQIDRAELARQSAELGAELMKLEQEAAYAGQPFNLNSPKQLQEILFDKMGIPTKGLKKTAKGGI STNEAVLEQLAPDYPLPKIILQNRSLAKLKSTYTDKLEPMISPKDGRVHTTYAQAVAITGRLASNNPNLQNIPIRT EEGRKVRRAFTAPQGSVIVSADYSQIELRIMAHLSGDKTLIAAFQNGEDVHRRTAAEVFGTAPENVSSEQRRYAKS INFGLIYGMGQYGLAKSLGIDNLSAKNFIDRYFARYPGVAEYMQRTKEQAAAQGYVETLFGRRLYLPDIRKNANA RAGAERAAINAPMQGTASDLIKRAMIDVSRWLSECEASPWDELLQSKLIMQVHDELVLVETELDFVKEKLPQIM AKVDGGLLDVPLVAEVLGVGENWEEAH
192	1996	MSVVLPLRGVTALSDFRVEKLLQKAAALGLPEVKLSSEFWYFVGSEKALDAATVEKIQALLAAQSVEQTPKAREGL HLFLVTPRLGTISPWASKATNIAENCGLAGIERIERGMAVWLEGRNLNDEQKQQAALLHDMTESVLPDFQTASKL FHHLESETFSGVDVLGGKEALVKANTEMGLALSADIEDLVENYQALQRNPSDELMMFAQANSEHCRHKIFNAD FILNGEKQPKSLFGMIRDTHNAHEPCTVAYKDNSSVIEGAKIERFYPNAAENQGYRFHEEDTHIMKVETHNHPT AIAPFAGAATGAGGEIRDEGATGKGSRPKAGLTGFTVSNLNIPLDKQWEQDYKPEHISPLDIMIEGPIGGAFF NNEFGRPNLLGYFRTFEEKFDGQVRGYHKPIMIAGGLGSIQAQQTHKDEIPEGALLIQLGGPGMLIGLGGGAASSM DTGTNDASLDNFNSVQRGNPEIERRAQEVIDRQCWLGGKNPIISIHVDGAGGLSNAFFELVNDARRGAVFKLREVP EEHGLNPLQIWCNESQERYVLSILEKDLDAFRAICERERCPFAVVGATDDGHLKVRDDLFAANNPVDPLNVLGK LPKTRTRDKTVAPSKKPFHAGDIDI TEAAYRVLRLPAVAAKNFLTITIGDRSVGGLTHRDQMVGYQTPVADCAVTM MGFNTYRGEAMSMEKPTVALFDAPASGRMCVGEAITNIAAVNIGDIGNIKLSANWMAACGNDEKLYRTVEAV SKACQALDLSIPVKGKDSLMTKTVWQDGEKKS SVSPSLIISAFAPVKDVRKTVTPELKNVEDSVLLEFVLDLGFKA RMGGSFAFGQVYNMNSGDAPDLDDTGRKAFYSVIQQLVAENKLLAYHDSRSGGLFAVLVEMAFAGRCGLDIDLNLL LAQTFTITNHTALSQSLRTEEVKALAWEQETIARTLFNEELGAVIQVRKQDVADIINLFYQQQLHNNVFEIGTLTDE NTLIIRDGQTHLISDNLIKQQTWQETSHQIQRLRDNPCADSEFALIGDNERSALFADVKFVDNEDIAAPFINSG AKPKIAILREQVNGQIEMAAAFTRAGFDAYDVHMSDLMAGRIHLADFKMLAACGGFSYGDVLGAGEGWAKSILFH PALRDQFAAFADPDTLTLGVCNCGQMVSNLAEIIPGTAGWPKFKRNLSEQFEARLSMVHVPSKASLILNEMQSS LPVVVSHGEGRADFALHGGNISADLGIALQYIDGQNVQTYPLNPNNGSPQGIAGVTNADGRITIMPHPERVYRA AQMSWKPEGWTELSGWYRLFAGARKALG
193	2000	MNQTAIRNADVRTRFIDDMFVRGLHVRLENVQHVQKQNYPAAIRRALGELLAAGVLLSGNLKNEGTLLIVQVQ RQRLKMLVAEASDRTRATARARDETAEIADDESGLDGLGEGGVFLTLQPKDGEPPQGVVPLEGGGIAQMLVNYM KRSEQLDTHIVLSASDEAAGLLVQRLPEEVLDEEAWEHVSTLARTLTAEELAGLDAQHVLYRLFHETPPRVFEPE TFEFSCCSRGVSDMLMLGGEVGGVVEQGSIEVDCDFCHSKYVDETDVNALFGEDVVGAKGLPRHTVQ
194	2039	MKKSIALTLAALPVAAMADVTLYGTIKAGVETSRVSFHQNGQVTEVTATGIVDLGSKIGFKGQEDLGNGLKAIW QVEQKASIACTDSGWGNRQSFIFLKGFGKLRVGRNLNSVLKDTGDINPWDSKSDYLGVNKIAEPEARLISVRYDSP EFAGLSGSVQYALNDNAGRHNSESYHAGFNYKNGGFFVQYGGAYKRHHQVQEGNLIEKYQIHRVLSGYDNDALYAS VAVQQQDAKLTASNSHNSQTEVAATLAYRFGNVTPRVSYAHGFKGLVDDADIGNEYDQVVVGAEYDFSKRTSALV SAGWLQEGKGENKFVATAGGVGLRHKF
195	2057	MKTFSAPHEVKREWFVIDAQDKVLGRVAAEVASRLRGKHKPEYTPHVDTGDIYIVINADKLRVTGAKFEDKKYFR HSGFPGGIYERTFREMGEQFPGRALEQAVKGMLPKGPLGYAMIKKLKVYAGAHAHAQQPKVLELK
196	2079	MKVGVFVGRGMVGSVLMQRMKEENDFAHIEAFFFTTSNVGGAAPDFGQAATLLDANNVAELAKMDIIVTCQGGD YTKSVFQALRDSGWNGYWI DAASSLRMKDDAIIVLDPVNRDVLNGLKNGVKNYIGGNCVSLMLMALGGLFQNDL VEWATSMTYQAASGAGAKNMRELISGMGAVHAQVADALADPAGSILDIRKVSDFLRSEDYPKANFGVPLAGSLIP WIDVDLNGQSKEEWKGGVETNKILGRSDNPTVIDGLCVRVGAMRCHSQAITLKLKDLVPSEIETILAGANDWVK VIPNEKEASIHETPAKVTGTLSPVGRIRKLGMGGEYISAFVTGDQLLWGAAPLRRVLRLVGLSL
197	2086	MKFIDEAKIEVAAGKGGNGATSFRREKFVPRGPGDGGDGGKGSVWAEADENTNTLVEYRFVKRYQAKNGEKHGHS DRYGAGADDIVLKMPVGTILRDLDTGETVADLYTHGQVRCLAKGGKGLGNIHFKSSVNRAPKQSTPGEEGEARSL QLELKVLAADVGLLGMNPAGKSTLITAVSAARPKIANYPFTTLHPNLGVVRIDENHSFVMADIPGLIEGAAGAGLG HRFLKHLSTGLLLHVVDLAPFDETVPNAEEALAIINELRKYDEELYGKPRWLVLNKLMDLDEEEAQTRTAAFLEA VGWDYKPKDDRFQFDMETPRLFQISALTHQGTQELVHQINQYLTEKKRIEAEKAEKAAANVEIEEQPKTDTGV FKPE

198	2101	MSQITMRQMI EAGVHFGHQTRFWNPMAQYIFGARNKIHI VNLKTLPMFQDAQEA VRRVLVANKGTVL FVGTKRQA RDI IREEATRAGMPFVDYRWLGGM LTNKTVKQSIKRLEEKTA ALENAE SFGSKKEILEMQRDVEKLESLGGIK NMKG LPAIFVIDTGYQKGT LVEAEKLGIPVIAVVDTNNSPDGVKYVIPGNDDSAKAI RLYCRGIADAVLEGKNQA LQETVAAAQEAAAAE
199	2102	MAEITAKMVADLRAATGLGMECKKALVEAEGNFDKAEELIRIKSGAKAGKLAGRTAAEGV LAYAINGNV GALVEV NCETDFVAKDAGFVEFANFVAKTAAEKKPASVEELSELVEAERKAI IAKLGENMSVRRFQVIDTANQLVAYIHGAL ATEGVLVEYKGS EDVARKIGMHIVAAKPQC VSEAEVDAETVEKERHIYTEQAIASGKPADIAAKMVEGRIRKFLAE ITLNGQAFVMNP DQTV AQFSKENGTEVISFVRYKVG DGEIKKAVDYAAEVA AAAKV
200	2103	MTQQIKYKRVLLKLSGESLMGSDPFGINHDTIVQTVGEIAEVVKMGVQVGVIVGGGNI FRGVSQAQGSMDRATADY MGMATVMNALALKD AFETLG I KARVQSALSMQOIAETYARPKAI QYLEEGKVVI FAAGTGNPFFTTDTAAALRGA EMNCDVMLKATNVDGVYTADPKKDPSATRYETITFDEALLKNLKVMDATAFALCRERKLNI VVFGIAKEGSLKRVI TGEDEGTLVHC
201	2129	MSQNHTILQSLPVGQKVGIAFSGGLDTSALLWMLKLGALPYAYTANLQGPDEDDYNAI PKKAMEYGAENARLIDC RAQLAHEGIAAIQCGAFHVSTGGIAYFNTTPLGRAVTTGMLVSAMKEDDVNIWGDGSTYKGNDIERFYRGLLTNP ALKIYKPWLDQQFIDELGGRHEMSEFLIANGFNKYMSVEKAYSTDSNMLGATHEAKDLEFLNSGKIKV KPIMGVAF WDENVEVSPEEVSVRFE EGV PVALNGKEYADPVELFLEANRIGGRHGLGMSDQIENRIIEAKSRGIYEAPGMALFH IAYERLVTGIHNEDTIEQYRINGLRLGRLLYQGRWFDSQALMLRETAQRWVAKAVTGEVTELELRGNDYSILNTES PNLTQPERLSMEKVEDAAFTPLDRIGQLTMRNLDTITRVKLG IYSQSGLLSLGEGSVLPQLGNKQ
202	2138	MEAEVINQLNNTLNDLEKRS EDIRVMDYQGGKDRLEEVIGLSEDP ELWNDPKRAQETGKERKILEGIVLTLDNIA SGIEDNRMLIEMTVEENDEEGFAAVQEDVAGLEKQMADELFKRMFNQPADPNCFIDITAGAGGTEAEDWAGMLFR MYSRYAERKGFRIEILEEDDGEIAGINRATIRVEGEYAGLLRTETGVHRLVRYSPFDSNNKRHTSFASVFVYPEI DDSI EIEINPADLRIDTYRASGAGGQHINKTDSAVRITHEPTGIVVQCQNDRSQHANKAAAMEMLKSKLYELEM RK RNEEKQALEEGKSDVGWGSQIRSYVLDSSRIKDLRTGYEVGNTKAVLDGDLGDFIEASLKQGV
203	2154	MSVLIIVEHDNKQLNPTTLHAVTAAAKLGKVDLLVAGNGASAVVEFAKQVAGVKKVLVADAHAHYAEGLAELAPLV VKLAADRYVAATATTFGKNLLPRVAALLDVQISDLTEIVDNTTFVRPIYAGNAFETVQADSEKLVLTFRATVFD AVAAQGGNAE VINVEATPAQNLSRFVNRQLSHSDRPELTQAKVIVSGGRALGSAEFNEVLTPLADVLGAAIGASR AAVDAEYAPNDAQVQGTGKVVPQLYFAIGISGAIQHVAGMQDSKVIVAINKDADAPIFNVDYGLVGLDFEIVPQ LTEVLKN
204	2155	MKALVAVKRVVDYNV KVRVKADGSDVDIGNVKMSMNPFEI AVEEAVRLKEAGKVSEIVAVSLGEKKCEETLR TAL AMGADRAIHVETDTKLESLAVAKLLKAVADKENPQIFL GKQAI DDDANQVAQMLAALLNAAQGT FASKVQIEGDE VQIVREIDGGEETI ALKLPAVISADLR LNEPRFVKLPNIMAAKKKPLEKLT PDDL VADISPRLKTVKFAEPKARQA GVKVASVAELVEKLKNEAKVI
205	2159	MSIKVAINGFGRIGRLALRQIEKAHDIEVAVNDLTPAEMLLHLFKYDSTQGRFQGTAE LKDDAIVVNGKEIKVFA NPNPEELPWGELGVDVILECTGFFTNKT KAEAHIRAGARKVVISAPGGNDVKTVVYGVNQDILDGSETVISAASCT TNCLAPMAAVLQKEFGVVEGLMTTIHAYTGQNTLDAPHRKGLRRARAAALNIPVNSTGAAKAIGLVIPELNGKL DGSAQRVFPVASGSLTELVSILERPVTKEEINAAKMAAASESYGYNEDQIVSSDVVGIEYGS LFDATQTRVMTVGGK QLVKTVAWYDNEMSYTCQLVRTLEYFAGKI
206	1126 1164	MKTVSTAVVLA AAAVSLTGCATESSRSLEVEKVASYNTOYHGVRTPI SVGTFDNRSS FQKGI FSDGEDRLGSQAKT ILVTHLQQTNRFNVLNRNLNALKQESGISGAHN LK GADYVVTGDVTEFGRRDVG DGHQLFGILGRGKSQIAYAKV ALNIVNVNTSEIVYSAQGAGEYALNSREIIGFGGTSGYD ATLNGKVLDAIREAVNSLVQAVDNGAQNPNR
207	1799	MSEYLF TSES VSEGHDPKQVADQVSDAILDALAQDPKARVAETLVNTGLCVLAGEITTTAQVDYIKVARETIKRI GYNSELGFDANGCAVGYYDQ QSPDIAQGVNEGEGIDLNQAGDQGLMFGYACDETPTLMPFAIYYSHRLMQRQS ELRKDGRPLWRPDAKAQLTVVYDSETGKVKRIDTVVLSTQHDP SIAYEELKNVIEHIKPVLPSELLTDETKYL INPTGRFVIGGPQGDCLTGRKIIVDTYGAAPHGGGAFSGKDPSKVD RSAAYACRYVAKNIVAAGLATQCQIQVS YAIGVAEPTSSIDTFGTGKISEEKLIALVREHFDLRPKGIVQMLDLLRPIYSKSAAYGHFGREEPEFTWERTDKA AALRAAAGL
208	0110	MALLNILQYPDERLHTVAKPVEQVDERIRKLIADMFETMYESRGILAA TQVDVHERVVMDLTEDRSEPRVFINP VIVEKDGETTYEEGCLSVPGIYDTVTTRAERVKEALNEKGEKFTLEADGLLAICVQHELDHLMGIVFVERLSQLKQ GRIKTKLKKRQKHTI
209	0957	MSQYDVVVI GAGPGGYVAAIRAAQLGFKTACVDAGVNKAGNAPALGGTCLNVGCI PSKALLQSSEHFHAAQHEFAE HGITVGDVKF DAAKMIERKDAIVTKLTGGVKFLPQKNKVTSLFGTASFAGKNGDAYQIEVDNKGKETVIEAKHVIV ATGSVPRPLQVAIDNVNVLNNEGALNLTEVP AKLGIVSGVIGLEMGSVWNRVGAETVILEAAPTFLAADQOIA KEAFKYFTKEQGLSIELGVKIGDIKSEKGVS VAYETAAGEAKTEVFDKLIVAGRI PNTKGLNAEAVGLEKDERG FIKVDGECRTNLPNVWAIGDVVRGPM LAHKASDEGVAVAERIAQKPHIDFNNVPFVIYTDPEIAWVGKTEEQLKA EGVEYKKGTSFGFANGRALAMGKAKGTVKVLADAKTDRILGVHMI GPVVSELVTEGVTALEFFASSEDIAIRIHAH PTLSEVVHEAALADKRALHG
210	1011	MMIEKSISIVDGKEYSVFAVSHEFRYTFDEPILVADLISSLKAYETLTSSYLPAILNQLFDVKIQIKVAVSEIER GSFLEKLI FNLFFKDEDAYNEFCLKIRKFLGTENQDGSINMSKIIMFAMTLLGVGAGYLLFKNPPQEKQAITNNI VTVINADSSVALDGEHLVSVVKEVTGSSKQKTAENVAKVYAPASKNNGSITLGTDDVRIEPVAQQT VATLPKVDL RDTPLTETYTDIDVQIRATDRDKNSGWYAVIDQIVPSRVRLPEIDILNRLANNATIRANVTVEFDLKQNGSRKP KKIILTSLS TD

211	1055	MFSKSVTLAQYDPLAAAIQAEDQRQODHVELIASENYVSCAVMDAQGSQLTNKYAEGYPGKRYYGCEYVDIVEQ LAIDRVKELFGAAAYANVQPHSGSQANQAVYASVLKPGDTILGMSLAHGGHLTHGASVNISGKLYNAVTYGLDENEV LDYAEVERLALAEHKPKMIVAGASAYALQIDWAKFREIADKVGAYLFVDMAHYAGLVAGGEYPNVPVFCDFVTTTTH KTLRGPRGGVILCRDNTHKALNSSIFPSLQGGPLMHVIAAKAVAFKEALQPEFKQYAKQVKINAAAMAEELVKRG LRIVSGRTESHVFLVDLQPMKITGKAAEAALGKAHITVNKNAPNDPEKPFVTSGIRIGSAAMTTRGFNEADARVL ANLVADVLSNPEDEANLAKVRQVTALCNKYPVYGA
212	1437	MSARENILAKLKKADALPMEEPAVFDYIREMGVSWGSEVERLKHWAAMRAVKTEIYVVTKSNNMQVFREAAEGKG LKNILLPLATEHGQIARAALADSNIPIAFEREIDTWKTEFFTNIDAGFSGAQCGIARTGTLMLFSSPEEPRTL VPPVHFCLFDTSKMYNEFHNAVEGEKLVENGMPNTNVFLISGPSKTADIQLTLAYGAHGPRDLVILAILPDHISPAD LEENA
213	1460	MSLNKVLIGRLGRDPEVRYMPNGEAVCNFSVATSETWNRNGQRVERTEWHNITMYRKLAEIAGQYLKKGGLVYL EGRIQSRKYQKGDIERTAYDIVANEMKMLGGRNENSGGAPYEEGYQSQEAYQRPAAQSQRPASDAPSHQPEAPA APRRQPVPAAPVEDIDDDIPF
214	1540	MNKKHGFPLTLTALAIATAPFAAQAAGGATPDAAQTQSLKEITVRAAKVGRRSKEATGLGKIVKTSETLNKEQVL GIRDLTRYDPGVAVVEQNGASGGYSIRGVDKNRVAVSVDGVAQIQAFVQGSLSGYGGRGSGGAINIEIYENIST VEIDKGAGSSDHGSGALGGAVAFRTKEAADLISDGKSWGIIQAKTAYGSKNRQFMKSLGAGFSKDGWEGLLIRTERQ GRETRPHGDIADGVEYIGIDRLDAFRQTYDIKRKTREFFSVGEGERESKPVAKLAGYGKYLNNQLNRVWKERIEQNO PLSAEEEEQVREARHENLSAQAYTGGGRILPDPMDYRSGSWLAKLGYRFGGRHYVGGVFEDTKORYDIRDMTEK QYYGTDEAEKFRDKSGVYDGDGDFRDLGYFVFNIEEWKGDKNLVRGIGLYKYSRTKFIDEHRRRRRMGLLYRYENEAY SDNWADKAVLSFDKQGVATDNNTLKNCAVYPAVDKSCRASADKPYSDSSDRFHYREQHNVNLNASFEKSLKNKWT KHHLTLGFGYDASKAISRPQLSHNAARISESTGFDENNQDKYLLGKPEVVEGSGVCGYIETLRSRKCVPRKINGSN IHISLNDRFSIGKYFDFSLGGYDRKNFTTSEELVRSGRYVDRSWNSGILEKPNRHFSVSRYRASSGFRTSPFQELF GIDIYHDYPKGWQRPAKSEKAANREIGLQWKGDFGLEISSFRNRYTDMIAVADHKTCLPNQAGQLTEIDIRDY NAQNMSLQGVNILGKIDWNGVYKLPGLYTTLAYNRIPKPSVSNRGLSLRSYALDAVQPSRYVLGFGYDQPEGK WGANIMLTYSKGNPDELAYLAGDQKRYSTKRASSSWSTADVSAYLNLLKKRLTLRAAIYNIGNRYVYTWESLRQTA ESTANRHGGDSNYGRYAAPGRNFSLALEMKF
215	1554	MTKFI FVTGGVSSSLGKIAAASIAAILESRLNVTMLKLDPYINVDPGTMSPFQHGVEFVTDDGAETDLDLGHYE RFIDSTMTRRNSFSTGQVYENVIKERRGDYLGTVQVIPHITDEIKRRIHEGAAGYDVAIVEIGGTVGDIESLPF LEAIRQMRSQGLRNNTLFAHLSYVPIYIAAGEIKTKPTQHTVKEMLSIGLQPDILICRMDRTMPADERRKIALFCN VEERAIVGSYDSDSIYECPEMLHDQIDNIITEQLQNLVQADLTAWKKIVHAIQNPKHTVKIAMVGKYVDLTESY KSLIEALKHAGIHTETDVQITFVDSENIEKNKGDVSMKMDAILVPGGFGSRGVEGKIAAVRYARENVPYLGIC LGMQIALIEYARDVAGLKGANSTEFDLKCAAPVVALIDEWQTADGSVETRDESTDLGGTMRLGAQOEVELKAGSLAA KIYSGGHIRERHRHRYEVNNYVPTLEQAGLVIGGSAGRERLVETIELPNHPWFFACQFHPEFTSNPRKGHPFLT AFVKAALNNKKA
216	1576	MRHILSVLIENESGAMSRVVLFSARDYNIDSLAVAPTEDEKTLSRMTIVTHGDEQVIEQITKQLNKLIEVIKVVDL NESRFVERELMLVKVRAAGKDRDEFLRLTEIYRGSIIDVTDRTSYTIEITGSTDKLDSFLETVGRAQILETVRTGAA GIGRGERILKI
217	1808	MRLFKSLKNPKKTDAKLPKSSGLNNRAAIGIDIDQHSIKMVQLSGRSLNQIQLEKYVIAKLPKNIIQGNKVQNYD QLVTTYLQQAAYAKLTSCKNIIASVPQNLATIEQLTYTDKDAELDLQGFVESSISEVSSISLEEANYDYQVLSQSAA GEAVLAVASRKDEIEPLIDAFNAAGMKLSALDVIDFGQYNAYALWINHFAPELAAEKVAIFGVYAAQTYALVIQDG KILYKQETSVSEEQLNQLIQRTYQVTEEKAEIINSPQKPSDYQESVANYFNQITQEIQRVLQFYTTQTADDMT DIKHILLTGEAARQEGIAQTVASQTNADVQCVPARYFADNLKTDKQOFELDAPTLTRAFLAVRGL

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

Entrez-Protein - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Address http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=protein

NCBI Protein

Protein Nucleotide Genome Structure PopSet Taxonomy OMIM Books

Search Protein NMB1506 GO Clear

Display Summary Save Text Clip Add

Show 20 items 12,578

1: [Q9JYM8](#)
Arginyl-tRNA synthetase (Arginine--tRNA ligase) (ArgRS)
gi|23822209|sp|Q9JYM8|SYR_NEIMB|23822209| Links

2: [NP_274514](#)
arginyl-tRNA synthetase [Neisseria meningitidis MC58]
gi|15677359|ref|NP_274514.1||15677359| Links

3: [F81075](#)
arginyl-tRNA synthetase NMB1506 [imported] - Neisseria meningitidis (group B strain MD58)
gi|11271722|pir|F81075|11271722| Links

4: [AAF41862](#)
arginyl-tRNA synthetase [Neisseria meningitidis MC58]
gi|7226749|gb|AAF41862.1||7226749| Links

About Entrez
Entrez Protein
Help | FAQ
Batch Entrez Upload a file of GI or accession numbers to retrieve sequences
Check sequence revision history
How to create WWW links to Entrez
LinkOut
Cite
Related resources
Reference sequence project

PCT Application

IB0306281

